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ABSTRACT
Murine gammaherpesvirus (MHV-68) was isolated from a bank vole. It has
pathobiological and genetic similarities to other gammaherpesviruses including
Herpesvirus saimiri, Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated
herpesvirus (KSHV). It infects laboratory mice and forms plaques on cell
monolayers in tissue culture. The pathogenesis and immunology have been widely
studied in the mouse system and it has been identified as a useful "small animal
model".
Mice were infected with 4xl05 PFU MHV-68 intranasally. The virus infects alveolar
epithelial cells and causes interstitial pneumonia. In the lungs the virus undergoes
lytic replication which is cleared by day 10. Subsequently the virus is found latent in
B cells that have been found to be important in the establishment of latency and in
the transmission of virus from the lungs to the spleen. The spleen and the lymph
nodes at this stage exhibit splenomegaly and lymphadenopathy respectively. In B
cell deficient (pMT) mice, latently infected cells are not detected in the spleen and
splenomegaly is not observed.
In this study, the early events following MHV-68 infection in vivo were examined.
The work focused on the mediastinal lymph node (MEN) that drains the lungs.
Events occurring in the MLNs from the wild type C57BL/6 mice were compared to
those of the pMT mice. The results demonstrated the absence of lymphadenopathy in
pMT mice and indicated that lymphadenopathy in wild type C57BL/6 mice was
brought about especially by the accumulation of B cells. Depletion of CD4+ T cells
in wild type C57BL/6 mice demonstrated that the absence of CD4+ T cells only
partially affected the accumulation of B cells and enlargement of the MLN. The
pMT mouse showed the presence of latent virus in the MLN even in the absence of
B cells. However by day 10 these cells were below levels of detection and there was
no evidence of systemic transfer of virus.
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In order to characterise the cells latently infected with virus in the MLNs of pMT
mice, a recombinant MHV-68 virus expressing green fluorescent protein (GFP),
LHAgfp, was used. LHAgfp has a deletion in the left-hand end and it was therefore
characterised in vivo before further studies were initiated. In the MLN and spleen
LHAgfp did not show peak latent virus levels as seen with wild type MHV-68, but
eventually it was able to establish the same level of latency in these tissues.
Therefore LHAgfp was shown to behave similarly to wild type MHV-68 in vivo. The
use of LHAgfp helped identify infected cells in the MLNs of pMT mice. Dendritic
cells expressing CDllc and macrophages expressing F4/80 were found latently
infected in the MLN. LHAgfp was characterised in the IFN a/p receptor knockout
system and shown to act like the wild type virus in this immunodeficient host by
causing amplification of disease pathogenesis. This system also helped confirm that
in the presence of B cells CDllc and F4/80 positive cells were infected very early
during infection in the MLN.
In conclusion it can be said that the mediastinal lymphadenopathy is a critical event
in the pathogenesis of MHV-68 infection in which B cells played an important
regulatory role. Secondly, the use of recombinant virus expressing marker proteins is






TABLE OF CONTENTS VI
LIST OF FIGURES XI




1.1 Herpesviruses: a general introduction 1
1.2 Gammaherpesviruses 3
1.3 Epstein-Barr virus 3
1.3.1 Lytic Infection 4
1.3.2 EBV Latency 6
1.4 Kaposi's sarcoma-associated herpesvirus 8
1.4.1 Viral genes of KSHV 8
1.4.2 Cell cycle regulation by KSHV 10
1.4.3 Apoptosis regulation by KSHV 11
1.4.4 Cytokine and Chemokine regulation by KSHV 12
1.5 Murine gamniaherpesvirus-68 15
1.5.1 MHV-68 genome 16
1.5.2 Infection, pathogenesis and susceptible cell types 18
1.6 Immune response to viruses 19
1.6.1 Cells 19
1.6.1.1 Natural killer cells 20
1.6.1.2 Macrophages 21
1.6.1.3 Complement and collectins 22
1.6.1.4 Dendritic cells 23
1.6.1.5 T cells 24




1.7 Immune response to EBV
1.7.1 Antibody response
1.7.2 CTL response
1.8 Immune response to MHV-68
1.8.1 Innate immune response
1.8.2 Humoral response
1.8.3 T cell response
1.8.3.1 CD4+ T helper cells
1.8.3.2 CD8+ CTL
1.9 Evasion of immune responses by herpesviruses
1.9.1 Modulation of antigen presentation
1.9.2 Modulation of cell death by apoptosis
1.9.3 Modulation of cytokine and chemokine response
1.9.4 Modulation of humoral immunity











2.2.1 Preparation of virus working stock
2.2.2 Cocultivation assay for infective centres in the lymph nodes and spleen
2.2.3 Assay for infective virus
2.2.4 Biotinylation of antibody
2.2.5 Flow cytometric analysis of cells (FACS-fluorescent activated cell sorting)..
2.2.6 Imprints





































2.2.9 MHV-68 immunostaining of paraffin-embedded tissues 52
2.2.10 Magnetic activated cell sorting (MACS) 53
2.2.11 Interferon-y CTL assay 54
2.2.12 Staining cytospun cells 55
2.2.13 Confocal microscopy 55
2.2.14 Ammonium chloride lysis 55
2.2.15 Electron microscopy 56
2.2.16 Handling of DNA, RNA and molecular biological techniques 56
2.2.17 DNA agarose gel electrophoresis 56
2.2.18 RNA Extraction 56
2.2.19 Preparation of cDNA from total RNA 57
2.2.20 Polymerase chain reaction (PCR) 57
CHAPTER THREE 58
ROLE OF B CELLS IN THE DRAINING LYMPH NODE DURING THE EARLY
STAGES OF INFECTION 58
3.1 Introduction 58
3.2 Mediastinal lymphadenopathy and B cells 59
3.2.1 Mediastinal lymphadenopathy in the presence and absence of B cells 59
3.2.2 Changes in cell populations during the process of lymph node enlargement ..60
3.2.3 FACS analysis for B cell surface markers 61
3.3 CD4+ T cell signalling and B cells in the MLN 62
3.3.1 Requirement for CD4+ T cell signalling in lymph node enlargement 62
3.3.2 B cell numbers in the MLN following CD4+ T cell depletion 63
3.3.3 Presence of latently infected cells in the MLN following CD4+ T cell depletion
64
3.4 Latently infected cells in the absence of B cells, in the MLN 65
3.4.1 Latently infected cells in the MLN of pMT mice 65
3.4.2 Immunostaining for cells expressing virus encoded lytic proteins 66
3.4.3 Detection of virus particles using electron microscopy 66
3.4.4 Reverse transcription-polymerase chain reaction (RT-PCR) for viral transcripts
on whole tissues 67
3.5 CD8+ CTL and B cells in the MLN 68
3.5.1 MHV-68 specific CTL response, in the absence of B cells 68
viii
CHAPTER FOUR 69
APPLICATION OF A GREEN FLUORESCENT PROTEIN (GFP) EXPRESSING
GAMMAHERPESVIRUS 69
4.1 Introduction 69
4.2 Characterisation of LHAgfp 71
4.2.1 Infective virus in the lungs of C57BL/6 mice infected with LHAgfp as
compared to wild type MHV-68 71
4.2.2 Latently infected cells in the mediastinal lymph node 71
4.2.3 Extent of lymphadenopathy 72
4.2.4 Latently infected cells in the spleen 73
4.3 LHAgfp as a tool to study the trafficking of virus in vivo 73
4.3.1 GFP positive cells in the lungs and mediastinal lymph node imprints 73
4.3.2 CD1 lc expressing cells enriched from pMT mice MLN 74
4.3.3 CD1 lc enriched cells expressing GFP stained with F4/80 75
4.3.4 The advantages of using the IFN-a/p R' mouse system which displays an
exaggerated MHV-68 disease pathogenesis 76
4.3.5 CD1 lc enriched cells expressing GFP confirmed with surface staining 77
4.4 Pathogenesis of LHAgfp in IFN-a/p R"/_ mice versus WT129 mice 78
4.4.1 Infective virus in the lungs 78
4.4.2 Lymphadenopathy 79
4.4.3 Latently infected cells in the mediastinal lymph node and spleen 79
4.4.4 Cryosections of the MLN and spleens of IFN-a/p R mice to identify cells
expressing GFP .80
4.5 FACS analysis for various cell populations and the pattern of GFP expression
in the MLN of IFN-a/p R ' and WT129 mice 81
4.5.1 CD 11 c staining for dendritic cells 81
4.5.2 F4/80 staining for macrophages 82
4.5.3 CD19 staining for B cells 83
4.5.4 Staining for CD4+ T cells 83
4.5.5 Staining for CD8+ T cells 84
4.6 The FACS percentages of cells expressing GFP in the spleens of IFN-a/p R_/"




5.1 MLN is a critical site in MHV-68 pathogenesis where the B cells play an
important role 88
5.1.1 Requirement for B cells in lymphadenopathy 88
5.1.2 B cell expansion is only partly dependent on CD4+ T cell signalling 89
5.1.3 B cells are required for long-term latency and viral dissemination from the
MLN 90
5.1.4 Latently infected B cells are required for the presence of an active MHV-68
specific CTL response in the MLN 91
5.2 Cells other than B cells are infected in the MLN 92
5.2.1 Dendritic cells and macrophages, target cells for MHV-68 infection in the
MLN 92
5.2.2 Dendritic cells in trafficking virus 94
5.2.3 Dendritic cells and macrophages as reservoirs of virus 95
5.3 Pathogenesis and use of recombinant LHAgfp 95
5.3.1 Effects on disease pathogenesis of LHAgfp as a result of the deleted genes ... 95
5.3.2 LHAgfp, a useful marker virus 96
5.4 Pathogenesis of LHAgfp in IFN-a/p R"'"and WT129 mice 97
5.4.1 Disease pathogenesis in the lung, MLN and spleen 97
5.4.2 Reduced lymphadenopathy in IFN-a/p R7 mice 98






1.1 The organisation of MHV-68 genome as compared to EBV and KSHV 15-16
1.2 MHV-68 infection in mice deficient in lymphocyte subsets and cell 35-36
surface molecules
1.3 MHV-68 infection in mice deficient in lymphocyte subsets and cell 35-36
surface molecules
3.1 Lymphadenopathy of the mediastinal lymph node in wild type 59-60
C57BL/6 and B cell deficient (pMT) mice
3.2a Phenotype of cells in the enlarged lymph nodes of C57BL/6 mice 60-61
3.2b Phenotype of cells in the enlarged lymph nodes of C57BL/6 mice 60-61
3.3a Expression of B cell markers in the enlarged lymph nodes of C57BL/6 61-62
mice
3.3b Expression of B cell markers in the enlarged lymph nodes of C57BL/6 61-62
mice
3.4 FACS analysis for CD4+ T cells in the MLN 63-64
3.5 Cellularity of the mediastinal lymph node in C57BL/6 mice depleted of 63-64
CD4+ T cells
3.6 B cell numbers in the mediastinal lymph node of C57BL/6 mice 63-64
depleted of CD4+ T cells
3.7 Infective centres in the mediastinal lymph node of C57BL/6 mice 64-65
depleted of CD4+ T cells
3.8 Infective centres in the spleens of C57BL/6 mice depleted of CD4+ T 64-65
cells
3.9 Infective centres in the mediastinal lymph node and cervical lymph 65-66
node (CLN) in C57BL/6 and pMT mice
3.10 Lung and MLN tissues from IFN a/p R-/- mice immunostained for 66-67
MHV-68 lytic viral proteins
3.11 Transmission electron microscopy to detect virus particles in MLN 66-67
cells from pMT mice infected with MHV-68
3.12 RT-PCR for viral transcripts on whole MLNs from pMT and C57BL/6 67-68
mice
XI
3.13 MHV-68 specific CTL response in the MLN of pMT and C57BL/6 68-69
mice
4.1 Infective virus in the lungs of C57BL/6 mice infected with either 71-72
LHAgfp or MHV-68
4.2 Infective centres in the mediastinal lymph node of C57BL/6 mice 72-73
infected with either LHAgfp or MHV-68
4.3 Lymphadenopathy of the mediastinal lymph node of C57BL/6 mice 72-73
infected with either LHAgfp or MHV-68
4.4 Infective centres in the spleens of C57BL/6 mice infected with either 73-74
LHAgfp or MHV-68
4.5 GFP positive cells in the lungs and mediastinal lymph node imprints of 74-75
pMT mouse infected with LHAgfp
4.6 FACS analysis dot plots representing scatter data and staining of 75-76
CD1 lc cells obtained from MACS enrichment of pMT mouse MLN
4.7 GFP expressing cells stained with F4/80 antibody 75-76
4.8 FACS analysis dot plots representing scatter data and staining of 77-78
CDllc cells obtained from MACS enrichment of IFN a/p R7" mouse
MLN
4.9 Fluorescence images of cells enriched for CD1 lc using MACS 77-78
4.10 CDllc enriched cells from IFN a/p R7" mice MLN expressing GFP 77-78
and stained for surface markers
4.11 Infective virus in the lungs of IFN a/p R7" and WT129 mice infected 78-79
with LHAgfp
4.12 Lymphadenopathy of the mediastinal lymph node of IFN a/p R" and 79-80
WT129 mice infected with LHAgfp
4.13 Infective centres in the mediastinal lymph node of IFN a/p R7" and 79-80
WT129 mice infected with LHAgfp
4.14 Infective centres in the spleens of IFN a/p R7" and WT129 mice 79-80
infected with LHAgfp
4.15 Cryosections of tissues from IFN a/p R7" mice to identify cells 80-81
expressing GFP
4.16 The FACS percentages of different cell types and the percentage 81-82
expressing GFP in the mediastinal lymph node of IFN a/p R7" and
WT129 mice infected with LHAgfp
Xll
4.17 The total numbers of cells expressing GFP in the mediastinal lymph 85-86
node of IFN a/(3 R"A and WT129 mice infected with LFlAgfp
4.18 The FACS percentages of different cell types and the percentage 85-86





1.1 Characteristics of the gammaherpesviruses 3-4
2.1 Antibodies used in FACS analysis 48-49
2.2 PCR Primer sequence 57-58
xiv
ABBREVIATIONS
ADCC Antibody dependent cell-mediated cytotoxicity
AFC Antibody forming cells
APC Antigen presenting cells
BCBL Body cavity-based lymphomas
BFA Brefeldin-A
BH Bel homology
BHK Baby hamster kidney cell line
BHV-4 Bovine herpesvirus-4
cDNA Complementary deoxyribonucleic acid
CDK Cyclin dependent kinases
CLN Cervical lymph node
CMV Cytomegalovirus









FACS Fluorescent activated cell sorter
Fc Fragment crystallisable




GFP Green fluorescent protein





HHV 7 Human herpesviruses-7
HHV-8 Human herpesvirus-8
HIRF Cellular interferon regulatory factor
HIV Human immunodeficiency virus
HSV Herpes simplex virus
HVS Herpesvirus saimiri
IAV Influenza A virus
IE Immediate-early






IRF Interferon regulatory factor
INOS Inducible nitric oxide synthase
KS Kaposi's sarcoma
KSHV Kaposi's sarcoma-associated herpesvirus
LANA Latency-associated nuclear antigen
LC Langerhans ceii
LCL Lymphoblastoid cell lines
LCMV Lymphocytic choriomeningitis virus
LHAgfp Recombinant MHV-68 virus
LUR Long unique coding region
MA Membrane antigen
MACS Magnetic activated cell sorting
MCMV Murine cytomegalovirus




MLN Mediastinal lymph node
mRNA Messenger ribonucleic acid
NBCS New born calf serum
NK Natural killer cells
PE Phycoerythrin
ORE Open reading frames
PBS Phosphate buffered saline
PECs Peritoneal exudate cells
PEL Primary effusion lymphomas
PFU Plaque forming unit






RT-PCR Reverse transcription-polymerase chain reaction
SCID Severe combined immuno-deficient mice
slg Surface immunoglobulin
SP-A Surfactant protein-A
SWB Staining wash buffer
TAP Transporter associated with antigen processing
TBS Tris buffered saline
TLN Thoracic lymph node
Th T helper
TNF-a Tumour necrosis factor
TPA Tetra decanoylphorbol acetate
TPB Tryptose phosphate broth
TRITC Tetramethyl rhodamine isothiocyanate
tRNA Transfer ribonucleic acid
VCA Virus capsid antigen
v-cyclin Viral cyclin
XVII
vFLIP Viral FLICE inhibitory protein
vIRF Interferon regulatory factor homologues
VSV Vesicular stomatitis virus
WT129 Wild type 129/Sv/Ev mice
pMT B cell deficient mice
xviii
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CHAPTER ONE
INTRODUCTION
1.1 Herpesviruses: a general introduction
The Herpesviruses are large double stranded DNA viruses, classification of which
was previously based on the architecture of the virion. A typical herpesvirion
consists of a core containing linear double stranded DNA, an icosadeltahedral capsid,
a proteinaceous tegument and an envelope with lipid membrane carrying external
glycoproteins (Schrag et al., 1989). The family Herpesviridae comprises over 100
viruses that infect a wide range of vertebrates (Roizman et al., 1992). These viruses
are ubiquitous but are usually host specific and infection is restricted to a single
species. Herpesviruses vary in their biology, but one common feature is their ability,
following primary infection, to establish life-long latent infections.
On the criteria of host range, duration of reproductive cycle, cytopathology and
characteristics of latent infection herpesviruses have been divided into three sub¬
families: the Alpha-, Beta-, and Gamma Herpesvirinae (Roizman et al., 1992). More
recently classification has been reviewed and it now takes into consideration gene
content and sequence similarities.
Alphaherpesvirinae have a variable host range in cell culture, have a short growth
cycle, spread rapidly with efficient destruction of infected cells and are neurotropic
in that they can establish latent infection primarily in sensory ganglia. Examples are
Herpes simplex type 1 & 2 (HSV-1 and HSV-2) and Varicella zoster virus which
infect humans. This subfamily comprises the Simplexvirus and Varicellovirus
genera.
Betaherpesvirinae have a narrow host range, long reproductive cycle in cell culture
with slow virus spread. Infected cells become enlarged. Virus may become latent in
secretory glands and lymphoreticular cells. Examples are Cytomegalovirus (CMV)
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and human herpesviruses 6 & 7 (HHV 6 and HHV 7) which infect humans. This
subfamily comprises of Cytomegalovirus and Muromegalovirus genera.
Gammaherpesvirinae are associated with lymphoproliferative diseases in their
natural hosts, and infect lymphoblastoid cells in vitro. These viruses are specific for
B and T lymphocytes, in which they are found latent. Examples are Epstein-Barr
virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) which infect
humans. This subfamily includes two genera: the lymphocryptovirus (yl) and
rhadinovirus (y2). EBV is the prototype lymphocryptovirus (Kieff, 1996).
Herpesvirus saimiri (HVS) is the prototype for the rhadinovirus genus. KSHV has
also been classified as a rhadinovirus.
All herpesviruses specify enzymes and other factors involved in nucleic acid
synthesis metabolism, as well as a variable number of enzymes in DNA metabolism.
Herpesviruses specify at least one protease and a variable number of protein kinases.
DNA synthesis is initiated from one or more origins of DNA replication and genome
head-to-tail concatamers appear to be generated by a rolling circle mechanism. The
synthesis of viral DNA and assembly of capsids occur in the nucleus. Envelopment
of the capsid as it transits through the nuclear membrane is obligatory. Production of
infectious progeny virus is invariably accompanied by the irreversible destruction of
infected cells. The herpesviruses examined are able to remain latent in their natural
hosts. In cells harbouring latent virus, the viral genome takes the form of closed
circular molecules, where only a small subset of viral genes are expressed (Roizman
et al., 1992).
Herpesviruses persist within their hosts primarily in a state of latency, with only
occasional interruptions in the form of lytic infections. Latency is defined as the
inability to recover infectious particles from disrupted cells that harbour the virus.
This condition should be distinguished from a persistent infection in which a low
level of viral replication and infectious particles are recoverable from disrupted cells.
Once thought to be completely dormant, latent herpesvirus genomes are now
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recognised to be transcriptionally active. As many as 10 viral transcripts in EBV and
as few as one in Herpes simplex virus have been identified during latency.
Lytic genes can be divided into immediate early (IE) or a genes which are
transcribed prior to viral protein synthesis, early or P genes which are transcribed in
the absence of viral DNA synthesis, and late or y genes which represent the structural
proteins, and are expressed only after viral DNA synthesis (Honess and Roizman,
1974).
1.2 Gammaherpesviruses
The Gammaherpesvirus subfamily includes viruses that can establish latent infection
in lymphocytes as well as cause cell proliferation. This subfamily has also been
associated with the ability to cause malignancies in a related foreign host, although
under specific conditions natural hosts develop malignancies too e.g. EBV and
KSHV in humans. Table 1.1 lists the characteristics of gammaherpesviruses and the
lymphomas caused in their respective natural host or a related foreign host. The
human gammaherpesviruses EBV and KSHV are dealt with in the following sections
with emphasis on the genes encoded by these viruses.
1.3 Epstein-Barr virus
Epstein-Barr virus, a human gammaherpesvirus with a marked tropism for B
lymphocytes, is carried by a vast majority of individuals as a life-long asymptomatic
infection. However in some cases it acts as the causative agent of infectious
mononucleosis (IM). EBV is also strongly linked to at least three lymphoid
malignancies: endemic Burkitt's lymphoma, the immunoblastic B cell lymphomas
seen in immunocompromised patients, and a subset of cases of Hodgkin's disease, as
well as to the epithelial tumour, nasopharyngeal carcinoma (Rickinson and Kieff,
1996, Epstein and Crawford, 1998). This is believed to be due to the potent growth-
transforming ability of the virus, which maps to a specific subset of genes, namely
the latency genes. Allelic polymorphism in some of the latency genes defines two
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broad types of EBV isolates, type 1 and type 2, which show subtle differences in
transforming function. Spread of EBV occurs by close contact. Primary infection
classically occurs sub-clinically during childhood. Subsequently individuals become
life-long virus carriers. Primary infection results in IM in around 50% of cases. 1M is
a benign lymphoproliferative disease, which has been extensively studied as a model
for primary EBV infection and establishment of latency (Rickinson and Kieff, 1996).
EBV enters the body through the mouth and replicates in the oropharynx, producing
infectious virus into the oral cavity (Faulkner et al., 2000). The cellular site of this
replication is unclear, it is assumed that either some squamous epithelial cells in the
oropharynx become infected or that intraepithelial B-cells in this region are infected
directly (Anagnostopoulos et al., 1995). Studies on X-linked agammaglobulinemia
(lack of mature B cells) individuals showed no evidence of EBV infection indicating
that in the absence of B cells the environment is non-permissive for EBV latency
(Faulkner et al., 1999).
1.3.1 Lytic Infection
There is no effective in vitro culture system which mimics EBV lytic cycle phase,
and hence different methods and partially permissive cells lines have been developed
over time to overcome this problem. Genes expressed during the EBV lytic cycle
have been characterised in EBV infected lymphoblastoid cell lines (LCL) induced by
various agents, e.g. tetra decanoylphorbol acetate (TPA) (zur Hausen et al., 1978). A
few cell lines can be consistently induced to permit lytic virus replication in 10% of
the cells. One cell line, Akata, can be induced to higher levels of lytic infection by
cross-linking surface immunoglobulin (slg) and is currently the best source of large
quantities of EBV (Takada and Ono, 1989). As with other herpesviruses,
transcription follows a certain pattern, each set of genes being activated by the
previous set.
Induction of lytic infection in Akata cells by slg cross-linking and incubation of the
cells in the presence of moderately high concentrations of inhibitors of protein
synthesis (cyclohexamide) results in expression of the BZLF1 (Z) and BRLF1 (R)
mRNA, indicating that these are immediate early gene products (Takada and Ono,
1989). The products of these two genes are transactivators of early genes and are
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derived from three mRNA species, one of which encodes both R and Z sequences
(Kieff, 1996). Z is a DNA binding protein that shows homology to the DNA binding
domain API (Sinclair et al., 1991). The Z and R promoters (Zp, Rp) contain API
sites and so Z transactivates its own activity as well as that of R gene. Z facilitates
the transition from latent to lytic infection. Subsequently R protein too has been
shown to have the capacity to disrupt viral latency both in epithelial cells and in B
cells (Zalani et al., 1996, Rogoczy et al., 1998). Z appears to associate with p53,
which could lead to the inhibition of apoptosis during EBV DNA replication (Zhang
et al., 1994). As p53 plays an important role in cell cycle regulation, Z is also
thought to be able to arrest cell cycle progression and facilitate viral DNA
replication. R interacts with another cell cycle regulator retinoblastoma (Rb) protein
and it is thought to function in a similar fashion (Zacny et al., 1998). Z and R
transactivate early genes such as BMRF1 (Biggin et al., 1987), BHRF1 (Hardwick et
al, 1988) and BRLF1 (Sinclair et al., 1991).
Early genes are differentiated from late genes by their synthesis in the presence of
inhibitors of viral DNA synthesis (Baer et al., 1984, Biggin et al., 1987). The genes
expressed include BMLF1, BMRF1, BHRF1 and BORF2 as well as others involved
in viral DNA replication (Hardwick et al., 1988). Some of the components involved
in lytic viral DNA replication include BALF5, which encodes the core DNA binding
protein; BALF2, the single strand DNA binding protein; BMRF1, the processivity
factor; BSLF1 and BBLF4, the primase and helicase complex; BBLF2/3, a spliced
primase-helicase complex component and BKRF3, the uracil DNA glycosylase (Baer
et al., 1984, Kieff, 1996).
The viral capsid proteins have not been analysed in detail due to lack of a fully lytic
system in vitro. The major capsid protein pi60 is encoded by BALF4 open reading
frame (ORF). Seven EBV encoded glycoproteins have been identified, three of
which become components of the viral envelope (Kieff, 1996). Two, gp350/220 and
gp85 have been studied in detail because they induce production of neutralising
antibodies and are potential vaccine candidates (Thorley-Lawson and Geilinger,
1980). Gp350/220 is coded by the BLLF1. Alternate splicing of mRNA creates the
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two forms of the protein. Gp350/220 mediates virus attachment to the B cell surface
by binding to the EBV receptor CR2 (also called CD21) (Nemerow et al., 1987).
Thus both naturally occurring and experimentally induced antibodies to gp350/220
prevent infection by blocking attachment.
1.3.2 EBV Latency
There are at least three latency types defined in EBV, as latency I, II and III, based
upon the differential expression of latent genes. In vitro EBV infection of human B
lymphocytes leads to the establishment of latently infected transformed LCL. The
latency in LCL is called latency type III. The lymphocytes are immortal and can
cause tumours when injected into severe combined immuno-deficient mice (SCID)
mice (Rowe et al., 1991). In LCL the viral genome is seen in a circular episomal
form. A limited number of EBV genes are expressed in latently infected LCL cells,
these include genes encoding the six nuclear antigens, EBNA1, 2, 3A, 3B, 3C and
leader protein (LP) and the three membrane associated proteins LMP1, LMP2A and
LMP2B. In addition LCL show abundant expression of small RNA's, EBER1 and
EBER2. It is thought that six latent proteins (EBNA1, 2, 3A and 3C, LMP1 and
EBNA-LP) are required for B-cell transformation (Hammerschmidt and Sugden,
1989, Cohen et al., 1989, Kaye et al., 1993). The LMP2 proteins are thought to
function in the maintenance of EBV latency, possibly through blocking a switch into
lytic cycle after signalling through the B cell antigen receptor complex (Miller et al.,
1995). LCL generated by EBV infection of B cells at different stages of
differentiation all display the same cell surface phenotype and characteristic growth
in cell aggregates. EBV immortalised LCL express B cell activation antigens CD23,
CD30, CD39 and CD70 and the cellular adhesion molecules LLA1 (CD1 la/18),
ICAM1 (CD54) and LPA3 (CD58) (Wang et al., 1990, Rowe et al., 1991). Kempkes
et al (1995) demonstrated that expression of EBNA2 in B cells resulted in up-
regulation of the same cellular proteins as did polyclonal activation of primary B
cells.
In contrast to the above pattern of virus latent gene expression that characterises
LCL, a second type of non-productive EBV infection, designated 'latency I' has been
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identified in Burkitt's lymphoma biopsy cells/cell lines. These cells typically express
EBNA1, EBER and BamHIA transcripts, whereas the remaining EBNAs (EBNA2,
EBNA3A, 3B, 3C & LP) and three membrane proteins (LMP1, 2A & 2B) seen in
'latency HE are not detectable (Rowe et al., 1987). However, during early passage
EBV positive BL cells (latency I) are not stable and move towards a latency III
pattern of gene expression. An alternate pattern of transcription, 'latency II', is seen
in Reid-Sternberg cells in EBV positive Hodgkin's disease and the malignant
epithelial cells of nasopharyngeal carcinoma. Here EBNA1 is expressed along with
LMP1 and 2. Several studies have addressed a potential role of DNA methylation in
the control of viral gene expression and virus latency (Robertson and Ambinder,
1997).
EBV latency patterns in vivo in asymptomatic carriers provide us with clearer ideas
about the mechanisms the virus uses to establish life-long latency in humans. EBV
latency in the peripheral blood was found mainly restricted to the resting memory B
cells (Miyashita et al., 1995, Babcock et al., 1998). These cells, unlike EBV
immortalised B cells in vitro, do not express CD23 and are in a G0 state in cell cycle
(Miyashita et al., 1995, 1997). Infected cells were also found to down-regulate the
co-stimulatory molecule B7. This could prevent effective recognition by cytotoxic T
cells and help escape immune surveillance. EBV positive resting memory B cells
obtained from the peripheral blood expressed only LMP2A gene (Miyashita et al.,
1997). The LMP2A expression in vivo in B cells has been proposed as the true
"latency-program". Subsequent studies were able to show that memory B cells from
the tonsillar tissues of healthy carriers express EBNA1 from the Qp promoter as well
as LMP1 and LMP2 (Babcock et al., 2000a). This was the first demonstration in vivo
in normal B cells unlike in EBV-associated tumour cells where this pattern of gene
expression was shown to be present. On the other hand naive B cells isolated from
the tonsils were found to express EBNA2, LMPland LMP2 (Babcock et al., 2000b).
However, as all these different EBV gene expression patterns in vivo are unravelled,
it is becoming clearer that EBV uses the normal B cell differentiation biology to gain
access to long-lived memory B cells.
CHAPTER 1 INTRODUCTION 8
1.4 Kaposi's sarcoma-associated herpesvirus
Kaposi's sarcoma (KS) is the most frequent neoplastic complication seen in patients
infected with human immunodeficiency virus (HIV) and is especially prevalent in
male homosexual AIDS patients. In 1994, Yuan Chang, Patrick Moore and
colleagues at the Columbia University identified DNA sequences belonging to a new
infectious agent in AIDS-related KS patients. They used a PCR based technique
called representational difference analysis (RDA) in which short restriction
fragments from KS lesion tissues were compared to unaffected tissues from the same
patient. The sequences obtained showed close similarity to HVS and EBV sequences
however there were distinct tegument and capsid gene sequences indicating it was a
novel DNA sequence (Chang et al., 1994). These sequences were also identified in
non-Hodgkin's lymphomas in HIV-positive patients, especially in body cavity-based
lymphomas (BCBL). Cell lines established from these were termed BC-1 and BC-2
(Cesarman et al., 1995). Primary sequence characterisation showed that the DNA in
the nucleus was in an episomal form, a characteristic feature of herpesviruses.
Phylogenetic analyses showed that this was a gamma-2-herpesvirus of the
Rhadinovirus genus, the first member identified in humans (Moore et al., 1996b).
They called it Kaposi's Sarcoma-Associated Herpesvirus (KSHV). Being the eighth
human herpesvirus, it is also designated human herpesvirus 8 (HHV-8). Further
evidence of KSHV as the infectious agent was seen when BCBL derived cell lines
treated with TPA produced herpesvirus like particles (Renne et al., 1996). The
genome was fully sequenced and mapped using cosmid and phage genomic libraries
from BC-1 cell line (Russo et al., 1996). In addition to body cavity-based large cell
lymphomas, KSHV has also been found in HIV-seropositive patients with
multicentric Castleman's disease (MCD). Like EBV, KSHV has been detected in
latently infected B lymphocytes, endothelial cells and pluripotent mesenchymal
precursors (Boshoff, 1998).
1.4.1 Viral genes of KSHV
The KSHV genome sequenced from the primary effusion lymphomas (PEL) cell
lines (BC-1), consists of 140.5 kb long unique coding region (LUR) flanked by
CHAPTER 1 INTRODUCTION 9
approximately 800 bp terminal repeat sequences with high G/C content (Russo et al.,
1996). In the KSHV LUR, 81 open reading frames (ORF) have been identified,
including 66 with sequence similarity to HVS ORFs. Like other gammaherpesviruses
KSHV has blocks of conserved genes that are required for the replication and
assembly of virus progeny. They include major structural proteins, DNA synthetic
enzymes, glycoproteins, assembly protein, dihydrofolate reductase and thymidylate
synthase (Moore et al., 1996b, Russo et al., 1996). The non-conserved gene blocks of
KSHV are genes that are found in other rhadinoviruses, and also some that are
unique to KSHV designated K1-K15 (Russo et al., 1996, Nicholas et al., 1997a,
Dittmer et al., 1998). An extraordinary number of recognisable genes pirated from
eukaryotic cellular DNA are encoded by KSHV. KSHV encodes several homologues
of cellular proteins which are also up-regulated by EBV latent proteins, suggesting
that both viruses might employ the same cellular signalling pathways to survive in
their host (Moore et al., 1996a). So far, there are at least 14 reading frames of KSHV
that are homologous to known cellular genes. Although for most of these captured
genes it is not very likely that they are essential for virus replication in cell culture,
they may have important functions in the natural habitat of the virus. Virus encoded
cyclin, interleukin (IL)-6, and IL-8 receptor enhance cell proliferation and may thus
expand the pool of infected cells. The three macrophage-inflammatory proteins
(MIP-I, II and III) might help in attracting susceptible cells. Apoptosis is a typical
response of the host to infection by a virus. KSHV carries two genes ORF 16 (viral
bcl-2 or vbcl-2) and ORFK13 (viral FLICE inhibitory protein or vFLIP) both of
which can prolong the life span of infected cells through the inhibition of apoptosis
by different mechanisms. These pirated genes with functions similar to cellular genes
will be discussed in more detail in the following sections.
The team from Columbia University has classified KSHV gene transcription into
three classes. Class I genes, such as those encoding viral cyclin (v-cyclin or ORF72),
latency-associated nuclear antigen (LANA; ORF73) and vFLIP (ORFK13), are
constitutively transcribed in latently infected PEL cells and are unaffected by TPA
induction. Class II genes are transcribed without TPA stimulation of cells, but are
induced to higher transcription levels by TPA treatment (includes the vIL-6, vIRF
CHAPTER 1 INTRODUCTION 10
and vMIP-II). Class III genes are primarily structural and replication genes that are
transcribed only following TPA treatment and are thus mainly responsible for lytic
virion production (Sarid et al., 1998).
The class I genes ORF72 and ORF73 were reported as a cluster of latently expressed
genes in KSHV (Dittmer et al., 1998). These transcripts are found in BCBL-1 cells
prior to TPA induction. They were also expressed in >70% of KS spindle cells in
primary KS tumours which confirmed that these transcripts are indeed latent RNA
and suggested a role for their product in viral persistence and in KSHV associated
proliferation. Two major latent transcripts encoding v-cyclin were mapped using
5'RACE (5' rapid amplification of cDNA ends). They are LT1 and LT2 and both
transcripts are spliced. They have the same start site, and encode ORFK13 (vFLIP)
and ORF72 (v-cyclin). The latency-associated nuclear antigen (LANA; ORF 73) is
encoded by LT1 but is spliced from LT2. It is proposed that by encoding these
essential genes as a cluster, KSHV could control the expression of these genes
depending on different cell cycle signals and latency patterns during the course of
infection (Sarid et al., 1999).
1.4.2 Cell cycle regulation by KSHV
Work on tumour viruses has shown that they tend to exploit the cell cycle
checkpoints that are normally controlled by regulatory molecules such as D-type
cyclins, pRb (retinoblastoma) and p53. KSHV ORF 72 codes a cellular homologue
of the D-type cyclin, v-cyclin (Chang et al., 1996). The function of cyclins within a
cell is to bind to cyclin dependent kinases (cdk) and this complex is able to
phosphorylate cell cycle checkpoint proteins allowing the cell to move from G1
phase into S phase. KSHV v-cyclin was found to have kinase activity and the ability
to phosphorylate retinoblastoma protein (Rb) in vitro. When v-cyclin was co-
expressed with Rb in SAOS-2 osteosarcoma cells, it was able to reverse the cell
cycle block caused by Rb (Chang et al., 1996). KSHV v-cyclin complexed with
Cdk6 was shown to phosphorylate not only Rb but also histone HI. This was
distinctly different from the activity of cellular cyclin D-cdk6 kinase (Godden-Kent
et al., 1997). Viral cyclin was found expressed in primary KS biopsies and in PEL
CHAPTER 1 INTRODUCTION 11
(Chang et al., 1996, Cesarman et al., 1996). In normal cells, proteins such as cdk
inhibitors would regulate cyclin/cdk complex activity. The v-cyclin was shown to
form active complexes with cdk6 and this complex is resistant to inhibition by cdk
inhibitor proteins such as pi6, p21 and p27 (Godden-Kent et al., 1997, Swanton et
al., 1997). They also showed that the osteosarcoma cell line U2-OS when transiently
transfected with cdk inhibitors (pi6, p21 or p27), underwent a G1 arrest but on co-
transfection with v-cyclin the cells overcame the inhibition. It was later shown that v-
cyclin/cdk6 complex phosphorylates p27kip and destabilises this inhibitor. They were
also able to isolate p27kip phosphorylating cdk6 complex from cells lines derived
from PEL and KS lesions (Ellis et al., 1999).
Viral cyclin/cdk6 complex was shown to induce apoptosis in U20S and COS-7 cells
and this was not prevented by cellular bcl-2 (Ojala et al., 2000). On the other hand
vbcl-2 was able to prevent apoptosis induced by v-cyclin/cdk6 complex to a large
extent. It was shown that v-cyclin and cellular cdk6 complex can phosphorylate bcl-2
and inactivate the anti-apoptotic function and induce apoptosis in cells expressing
large quantities of both v-cyclin and cdk6. This could be a mechanism the virus uses
to negatively regulate the v-cyclin/cdk6 induced proliferation.
1.4.3 Apoptosis regulation by KSHV
KSHV ORF16 encodes a viral bcl-2 molecule that is homologous to other
gammaherpesvirus bcl-2 genes such as EBV BHRF1 and HVS ORF16. Bcl-2 family
members can block cell death caused by growth factor deprivation, y-irradiation and
cytotoxic drugs. In a cell, the bcl-2 molecule is an inhibitor of apoptotic death but
some other members in this family such as bax and bak are promoters of apoptosis.
These proteins are expressed in normal cells and interact with each other maintaining
a critical balance. However, when the cell is subjected to stress this balance is
disrupted and the cell will either undergo apoptosis or survive depending on the
levels of these different proteins (Meinl et al., 1998).
KSHV vbcl-2 has conserved domains similar to human bcl-2, BH (Bel homology) 1
and BH-2 domains are well conserved while BH-3 is poorly conserved. These
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domains in cellular bcl-2 are normally involved in the formation of homodimers or
heterodimers (Cheng et al., 1997). KSHV vbcl-2 is found in low levels in BCBL cell
lines but on stimulation with TPA higher levels are induced and therefore categorised
under class II genes (Sarid et al., 1998). Over expression of vbcl-2 inhibits Sindbis
Virus-I induced apoptosis in cells. Co-immunoprecipitaion and yeast two-hybrid
analysis have shown that vbcl-2 neither homodimerizes nor heterodimerizes with
cellular bcl-2, bcl-xL, bax or bak (Cheng et al., 1997). It has been speculated that by
not binding to proapototic molecules such as bax and bak within infected cells vbcl-2
escapes from negative regulation by these molecules.
KSHV ORFK13 encodes viral FLICE inhibitory protein (vFLIP) which is involved
in inhibiting Fas induced apoptosis (Thome et al., 1997), the first evidence of such a
specialised molecule. Thome et al (1997) were also able to find similar sequences to
vFLIP encoded by HVS, EHV-2, BHV-4 and a human mollusci poxvirus
{Molluscum contagiosum virus, MCV). FLIP protein was subsequently detected in
uninfected cellular cytoplasm as well. Cytotoxic T cells expressing FasL (Fas-
Ligand) can trigger apoptosis in virus infected cells through Fas/FasL interactions.
The KSHV-FLIP expressing B cell lymphoma cells when injected into mice
developed tumours that were resistant to apoptosis triggered by T cells, indicating
vFLIP to be a tumourigenic factor (Djerbi et al., 1999).
1.4.4 Cytokine and Chemokine regulation by KSHV
KSHV gene ORFK2 codes for a vIL-6 that is 25% identical to human IL-6 and is a
secreted cytokine which maintains proliferation of IL-6 dependent cells lines (Moore
et al., 1996a; Nicholas et al., 1997a). The specific function is unknown but it is
speculated that the KSHV cytokine would behave in a similar fashion to cellular IL-6
that is induced by EBV (Tanner et al., 1996). Cellular IL-6 has been demonstrated to
be a paracrine or autocrine growth factor (Tosato et al., 1990) for EBV-immortalised
B cells, resulting in increased immunoglobulin (Ig) production and B cell
immortalization. It has also been shown that if IL-6 is expressed at high levels in
EBV immortalised cells, it will promote tumour formation by impairing the activity
of natural killer (NK) cells. Studies on vIL-6 using ELISA and co-
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immunoprecipitation assays have shown that vIL-6 can bind directly to receptor
subunits gpl30 and IL-6R. Viral IL-6 can also induce gpl30 and IL-6R complex
formation (Li et al., 2001b). However the vIL-6 is different from the cellular IL-6 in
that it can signal through the gpl30 subunit alone while the cellular IL-6 needs both
gpl30 and IL-6R complex for effective signalling. KSHV vIL-6 has been classified
as a class II gene which is seen in BC-1 cells, but can be induced to higher levels on
TPA treatment (Moore et al., 1996a). Comparative studies on the expression of vIL-6
in KS and multicentric Castleman's disease (MCD) have shown that vIL-6 can be
found co-localised mainly in the nucleus of lymphoid cells in MCD tissues and also
at very low frequencies in the spindle cells of KS. It is believed that vIL-6 can be
expressed in latently infected cells even in the absence of replicative cycle (Brousset
et al., 2001). There is evidence of vIL-6 in the sera of both classical KS patients as
well as KS positive HIV+ patients. Higher levels of serum IL-6 were detected in
HIV+ patients even in the absence of malignancies such as KS, PEL or MCD. It is
believed this is due to increased replicating virus in an immune deficient
environment (Aoki et al., 2001).
KSHV gene ORFK4, K4.1 and K6 code for proteins that have homology to the
chemokine macrophage inflammatory protein (MIP) family of proteins and are
named the vMIP-II, vMIP-III and vMIP-I respectively (Moore et al., 1996a; Russo et
al., 1996; Nicholas et al., 1997b). ORFK4 and ORFK6 code for CC chemokines.
They are expressed at low levels in BCBL cells and can be induced with TPA
treatment. HIV requires attachment to chemokine receptors along with CD4 for
cellular entry and therefore CC and CXC chemokines can block chemokine
coreceptors and prevent virus entry. Synthetic peptides derived from vMIP-II
(Klendal et al., 1997, Boshoff et al., 1997) and vMIP-I sequences (Boshoff et al.,
1997) showed the KSHV chemokines to have significant HIV inhibitory activity.
Viral MIP-II acts as an antagonist by binding to members of the G-protein coupled-
receptor (GPCR) CCR3, CCR5 and CXCR4 families (Klendal et al., 1997). KSHV
vMIP-II also acts as an agonist and signals through CCR3 leading to eosinophil
chemotaxis (Boshoff et al., 1997). KSHV vMIP-II has amino acid sequence
homology of 37-43% to other cellular CCR3 agonists such as Eotaxin-1, RANTES
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and MCP-3, but it exhibits distinct topology that is unique to vMIP-II particularly in
the presumed receptor binding site (Moore et al., 1996a, Fernandez et al., 2000).
Although these genes were originally pirated from cellular genes they have evolved
over time to help the virus and give it a growth advantage over the host. For
example, vMIP-I and vMIP-II induce new blood vessel formation or angiogenesis in
the chick chorioallantoic membrane. This angiogenic activity may play an important
role in KSHV derived tumours (Boshoff et al., 1997).
KSHV ORFK9 encodes a protein homologous to interferon regulatory factor (vIRF-
1) (Russo et al., 1996). Viral IRF is expressed in moderate amounts similar to IL-6 in
BC-1 cell lines even before treatment with TPA (Sarid et al., 1998). ORFK9
expression inhibits interferon (IFN)-a and IFN-y signalling although no direct
binding of vIRF-1 to the DNA binding domains of IFN genes has been detected
(Zimring et al., 1998). KSHV vIRF-1 when cotransfected with cellular IRF was
found to inhibit the transcription activation of cellular IRF. These in vitro assays
suggest an important role for vIRF in immune evasion and immune regulation in
vivo. KSHV genome analysis has shown that it can encode four proteins of IRF
family. Other than vIRF-1, two more IRF molecules vIRF-2 and vIRF-3, have been
cloned and characterised. Viral IRF-3 was found to down-regulate the synthesis of
interferon by inhibiting the activity of cellular IRF-3 and IRF-7 (Lubyova and Pitha,
2000). Detailed characterisation of vIRF-2 has shown that it is a nuclear protein that
is constitutively expressed in PEL cell lines. Moreover, vIRF-2 is a class I protein
that is expressed along with LANA and vCYC during latency. vIRF-2 interacts with
protein kinase (PKR) and inhibits the kinase activity of this protein on activation by
double stranded RNA (Burysek and Pitha, 2001). PKR down-regulates protein
synthesis by blocking eukaryotic translation initiation factor 2a (eIF-2a). Therefore
vIRF-2 inhibits interferon mediated surveillance by inhibiting PKR but it is not
known whether vIRF-1 and vIRF-2 act in a similar manner or are involved in the
inhibition of other pathways.
KSHV ORF74 encodes a viral G-protein coupled-receptor (vGPCR) (Cesarman et
al., 1996). The sequence is similar to the human IL-8 receptor (IL-8R) which is the
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receptor for CXC chemokines. NIH3T3 cells expressing vGPCR exhibited foci of
transformed cells. These cells cause tumours when transferred into nude mice (Bais
et al., 1998) indicating that vGPCR alone can lead to transformation of cells. The
vGPCR was able to induce constitutive stimulation of down-stream signalling
cascades involving JNK/SAPK and p38MAPK kinases. Signalling through this
receptor induces vascular endothelial growth factor (VEGF) that can induce
angiogenic phenotype in human umbical vein endothelial cells (HUVECs) (Bais et
al., 1998). Studies on Xenopus oocytes and mammalian cells have shown that
constitutively signalling through vGPCR results in depletion of calcium pools within
the cell which leads to heterologous desensitisation of responses mediated by other
GPCR receptors (Lupu-Meiri et al., 2001). KSHV vGPCR induced constitutive
stimulation may be a phenomenon used by the virus for protection from extracellular
regulatory factors and survive within cells.
1.5 Murine gammaherpesvirus-68
Murine gammaherpesvirus-68 (MHV-68) was originally isolated from
Clethrionomys glarolus (bank vole) in Slovakia (Blaskovic et al., 1980). Preliminary
analysis of the viral genome revealed homology to gammaherpesviruses (Efstathiou
et al., 1990a). The infection pattern in mice was similar to that seen in infectious
mononucleosis with EBV infection in humans. The observation that MHV-68
establishes infection in B cells that are harboured mainly in the spleen indicated its
biological similarity to EBV and other members of the B cell lymphotropic
gammaherpesvirus subgroup (Sunil-Chandra et al., 1992b). The genome organisation
of MHV-68 as compared to EBV and KSHV is represented in Figure 1.1.
A common feature of gammaherpesvirus infection is the development of
lymphoproliferative disorders, such as lymphomas that are seen in humans infected
with EBV and KSHV. MHV-68 has been linked to lymphoma induction in mice. 18-
24 months after infection 10% of the infected mice developed lymphoproliferative
disease, and 50% of these had high-grade lymphomas (Sunil-Chandra et al., 1994).
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gammaherpesviruses. The model is also considered an ideal system for studying the
interaction between gammaherpesviruses and the CD4+ and CD8+ T-cell responses
in the host system (Doherty et al., 2001). MHV-68 pathogenesis in knockout models
offers a good experimental system for assessing the mechanisms underlying
compromised immune surveillance and for screening possible chemotherapy-,
cytokine-, or cell based protocols to limit gammaherpesvirus associated diseases.
1.5.1 MHV-68 genome
The MHV-68 genome has been sequenced (Virgin et al., 1997, Nash et al., 2001). It
consists of 118kb unique double-stranded DNA, flanked on either side by terminal
repeat region made up of variable number of 1.2kb repeat unit (Efstathiou et al.,
1990b). In addition to the terminal repeats the genome contains two internal repeats,
a 40bp repeat and a lOObp repeat. There are 80 predicted ORF. Of these ORFs there
are blocks of genes that are similar among other gammaherpesviruses including
HVS, EBV and KSHV. There is a gene block unique to MHV-68 (Ml- M4) located
at the left-hand end of the genome interspersed with tRNA like sequences (vtRNA).
The role of the putative vtRNAs is unknown and it is believed that they do not
function as tRNAs since five out of eight sequences lack clear anticodons. These
vtRNA sequences are expressed both in lytic and latent MHV-68 infected cells. This
has proved to be a very useful tool in the detection of virus infected cells using RNA
in situ hybridisation techniques (Bowden et al., 1997).
In the last couple of years, some of the unique M genes in the MHV-68 genome have
been characterised in vitro. The Ml gene sequence shows some limited homology to
poxvirus serpins, although Ml lacks the active site (Bowden et al., 1997). The Ml
gene is found to be most homologous to M3 gene of MHV-68. The characterisation
of a mutant MHV-68 lacking four tRNA sequences and the Ml gene showed that
these genes were dispensable for lytic replication in vitro. Mice infected with this
virus showed that these genes did not affect the establishment of latency in vivo
(Simas et al., 1998). More recently with the help of a Ml gene knockout virus this
result was confirmed (Clambey et al., 2000). The mice were infected
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intraperitoneally and they carried peritoneal exudate cells (PECs) that harboured
latent virus that reactivated with greater efficiency than in the case of wild type
MHV-68 infection. It was not established whether the Ml gene and/or a closely
linked gene or genes brought this about.
The M2 gene has been identified as a latency-associated gene although with
unknown function (Husain et al., 1999). Husain et al showed that M2 epitope
specific CD8+ T cells could be isolated from infected mice and that a CTL line
specific to this epitope can kill Sll cells (MHV-68, latently infected B cell tumour
cell line). The M3 gene is found expressed during both lytic and latent stages of the
virus infection. It was found to be an abundantly secreted protein (van Berkel et al.,
1999). It was subsequently shown to have the capacity to bind to most classes of
chemokines, CC-, CXC, C- and CX3C (van Berkel et al., 2000 and Parry et al.,
2000). M4 is also characterised as a secreted protein (Wan, unpublished data) and
appears early during lytic cycle. Knockout viruses lacking M2, M3 and M4 are being
constructed in different laboratories to identify their role in pathogenesis and in
immune evasion strategies in vivo.
MHV-68 genome encodes homologues of cellular genes such as complement
regulatory protein, D-type cyclin, bcl-2 and IL-8 receptor. MHV-68 ORF4 has
significant homology to multiple complement regulatory proteins. There are four
regions within ORF4, which bear homology to complement regulatory proteins,
particularly murine decay accelerating factor (DAF) and human membrane cofactor
protein (MCP). Both DAF and MCP regulate C3 convertase. This suggests a
potential role for ORF4 of MHV-68 in regulating C3 convertase, possibly by
inhibiting C3 mediated lysis or chemotactic effects of C3a (Virgin et al., 1997).
ORF72 of MHV-68 encodes a D-type cyclin. This gene is found expressed during
lytic cycle. The generation of MHV-68 v-cyclin transgenic mice expressing v-cyclin
under control of the lck promoter which is expressed early in T cell development was
used to examine the role of this gene on primary T cells (van Dyk et al., 1999). The
T cells showed increased proliferation indicating that MHV-68 v-cyclin promotes
cell cycle progression and the transgenic mice developed high grade lymphoblastic
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lymphomas indicating that this gene was also oncogenic. ORFM11 has a weak
homology to bcl-2 family members and encodes a protein with 24% identity to EBV
BHRF1 gene product. The latter has been shown to inhibit apoptosis in several
systems (Henderson et al., 1993). Similarly, the KSHV bcl-2 homologue inhibits
apoptosis (Cheng et al., 1997). The MHV-68 bcl-2 is expressed during lytic as well
as latent infection in vivo. Cells expressing vbcl-2 have shown that the expression of
this gene can inhibit apoptosis induced by tumour necrosis factor (TNF)-a and
Fas/FasL pathways (Wang et al., 1999, Roy et al., 2000). MHV-68 ORF74 is
homologous to genes encoding G-protein coupled receptors (GPCRs) in particular to
IL-8 receptor. The MHV-68 GPCR is found expressed in vivo during lytic and latent
infection (Wakeling et al., 2001). In vitro expression of the MHV-68 GPCR leads to
transformation and therefore it is thought to be an oncogenic gene.
1.5.2 Infection, pathogenesis and susceptible cell types
To mimic the likely natural route of infection, mice were infected with 4 x 105
plaque forming units (PFU) MHV-68 intranasally. The virus infects alveolar
epithelial cells and causes interstitial pneumonia of the lungs leading to an
infiltration of mononuclear cells. The virus at this stage is predominantly lytic. The
lytic infection in the lungs is cleared by day 10 post-infection (Sunil-Chandra et al.,
1992a). The virus is found latent in alveolar epithelial cells and when uninfected B
cells are adoptively transferred into a previously infected pMT (B cell deficient)
mouse, the latent virus in the lungs was shown to be capable of infecting these cells
which could then be detected in the spleen (Stewart et al., 1998). This indicated that
the lungs could be an active reservoir for infecting new cells during the lifetime of a
host.
The clearance of the lytic infection from the lungs, mainly mediated by CD8+ T
cells, is followed by latent infection of cells in the lymphoid tissue in particular the
spleen (Ehtisham et al., 1993, Sunil-Chandra et al., 1992a). The cells predominantly
containing latent virus are the B cells and peak levels of those are seen two weeks
post-infection. The spleens at this stage exhibit splenomegaly and the lymph nodes
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that drain the lungs such as the mediastinal lymph node (MLN) and some
neighbouring lymph nodes harbour latently infected cells and exhibit
lymphadenopathy (Sunil-Chandra et al., 1992a, Sarawar et al., 1996). The number of
latently infected cells decreased by four weeks post-infection but a constant low level
was maintained for the lifetime of the host. Latently infected cells were also found in
low frequency in the bone marrow (Cardin et al., 1996).
Mice infected intraperitoneal^ with MHV-68 showed for the first time that
macrophages expressing F4/80 marker among the peritoneal exudate cells (PECs)
carried latent virus (Week et al., 1999b). This was later seen with mice infected
intranasally (Week et al., 1999a). Dendritic cells expressing the CD1 lc marker have
also been reported to harbour latent virus (Flano et al., 2000). However the data are
restricted to spleens removed from mice on day 14 post-infection. The dendritic cell
population sorted from the spleen on day 14 exhibited a higher frequency of latently
infected cells than B cells or macrophages. However experiments showed that these
latently infected dendritic cells could not activate T cell hybridomas specific to
MHV-68 in vitro whereas the latently infected B cells could activate T cells (Flano et
al., 2000). All three known professional APC can be infected by MHV-68, which
may provide information on how the virus escapes immune surveillance
mechanisms.
1.6 Immune response to viruses
1.6.1 Cells
The defence mechanism in higher order vertebrates is comprised of innate and
adaptive immune responses. Innate immune response is the initial response to a
foreign antigen and is non-specifically aimed towards molecular structures or
"patterns". These patterns are recognised by the pattern recognition receptors (PRRs)
on the surface of cells that mediate these responses against "pathogen associated
molecular patterns" (PAMPs). On the other hand adaptive immune response is
specific to a particular foreign antigen and exhibits long lasting recognition or
memory (Medzhitov and Janeway, 1998).
CHAPTER 1 INTRODUCTION 20
The cellular mediators of the innate immune response are mainly macrophages and
natural killer (NK) cells and these responses localise to the specific region that is
affected. This is followed by specialised cells involved in adaptive immune response
such as the T and B lymphocytes. These cells undergo clonal selection on
recognition of antigens on the surface of APC such as the dendritic cells and
macrophages. These events occur in specialised regions of the immune system called
the lymphoid organs.
1.6.1.1 Natural killer cells
Natural killer (NK) cells are large lymphoid cells with prominent intracellular
granules. NK cells form a small fraction of the peripheral blood lymphoid cells. They
are mainly involved in early defence against pathogens and play a prominent role
especially against herpesviruses. In vitro NK cell activity is enhanced by exposing
them to interferon (IFN)-a, p and IL-12 (Biron, 1998). Infection is controlled by the
production of IFN-y and TNF-a. The specific ligands that NK cells recognise are not
known, hence it is proposed that NK cells differentiate between normal host cells and
infected cells by the recognition of "altered-self'. They possess two types of surface
receptors. One type is the calcium-binding C-type lectins that can trigger killing on
recognition of an altered cell. The second type is the one that can inhibit activation
and prevent killing of host cells. These are multigene family of C-type lectins called
Ly49 in mice and KIR (killer inhibitory receptors) in humans. These receptors are
specific for major histocompatabilty complex (MHC) class I alleles and therefore
selectively kill target cells bearing low levels of MHC class I or altered MHC
(Brutkiewicz and Welsh, 1995, Karre and Welsh, 1997). They also recognise
changes in cell surface glycoproteins induced by viruses.
NK cell deficient individuals show sensitivity to severe dissemination of HSV, EBV
and HCMV. A severe herpesvirus infection has been observed in an adolescent
human deficient in NK cells. Elevated NK cell activity is also observed during
murine cytomegalovirus (MCMV) and lymphocytic choriomeningitis virus (LCMV)
infections and these infections in mice have helped study some of the in vivo NK cell
responses (Welsh et al., 1991, Salazar-Mather et al, 1996). MCMV infected livers
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produce high levels of MlP-la that induces NK cell recruitment and focal
inflammation in the tissue. These elevated numbers of NK cells recruited into the
region were shown to be important in controlling the infection (Salazar-Mather et al.,
1998). Systemic IFN-a/p that is produced following most viral infections has been
shown to induce NK cell trafficking from bone marrow to secondary sites such as
spleen (Salazar-Mather et al., 1996). NK cell mediated immune responses can be
mediated by production of cytokines such as IFN-y and TNF-a, that can activate
macrophages. IFN-a/p and interferon inducers have been found to be potent at
stimulating NK cell mediated cytotoxicity (Gidlund et al, 1978). Cytotoxic attack by
NK cells is similar to cytotoxic T lymphocytes (CTL) and is mediated through
perforin/granzyme.
NK cells can also play a role during humoral immunity by recognising antibody
coated target cells. The surface receptor CD 16 recognises the Fc (fragment
crystallisable) region of IgGl and IgG3 antibodies and mediates what is called
antibody dependent cell-mediated cytotoxicity (ADCC) (Nash and Usherwood,
1998).
1.6.1.2 Macrophages
Macrophages are derived from circulating monocytes as they leave the circulation
and move into tissues. They are found in large numbers in the gastrointestinal tract,
lung, liver (Kuppfer cells) and spleen. Macrophages can engulf opsonised particles
coated with antibodies or complement and pathogens directly. Pathogens crossing the
epithelial barrier encounter phagocytes that can engulf and destroy them directly, or
secrete cytokines that can lead to non-adaptive responses from other cells.
Macrophages can also act as professional antigen-presenting cells by processing
antigens along with co-stimulatory molecules triggering an adaptive immune
response (Nash and Usherwood, 1998). CD4+ T cells involved in the adaptive
immune response can recruit macrophages e.g. HSV (Nash and Cambouropoulos,
1993). This leads to macrophage activation and involves two signals, IFN-y and the
second provided by a variety of other means for example CD40 ligand. These
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activated macrophages can produce proteins involved in anti-viral activity such as
IFN-a/p, TNF-a and arginase.
T and B cell independent macrophage activation seems to play a critical role in the
innate immune response to herpesviruses such as MCMV infection in SCID mice.
Macrophage activation and recruitment is induced by IFN-y and TNF-a and
depletion of these cytokines gave rise to increased virus titres in peripheral organs
(Heise and Virgin, 1995). Macrophages produce an enzyme called inducible nitric
oxide synthase (iNOS) which synthesises nitric oxide (NO) and is involved in the
inhibiting replication of certain viruses for example, vaccinia virus (Harris et al,
1995).
1.6.1.3 Complement and collectins
Collectins are soluble proteins found in serum, lung and nasal secretions and they
can act as a first line of defence against infectious agents. They include mannose-
binding protein (MBP), conglutinin and lung surfactant proteins A and D. In vitro
and in vivo experiments with Influenza A virus infection strongly support an
important role for surfactant collectins in the initial containment of this virus in the
airway. This is thought to be brought about by direct inhibition of viral infectivity,
agglutination of viral particles and/or the promotion of viral uptake by phagocytic
cells (Eggleton and Reid, 1999, Crouch et al., 2000). Surfactant protein-A (SP-A)
has been shown to promote the uptake of HSV by alveolar macrophages. Work on
SP-A deficient mice showed increased susceptibility to respiratory syncytial virus.
Complement proteins can directly target viruses or virus infected cells and they can
also function in association with antibodies (Lambris et al., 1999) Activation of
complement leads to generation of highly potent proinflammatory mediators C3a and
C5a. These are peptide fragments cleaved from C3 and C5 that are commonly called
anaphylatoxins. Both C3a and C5a can bind to specific G-protein coupled receptors
on the surface of phagocytic cells and cause their migration and activation. They can
also attract neutrophils and eosinophils (Song et al., 2000). The fact that several
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herpesviruses and poxviruses carry homologues of complement regulatory proteins,
suggests that complement is important in defence against these viruses.
1.6.1.4 Dendritic cells
Dendritic cells (DC) are the most specialised among the professional antigen-
presenting cells. They are found traversing most non-lymphoid tissues especially the
mucosal tissues and skin. The Langerhans cells in the skin and the pulmonary
dendritic cells in the lungs are in an immature state and have the capacity to sample
the environment through a process called macropinocytosis. Immature dendritic cells
can also capture antigens and microbes by phagocytosis and also by receptor
mediated antigen uptake. Once these processes are initiated these dendritic cells
migrate into lymph nodes and undergo differentiation. The maturing cells stop
phagocytosis and start processing antigens for presentation on MHC class II
molecules on the surface of cells along with other co-stimulatory molecules
(Steinman, 1991, Banchereau and Steinman, 1998). The mature dendritic cells can
stimulate quiescent, naive and memory B and T lymphocytes. They are unique in that
they are the only cells that can stimulate nai've T cells. Mature DCs produce large
amounts of IL-12 that can enhance innate immunity through NK cells and also
adaptive immunity through B and T cells (Lane and Brocker, 1999). It has also been
shown that dendritic cells can also present exogenous antigens on MHC class I by
their ability to engulf apoptotic cells and present them for CD8+ T cell activation
(Albert et al., 1998).
In the secondary lymphoid organs of mice, three major subpopulations of DCs have
been described: CD8a+ lymphoid DCs, CD8a- myeloid DCs and Langerhans cell
(LC) derived DCs. LC-derived DCs in the lymph node have the phenotype CD1 lc +
CDllb+ DEC205+ CD8+/-. Both the lymphoid and myeloid subsets express high
levels of CD 11c and MHC class II and significant levels of CD86 and CD40, but
differ in the expression of several other markers (Steinman, 1991, Pulendran et al.,
2001). Plasmocytoid cells from the human blood expressing CD4+ and MHC class I
have been identified as precursors of type 2 dendritic cells (pDC2s). These cells
constitutively express type 1 interferon and have been shown to be the major
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interferon producing cells (IPCs) in the blood (Siegal et al., 1999). They are believed
to play an important role in fighting viruses by migrating to virus infected cells and
tissues.
1.6.1.5 T cells
T cells form a major subset of effector cells of the adaptive immune response. They
are derived from bone marrow stem cells but undergo selection and differentiation in
the thymus. Mature T cells are then seen in the T cell areas of the lymphoid tissues as
well as in circulation. There are two main types of T cells: CD4+ T-helper cells and
the CD8+ cytotoxic T lymphocytes (CTL). Both these subsets recognise antigens
presented on MHC molecules on the cell surface. They require a 'second signal'
from a co-stimulatory molecule to become activated.
The CD4+ T helper cells recognise antigens loaded on MHC class II molecules on
the cell surface of specialised APC such as dendritic cells, macrophages or B cells
(Jenkins et al., 2001). In this case free pathogen or target cells infected with the
pathogen are phagocytosed by APC, processed in the cytoplasmic compartment into
peptides of 20 amino acids or longer, and loaded on to MHC class II molecules and
transported to the surface (Miller and Sedmak, 1999). T helper cells recognise this
with the help of their T cell receptor (TCR) complex. A viable second signal from
molecules such as B7, CD40, OX40 or 4IBB is mandatory for the successful
activation of the cell (Whitmire and Ahmed, 2000). These T cells in turn can
stimulate the humoral response by signalling B cells through CD40/CD40L and/or
activate macrophages by the production of cytokines such as IFN-y and TNF-a. T
helper cells have been classified into two main subsets depending on their response.
Thl type response is dominated by the production of IFN-y and associated with cell-
mediated immunity and Th2 type response is characterised by the production of IL-4
and IL-5 and is associated with humoral immunity. In the case of viral infections this
distinction of T helper cell subsets is not as well defined as in other microbial or
parasitic infections.
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CD8+ T cells recognise antigens loaded on MHC class I molecules on the surface of
host cells infected with a pathogen. In this case the foreign proteins synthesised in
the cytoplasm are broken down into peptides of 8-10 amino acids and transported to
the surface on MHC class I molecules (Ehrlich, 1997). The activation of CD8+ T
cells can be CD4+ T cell dependent in which case the APC bound through the
CD40L/CD40 on CD4+ T cell acts as a bridge and activates the CD8+ T cell.
However, in many viral infections a CD8+ T cell response can be brought about in
the absence of CD4+ T cells. This has led to the conclusion that CD8+ T cells use
different co-stimulatory signals from those of the CD4 + T cells (Whitmire and
Ahmed, 2000). CD8+ T cells, also called cytotoxic T lymphocytes (CTL), destroy
infected cells with the help of perforins/granzymes or Fas/FasL signalling (Trapani et
al., 1999). They can also control microbial infection through the production of TNF-
a and IFN-y (Slifka and Whitton, 2000).
Following a viral infection both CD4+ T cells and CD8+ T cells undergo an
activation/expansion phase in which the naive cells proliferate and differentiate into
effector cells. This is dealt with in detail in the section on immune response to MHV-
68. This initial phase is followed by a death phase in which cells undergo apoptosis
and cells with the highest overall antigen affinity survive giving rise to a memory
pool. The memory cell repertoire comes into action during a subsequent infection
(Freitas and Rocha, 1999).
1.6.1.6 B cells
B cells are the major players in the humoral immunity against pathogens. The mature
B cells in the periphery can be subdivided broadly into two groups depending on
surface phenotype. These are CD5+ B cells and CD5- B cells which are referred to as
B-l versus B-2 B cells, respectively. The B1 cells mainly develop at the foetal stage
in the liver while the B2 cells develop in the bone marrow in the adult (Hardy and
Hayakawa, 2001). The CD5+ B cells produce natural antibodies mainly of the IgM
class. The natural antibodies produced by these cells were shown to play an
important role during Vesicular stomatitis virus (VSV) and FCMV infections, by
preventing the dissemination of virus to peripheral organs such as the kidney and
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brain while trapping the antigens in secondary lymphoid organs (Ochsenbein et al.,
1999). The B-2 B cells are the major subset of B cells found in adults and they
undergo their initial development in the bone marrow (BM) and the rest in the
periphery. Unlike T cells that leave the thymus only as mature T cells, the B cells
leave the BM as transitional B cells. At this stage the B cells have undergone germ-
line rearrangements coding for the heavy chain and the light chains of the
immunoglobulin receptor and express surface IgMhlgh/IgDlow. The next stage of
development depends on antigen recognition that drives somatic mutations followed
by class switching and antibody production (Benschop and Cambier, 1999). The
second level of maturation takes place mainly in the T cell rich regions of the spleen
and secondary lymphoid tissues called the germinal centres (GC). Germinal centres
are highly specialised microenvironments where the B cells undergo massive
proliferation and selection. The B cells selected in the GC express antigen specific B
cell receptors (BCR) and re-enter the GC cycle or leave the GC cycle and enter the
memory compartment. The cells that leave the GC are of two kinds, antibody
secreting plasma cells or the non-secreting memory cells (McHeyzer-Williams and
Ahmed, 1999). The antibody secreting plasma cells are long lived and can secrete
antibody long after the antigen is cleared and are seen to migrate and localise in the
bone marrow. The non-secreting memory cells on the other hand undergo GC cycle
on secondary exposure to the antigen and it is many fold higher than the primary
antibody produced.
Viral infections trigger the humoral arm of the adaptive immune system and the
antibodies produced are able to clear the infection on their own, for example in VSV
infection. In other cases they act in combination with virus specific CTL. It is seen
that during primary VSV infection the B cell activation and maturation can also be
brought about in the absence of T cells (Szomolanyi-Tsuda and Welsh, 1998). It is
believed under these conditions B cells are stimulated by repetitive antigen
sequences present on the virus surface and control infection by secreting IgM
neutralising antibodies. Influenza virus needs T cell help for the activation and
maturation of B cells and this is brought about by the CD40L-CD40 interactions
(Bachmann and Zinkernagel, 1997). Antibodies are able to restrict viral infections by
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binding to them and blocking entry into host cells through their cellular receptors. A
second way of blocking is by changing the conformation of the coat proteins of the
virus (Bachmann and Kopf, 1999).
1.6.2 Chemokines
Chemokines are a superfamily of small 8-10kDa proteins. They are pro¬
inflammatory and are involved in leukocyte trafficking. They play a crucial role in
immune reactions and in viral infections (Mantovani, 1999). Chemokines can also
affect angiogenesis and proliferation of haematopoietic precursors. Four main
subsets have been identified depending on the arrangement of cysteine residues and
designated CXC, CC, C and CX3C. They function as signalling molecules by
interacting with different G-protein coupled receptors on the surface of leukocytes.
Some of the chemokine receptors identified so far are CCR1, CXCR1 and CX3CR1.
The chemokines and chemokine receptors exhibit redundancy where a single
chemokine can bind to different receptors and vice versa (Mantovani, 1999). The
CXC chemokines are active on polymorphonulear neutrophils (PMNs), T and B
cells. The CC chemokines do not act on PMNs but act on a wide range of other cells
such as monocytes, eosinophils, T cells, dendritic cells and NK cells. The main
function of chemokines is chemotaxis of leukocytes. Monocytes respond to the
widest array of chemokines, for example, macrophage inflammatory proteins (MIP),
monocyte-chemotactic protein (MCP), RANTES, fractalkine and others.
In the past couple of years the mechanisms by which chemokines recruit
lymphocytes from the blood into tissues by arresting them through an integrin-
dependent adhesion mechanism have been identified (Campbell et al., 1998).
Chemokine based mechanisms involving tissue homing of leukocytes too have
rendered very useful insights into the function of chemokines (Campbell and
Butcher, 2000). Studies on viral pathogenesis have also been instrumental in
furthering our knowledge of chemokines and their importance in normal immune
responses.
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1.6.3 Cytokines
Cytokines are secreted proteins that serve a critical role as regulators of immune and
inflammatory responses. IFN-a and IFN-P also called the type I interferons are
potent cytokines involved in anti-viral defence (Biron, 1998, Bogdan, 2000). They
are produced by most cells and are encoded by one IFN-P and several IFN-a genes.
Only a single IFN-a/p receptor has been identified so far. Increased levels of IFN-
a/p are seen during viral infection for example LCMV and MCMV. They play a
major role in the innate response to viruses and were initially identified as molecules
that restrict viral replication. One of the ways this cytokine family is stimulated is by
the presence of double stranded RNA (dsRNA). This activates RNAseL via 2'-5'
oligoadenylate synthetase and dsRNA dependent protein kinase R (PKR) to degrade
RNA and inhibit translation initiation respectively, thereby restricting the protein
synthesis in the host cell. A second route for some viruses is production of virus-
activated factor (VAF), containing interferon regulatory factors such as IRF-3 and
IRF-7. They bind to the IFN-P promoter and lead to transcription activation (Biron,
1999). IFN-a/p produced following MCMV and LCMV infections have been shown
to be involved in bone marrow derived NK cell trafficking into the splenic sub-
compartments and the production of IFN-y during immune response to these viruses
(Salazar- Mather et al, 1996). IFN-a/p can also modulate the adaptive immune
response. IFN-a/p produced during viral infections has been shown to help CTL
response, by mediating the survival of pre-existing memory cells and in augmenting
primary immune response by acting as an adjuvant (Tough et al, 1996).
The other cytokines involved in direct anti-viral responses are TNF-a, IL-1, IL-6, IL-
12 and IL-18 (Biron, 1998). TNF-a, IL-1, IL-12 and IL-6 pro-inflammatory
cytokines overlap in function with IFN-a/p although IL-12 is seen in some viral
disease as negatively regulated by IFN-a/p. Murine models of HSV infection have
been useful in demonstrating the anti-viral effects of cytokines such as IL-12 and IL-
18 (Carr et al., 1997, Fujioka et al., 1999).
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1.7 Immune response to EBV
Host immune responses are of great importance in limiting the primary infection and
in controlling the life-long virus carrier state. Primary and persistent phases of
infection are associated with the appearance of different combinations of antibodies
specific to lytic and latent antigens (Rickinson and Kieff, 1996). Of these, antibodies
to the envelope glycoprotein gp350 are of importance due to their capacity to
neutralise viral infectivity (Thorley-Lawson and Geilinger, 1980), and to mediate
antibody dependent cellular cytotoxicity against cells in the late phase of virus
replication. The frequency with which EBV-positive lymphoproliferative disease and
clinically apparent virus replication lesions are seen in T cell immunocompromised
patients strongly suggests an important role for the cell mediated immune response in
the context of EBV. There are a few other non-specific immune mechanisms that
have been identified that can delay or prevent virus-induced transformation of B cells
in vitro such as cytokines from T or NK like cells (Rickinson and Kieff, 1996). The
most effective mechanism that leads to regression of B cell transformation is
mediated by virus-specific cytotoxic T lymphocytes as seen from in vitro cultures.
1.7.1 Antibody response
The immune response to primary EBV infection in humans has been mainly worked
out from IM patients. The antibody response to this virus is usually measured using
an immunofluorescence assay. It measures antibody response to the following:
ANTIGEN VIRAL PROTEINS INFECTIVE PHASE
EB nuclear antigen (EBNA) EBNA 1,2, 3A, 3B, 3C & LP Expressed within latently
infected cells
Early antigen (EA) BZLFl(I.E), BALF2, BHRF1,
BMRF1 &BSMLF1
Expressed within cells early in
lytic cycle
Virus capsid antigen (VCA) Virus encoded nucleocapsid &
envelope proteins(gpl 10,gp350)
Expressed within cells late in
lytic cycle
Membrane antigen (MA) Gp 350 Expressed on the surface of
cells late in lytic cycle
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At the onset of clinical symptoms most IM patients secrete IgM antibodies to VCA
and rising IgG titres to both VCA and EA (Henle et al., 1987). A transient IgA
response to these antigens is also detected (Sixbey and Yao, 1992). IgM anti-VCA
disappears over the next couple of months whereas IgG anti-VCA titres rise to a peak
and then fall slightly in the next couple of months and reach a stable steady state. IgG
anti-EA levels fall faster than anti-VCA IgG levels and are almost undetectable or at
very low levels. Neutralising antibodies against MA antigen gp350 (Thorley-Lawson
and Geilinger, 1980) are at low titres during IM but slowly rise and reach a stable
level. The anti-EBNA antibodies against latent proteins in acute IM patients are
mainly IgG against EBNA-2 protein whereas the response to EBNA-1 is seen mostly
during convalescence (Henle et al., 1987). In addition to EBV specific antibodies
there are increased levels of total serum IgM, IgG and IgA which are thought to be
caused by the polyclonal activation of B cells that EBV infection initiates. There is
also a transient appearance of heterophile antibodies with the capacity to agglutinate
sheep and horse erythrocytes, which are used as a diagnostic test for classic EBV-
associated IM.
There is a strong antibody response to lytic cycle antigens in IM patients but the
importance of these antibodies in the overall control of primary infection is uncertain
(Rickinson and Kieff, 1996). The polymeric IgA anti-gp350 is thought to facilitate
the transfer of virus through epithelial compartments (Sixbey and Yao, 1992). The
IgG response to gp350 may help in antibody-dependent cellular cytotoxicity
(Thorley-Lawson and Geilinger, 1980) but this IgG is not found during acute IM.
Antibodies to VCA, gp350 and EBNA-1 are seen in healthy virus carriers. However
it is doubtful that any of the antibodies raised against lytic cycle antigens play a role
in control of persistent infection. The virus is mainly found latent and is almost
unrecognisable to the immune system. It is only when some of these cells reactivate
and undergo lytic cycle that antibody-dependent cellular cytotoxicity (ADCC) may
have a role to play (Rickinson and Kieff, 1996).
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1.7.2 CTL response
Svedmyr and Jondal (1975) were the first to show the presence of effector cells
specific to EBV from the peripheral blood of patients with IM. Analysis ex vivo
indicated that these cells could mainly be T cells specific for EBV genome carrying
B cells. However the role of cell mediated immunity in limiting primary EBV
infection had come into focus (Rickinson and Moss, 1997).
Acute IM is characterised by lymphocytosis involving CD4+ and CD8+ T cells. It
was thought that CD8+ T cells underwent polyclonal expansion and that
superantigen or non-specific activation drove this expansion. Experiments using
antibodies against TCR variable beta chain-specific monoclonal antibodies in
combination with polymerase chain reaction (PCR) to their Vp transcripts
demonstrated the presence of a large monoclonal or oligoclonal rather than
polyclonal population of CD8+ T cells, which was driven by antigen specific
activation (Callan et al., 1996). The results showed that few dominant clones of
CD8+ T cells expanded and indicated that they might be the ones playing an
important role during initial infection. These clones were also seen to disappear as
the patients recovered from IM.
The CD8+ CTL in IM patients are mainly targeted towards the latent antigens EBNA
3A, 3B and 3C (Steven et al., 1996). However CTL responses to multiple lytic
antigens also can be detected against immediate early proteins BZLF1 and BRLF1
and to three out of six early proteins BMLF1, BMRF1 and BALF2 (Steven et al.,
1997). The use of advanced techniques such as tetrameric major histocompatibility
complex-peptide complexes to directly visualise antigen-specific clusters of CD8+ T
cells has helped identify massive expansions of activated, antigen-specific T cells in
IM patients (Callan et al., 1998). One patient showed as high as 44% CD8+ T cells
in the peripheral blood specific for a single epitope. The antigen specific cells had
activated/memory phenotype CD45RO, HLA-DR, CD38 positive and low levels of
CD45RA and CD62 leukocyte (CD62L). After recovery from IM, the frequency fell
but could still be detected 3 years after infection.
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The persistent viral infection is primarily controlled by CD8+ CTL (Rickinson and
Moss, 1997). The CTL show specificity to all viral encoded latent proteins except
EBNA1 (Murray et al., 1992; Levitskaya et al., 1995). In vitro reactivation studies
using autologous LCL showed the bulk of the effector population to be CD8+ CTL
(Wallace et al., 1982). Assays to determine the antigenic specificity showed a
marked skewing of responses towards the EBNA 3A, 3B, 3C subset of antigens
(Murray et al., 1992). Subdominant responses recognising other latent proteins have
been detected, the most frequent target being LMP2, less frequently EBNA2, EBNA-
LP or LMP1 and very rarely EBNA1 (Khanna et al., 1992).
There appears to be a hierarchy of immunodominance among the EBV latent
antigens. Another striking finding is the extreme rarity of CD8+ CTL responses to
EBNA1. There is evidence that an internal glycine-alanine repeat (GAr) domain
protects the EBNA1 protein from the HLA class I pathway of antigen presentation
(Levitskaya et al., 1995). Inserting a known CTL epitope into the EBNA1 primary
sequence renders it not presentable to CD8+ CTL unless the GAr domain is deleted
in the chimeric protein; conversely, insertion of the GAr domain into the EBNA3B
sequence greatly induces its capacity to be presented. Significantly, all natural EBV
isolates do show conservation of this GAr domain even though this domain is not
required in its principal function, namely maintenance of the episomal viral genome
in latently infected cells. This may reflect the importance to the virus of rendering
nonimmunogenic the one viral protein whose expression is likely to be essential for
virus persistence. A second unusual feature of antigen processing in the EBV system
involves the subdominant antigen LMP2. Experiments in a transporter associated
with antigen processing (TAP) negative LCL background showed that while EBNA
3A, 3B or 3C proteins are not presented for CTL recognition, some CTL epitopes
within LMP2 are still presented (Khanna et al., 1996). This is an example of TAP-
independent processing of an endogenously expressed viral protein.
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1.8 Immune response to MHV-68
1.8.1 Innate immune response
Much of our insight into the immune response to MHV-68 comes from work done on
gene knockout mice. The importance of IFN-a/p in restricting MHV-68 infection
came from work on IFN-a/p R~" mice (Dutia et al., 1999a). These mice suffered
from severe lung infection followed by ten times increase in latently infected cells in
the spleen. The majority of mice succumbed to the infection and died. If mice were
infected with a lower virus titre of 4 x 103 instead of 4 x 105, 50% mice still died
within two weeks of infection. A similar effect was seen in IRF-1 deficient mice, an
important activator of IFN-a/p response. The published data representing the effect
of MHV-68 infection in IFN-a/p R"/_ mice is depicted in Figure 1.2. The results
indicate that in the absence of IFN-a/p response the viral replication leads to
increased virus load in the lungs and spleen.
Macrophages in the peritoneum and spleen harbour latent MHV-68 (Week et al.,
1999b, Flano et al., 2000). However there is no direct evidence of the role of
macrophages during innate immune response. The importance of macrophages and
nitric oxide is based on a study on inducible nitric oxide synthase (iNOS) gene
knockout mice in which all the mice died following MHV-68 infection (Kulkarni et
al., 1997). There is also a contradictory result where MHV-68 infected iNOS
knockout mice fully recovered from MHV-68 infection, but this may be due to the
genetic background of the mice (Dutia et al., 1999a). The cytokine profile following
MHV-68 infection shows that high levels of IL-6 and IFN-y are produced in the
mediastinal lymph node and cervical lymph node (Sarawar et al., 1996). The high
levels of IFN-y seen by day 10 post-infection are thought to be produced by
macrophages and NK cells activated during the early phase of MHV-68 infection.
1.8.2 Humoral response
MHV-68 specific antibodies were detected on days 12 and 28 post-infection in
normal C57BL/6 mice, CD8+ T cell deficient mice and in IFN-y deficient mice
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(Kulkarni et al., 1997). The neutralising antibodies to MHV-68 were low during the
first two weeks following infection and then increased over the subsequent 50-70
days post-infection (Stevenson and Doherty, 1998). It has also been shown that
following MHV-68 infection total serum IgG levels increase and remain high
(Stevenson and Doherty, 1998). This is different from the increased IgM levels that
are seen in the case of EBV infected IM patients. In the case of MHV-68 it was
shown that infection of B cells in vitro causes non-antigen specific activation of B
cells in the absence of CD4+ T cell stimulation and is marked by increased cell size,
increased CD69 activation marker and the production of IgM antibodies. However in
vivo CD4+ T cells are required for the production of anti-MHV-68 specific IgG and
neutralising antibodies (Stevenson and Doherty, 1999).
Experiments with pMT mice have shown that the initial clearance of the virus from
the lung following MHV-68 infection does not require antibodies (Figure 1.2)
(Usherwood et al., 1996b, Kulkarni et al., 1997). However subsequent experiments
that dealt with the control of MHV-68 infection in the long-term showed antibodies
to be important. Wild type C57BL/6 and pMT mice 54 days post-infection with
MHV-68 were subjected to depletion of CD8+ and CD4+ T cells. The C57BL/6 mice
exhibited only a minimal reactivation of virus in the lung while the pMT mice
showed very high titres of infective virus equivalent to levels found during acute
infection (Stewart et al., 1998). This demonstrated that antibodies do play an
important role in preventing reactivation of MHV-68 over time in infected hosts.
A recent study of the MHV-68 specific antibody response showed that this response
was similar to that caused by other viruses such as Sendai virus and Influenza virus,
with a general predominance of IgG2a and IgG2b isotypes (Sangster et al., 2000).
Antibody forming cells (AFC) specific to MHV-68 were detected in the MLN and
cervical lymph node (CLN) although delayed and of a smaller magnitude compared
to other respiratory viral infections like Influenza A virus. Non-specific AFC were
also detected in the lymph nodes and spleen and this was due to the non-specific
stimulation of B cells that were also undergoing germinal centre processes and
producing increased IgG2a and IgG2b antibodies. Substantial numbers of these non-
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specific AFCs were found over long-term and fascinatingly found localised in the
bone marrow. It is thought that these AFCs were involved in the increased levels of
IgG that was seen in the serum following MHV-68 infection (Sangster et al., 2000).
1.8.3 T cell response
1.8.3.1 CD4+ T helper cells
Depletion of CD4+ T cells in BALB/c mice prior to infection with MFIV-68 led to
only a slight delay in the clearance of lung infection compared to normal control
mice (Ehtisham et al., 1993). The main difference was observed during the initial
establishment of latency where the CD4+ T cell depleted mice failed to exhibit peak
levels of latently infected cells compared to the control mice (Usherwood et al.,
1996a). However over the long-term the CD4+ T cell depleted mice had the same
number of latently infected cells as the control mice. The characteristic
lymphoproliferation leading to splenomegaly was not observed in the depleted mice
(Ehtisham et al., 1993 and Usherwood et al., 1996a). Similarly, no splenomegaly
was observed in MHC class II deficient mice infected with MHV-68 (Figure 1.3)
(Cardin et al., 1996). On day 22 positive infective virus could be detected in the
lungs of the MHC class II deficient mice. Virus titres rose and the majority of mice
died due to a wasting disorder by day 120-133. Subsequently it was shown that the
CD8+ T cell response was intact in the MHC class II deficient mice and this was not
the reason for the reactivation of the virus in the lungs (Stevenson et al., 1998).
Hence, CD4+ T cells were shown to be important in long-term control of MHV-68
infection.
CD4+ T cells can mediate protection by secreting IFN-y therefore experiments
looking at the effect of IFN-y gene knockout and IFN-y R"/_ have been carried out.
The infection patterns on IFN-y gene knockout mice from a BALB/c background
have shown no significant difference in infection patterns following MHV-68
infection (Sarawar et al., 1997). The experiments with IFN-y R-/" have shown similar
results where clearance of infection from the lungs was not affected although it was
seen that the spleen exhibited fibrosis and the destruction of splenic architecture























Figure 1.2 MHV-68 infection in mice deficient in lymphocyte subsets and cell
surface molecules In each case three graphs are shown representing data: the far
left hand side graph for infectious virus in the lungs as measured by plaque assays,
the middle graph for latent virus in the spleen as measured by infective centre assay
and the far right hand side graph for total spleen cell number. Data from Ehtisham et
al., 1993, Dutia et al., 1999 and Usherwood et al., 1996a. Diagram adapted from
Stewart et al., 1999.
























Figure 1.3 MHV-68 infection in mice deficient in lymphocyte subsets and cell
surface molecules In each case three graphs are shown representing data: the far left
hand side graph for infectious virus in the lungs as measured by plaque assays, the
middle graph for latent virus in the spleen as measured by infective centre assay and the
far right hand side graph for total spleen cell number. Data from Ehtisham et al., 1993,
Cardin et al., 1996, Dutia et al., 1997 and Ebrahimi et al., 2001. Diagram adapted from
Stewart et al., 1999.
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(Dutia et al., 1997). The number of latently infected cells was 10-100 fold higher on
days 14 to 17 but reached normal levels by day 21 post-infection. This was paralleled
by the fall in the total number of lymphocytes in the spleen and splenic atrophy. This
trend is depicted in Figure 1.3. The experiments in environments devoid of normal
IFN-y signalling did not indicate any direct role played by IFN-y in mediating
immune clearance.
In order to show that CD4+ T cells are important for controlling MHV-68 infection
irrespective of their help to B cells or to CD8+ T cells subset, pMT mice depleted of
CD8+ T cells were infected with MHV-68 (Christensen et al., 1999). It was seen that
CD4+ T cells alone could control the levels of virus in the lungs. It was further
shown that this effect was mainly mediated by IFN-y secreted by CD4+ T cells. The
flow cytometric (FACS) analysis for activation markers (CD62Llow) expressed by
CD4+ T cells showed a high prevalence of activated T cells in the spleens from day
15 to 25 following infection with MHV-68 (Christensen and Doherty, 1999).
MHV-68 infected SI 1 cells when injected subcutaneously into nude mice gave rise
to tumours. This tumour growth regressed on adoptive transfer of restimulated
splenocytes depleted of CD8+ T cells and failed when CD4+ T cells or both CD4+
and CD8+ T cells were depleted. These results too showed that CD4+ T cells are
important effector cells during MHV-68 infection (Robertson et al., 2001).
1.8.3.2 CD8+ CTL
The initial experiments to determine the importance of CD8+ T cells in MHV-68
clearance were carried out in CD8+ T cell depleted BALB/c mice. These mice could
not clear the infection and they died of increased virus infection (Figure
1.3)(Ehtisham et al., 1993). However C57BL/6 mice depleted of CD8+ T cells did
not succumb to the disease (Stevenson et al., 1999c). The experiments using perforin
knockout mice to determine whether the CTL mediated killing was brought about by
perforin did not show any difference in clearance from wild type mice. The
conclusion at this point was that CTL killing was brought about by other means such
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as Fas/FasL stimulation or that the perforin knockout mice had some other
compensatory pathways functioning (Usherwood et al., 1997).
CTLs specific to different lytic MHV-68 viral genes have been identified (Stevenson
et al., 1999b). The most highly immunodominant of the peptides named p56 and p79
are encoded by ORF6 and ORF61, respectively. These are peptides obtained from
lytic gene transcripts. The ELISPOT method of identifying MHV-68 specific CTL
was substantiated with the help of techniques like IFN-y CTL assay and MHC-
tetramer methods. Peak CTL response is seen around 20-25 days post-infection in the
spleen where 5% CD8+ T cells were found to be specific for viral peptides p56 and
p79. This percentage fell to 1% in the next 80 to 150 days post-infection (Stevenson
et al., 1998).
Work on MHC class II deficient mice that lack CD4+ T helper cells has shown that
CTL responses can develop in the absence of CD4+ T cell help (Stevenson et al.,
1998). These mice seem to have increased percentages of CTL on day 80-150 post¬
infection but they suffered from reactivating virus in the lung over long periods of
time. Therefore, both CD8 and CD4 responses are required to control the long-term
infection with MHV-68.
1.9 Evasion of immune responses by herpesviruses
The main strategy employed by herpesviruses to evade host defences is latency.
However, these viruses have evolved a number of other methods to disrupt
recognition of infected cells during primary and recurrent infection. The approaches
can interfere with a diversity of innate and adaptive responses that includes
interfering with IFN responses and down-regulating MHC class I expression,
thwarting CTL recognition.
1.9.1 Modulation of antigen presentation
The viral clearance brought about by cytotoxic T lymphocytes (CTL) depends on
effective processing and presentation of viral antigens by the MHC class I molecules.
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The MHC class I molecule is composed of a heavy chain and a light chain (P-2
microglobulin). This unstable complex is attached to the endoplasmic reticulum
(ER). Cytosolic proteins that are ubiquitinylated are broken down by the proteasome
complex. Peptides entering the ER are transported to the MHC by the transporter
associated with antigen processing (TAP). The TAP associated peptide is then loaded
onto the MHC by tapasin. The stable final complex is formed when an 8-10 amino
acids residue is loaded onto the peptide groove. The final complex leaves the ER and
is transported to the cell surface through the secretory pathway involving the Golgi
(Ehrlich, 1997). Virus immune evasion mechanisms studied so far are just the tip of
the iceberg but already there are examples showing their ability to block every step
in the assembly and trafficking of MHC class I molecule (Ehrlich, 1997, Ploegh,
1998, Miller and Sedmak, 1999, Tortorella et al., 2000).
Herpes simplex virus (HSV) in vitro infection of human fibroblast renders cells
resistant to CTL killing. Within 3 hours of infection, MHC class I molecules with no
peptide loaded were found retained in the ER. This effect is due to HSV immediate-
early (IE) protein ICP47 (York et al., 1994). ICP47 is found in the cytoplasm and
does not seem to be membrane associated. Using co-precipitation assays it was
shown that ICP47 binds to the cytosolic region of TAP and prevents the translocation
of peptides into the ER (Hill et al., 1995, Fruh et al., 1995). It has subsequently been
demonstrated that ICP47 binds specifically to the peptide-binding site of TAP with
very high affinity in a stable fashion (Tomazin et al., 1996).
A number of proteins have also been identified in the betaherpesviruses human
cytomegalovirus (HCMV) and MCMV that prevent MHC class I presentation by
blocking at different stages of assembly and transport (Reddehase, 2000). HCMV
encodes a phosphoprotein (pp65) that phosphorylates the principal IE1 protein and
makes it resistant to cleavage (Gilbert et al., 1996). HCMV US6 product inhibits
peptide translocation by TAP (Ahn et al., 1997). It functions slightly differently from
ICP47. It is inserted into the ER membrane and the luminal part of US6 prevents
peptide bound to TAP from being transported inside the ER. US6 itself is retained in
the ER and is not translocated to the cytoplasm for presentation. HCMV US11 also is
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an ER resident transmembrane glycoprotein that dislocates newly synthesised class I
molecules from the ER to the cytosol where they undergo rapid degradation (Wiertz
et al., 1996). US3 product of HCMV goes one step further; it can prevent a final
MHC complex with peptide from leaving the ER (Ahn et al., 1996). US3 is an IE
product while US11 and US6 are early/late products. Consistent with this expression
pattern it is thought that US3 prevents peptide loaded MHC class I complex from
leaving the ER immediately after infection (Ahn et al., 1996). Taking into
consideration all these different strategies it has been suggested that HCMV have
different T cell escape strategies at different times during infection cycle in the host.
MCMV seems to have evolved strategies that differ from that of the HCMV. MCMV
gene ml52 encodes a transmembrane glycoprotein that is expressed during early
infection. The expression of ml52 leads to the accumulation of MHC class I
complex loaded with peptide in the early Golgi compartments and prevents the
complex from being transported along the Golgi (Ziegler et al., 1997). MCMV m06
is also an early transmembrane glycoprotein. This protein forms a tight complex with
(32-microglobulin associated MHC class I molecule. After passing the Golgi the
complex enters the endocytic route and is transported to the lysosome where it is
degraded (Reusch et al., 1999).
All these HCMV and MCMV mechanisms reduce CTL killing but the reduced
expression of MHC class I can make them susceptible to NK cell recognition. These
viruses have evolved methods to evade this by expressing decoy MHC molecules on
the surface of cells. HCMV codes for a decoy class I homologue UL18. When UL18
was expressed in cells lacking MHC class I, they were found to be resistant to NK
cell killing (Reyburn et al., 1997). MCMV ml44 codes for a MHC class I
homologue. Recombinant MCMV virus with a ml44 gene mutation exhibited poor
replication in vivo in mice compared to wild type virus but on depleting NK cells the
replication was restored. This indicated that expression of ml44, a class I
homologue, partially rendered the virus infected cells resistant to NK cell lysis
(Farrell et al., 1997). MCMV coded gp34 is also thought to be involved in preventing
NK cell recognition. It binds to MHC class I complex and prevents ER retention and
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allows transport and expression on the cell surface (Kleijnen et al., 1997). It is
thought to act as a negative regulator for the rest of the proteins that prevent MHC
class I expression on the surface and prevents MHC class I on the surface from
falling too low.
Gammaherpesviruses too exhibit mechanisms like alpha- and betaherpesviruses
aimed at down-regulating CTL recognition. EBV latency associated protein EBNA1
is resistant to proteolytic cleavage due to the presence of glycine-alanine repeats in
the protein backbone (Levitskaya et al, 1995). The glycine-alanine repeat makes the
ubiquitinylated EBNA1 unstable for proteolytic cleavage and therefore the CTL
response to this protein requires exogenous processing (Blake et al., 1997). EBV
coded viral IL-10 (vIL-10) has been demonstrated to down-regulate cellular TAP1
protein expression. This in turn leads to reduced peptide translocation and expression
of peptides on MHC class I molecules (Zeidler et al., 1997). Two of KSHV unique
genes ORFK3 and ORFK5 are found to be capable of down-regulating MHC class I
expression. The mechanism is thought to be distinct from other herpesviruses as the
K3 and K5 proteins are involved in targeting MHC class I peptide complex from the
cell surface to the endocytic pathway for degradation (Coscoy and Ganem, 2000).
This down-regulation of MHC class I complex would render the KSHV infected
cells protection from CTL recognition but as in the case of HCMV and MCMV this
could make the cells susceptible to NK cell recognition and killing. However, it has
subsequently been shown that ORFK5 can prevent NK cell recognition as well.
ORFK5 was shown to be able to manipulate surface molecules such as ICAM-1 and
B7-2 that are the cellular ligands for NK cell-mediated cytotoxicity receptors (Ishido
et al., 2000). Human B cell line BJAB expressing KSHV K3 protein is susceptible to
NK cell mediated killing due to MHC class I complex down-regulation, but when K5
is expressed in these cells, they become resistant. This was brought about by the
down-regulation of ICAM-1 and B7-2. Preliminary in vitro characterisation of
MHV-68 K3 gene has shown similar effect to KSHV K3 at down-regulating MHC
class I presentation and inhibiting antigen presentation (Stevenson et al., 2000). It
would be interesting to see the effect of this gene in vivo and this might shed more
light on the activity of the KSHV K3 in infected humans.
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T helper cells or CD4+ T cells recognise antigens presented on MHC class II
molecules. Macrophages, dendritic cells and B cells are the main subsets of cells
expressing MHC class II on their surface. The antigens in this case are engulfed and
broken down in the endocytic or lysosomal compartments. The MHC molecule is
made up of a and (3 heterodimer and this is bound to an invariant chain (Ii).
Signalling through the Ii chain helps this complex to move into the endocytic
pathway. In this compartment proteases cleave the invariant chain into a fragment
called the CLIP that is attached to the peptide groove. The CLIP is later exchanged
for a peptide and the final complex transported to the cell surface (Miller and
Sedmak, 1999, Tortorella et al., 2000).
There are fewer examples where viruses disrupt MHC class II expression. HCMV
US2 degrades class II DR-a and class II DM-a molecules (Tomazin et al., 1999). It
prevents MHC class II presentation and exhibits reduced or abolished antigen
presentation to CD4+ T cells. It is thought that it almost would make HCMV
infected macrophages invisible to CD4+ T cells during the process of reactivation.
The EBV BZLF2 protein can bind to the cell surface as well as MHC class II. It
affects the generation of CTL in vitro in mixed lymphocyte cultures (Spriggs et al.,
1996). There are examples where viruses indirectly down-regulate MHC class II
expression, either by interfering with the endocytic pathway or by modulating
cytokines like IFN-y. For example, EBV secretes vIL-10 (BCRF1) which can
suppress T cell activation by affecting IFN-y production (Hsu et al., 1990, Bejarano
and Masucci, 1998). Human IL-10 has also been shown to inhibit MHC class II
presentation and activation of CD4+ T cells. Work on human monocytes has shown
that IL-10 specifically inhibits MHC class II complex exocytosis and recycling.
Complexes seem to be accumulating in intracellular vesicles rather than being
transported to the plasma membrane (Koppelman et al, 1997). It is thought that vIL-
10 secreted by EBV could act in a similar fashion.
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1.9.2 Modulation of cell death by apoptosis
Cells that have replicating virus undergo apoptosis or are detected by CTL or NK
cells and signalled for cell death. Viruses have to produce progeny virus and prevent
untimely death of the host cell therefore they have evolved various mechanisms that
subvert apoptosis. Apoptosis induced by NK cells and CTL is brought about by
TNF-a, granzymes, perforins or cell surface receptors like FasL. Work on
gammaherpesviruses (KSHV, HVS, BHV-4 {Bovine herpesvirus-4} and EHV-2
{Equine herpesvirus-2}) has identified viral encoded proteins called v-FLIP that can
disrupt the down-stream signalling through Fas by binding to FADD (Fas activated
death domain) and caspase-8 through their death-effector domains (DED) (Thome et
al, 1997).
A cellular protein that protects cells from apoptosis is bcl-2 and many
gammaherpesviruses (EBV, KSHV, MHV-68, HVS and BHV-4) encode viral
homologues (vbcl-2). The presence of vbcl-2 protein is thought to inhibit cells from
undergoing apoptosis. Recent work comparing the vbcl-2 molecule from five
different gammaherpesviruses (EBV, KSHV, HVS, BHV-4 and MHV-68) has shed
more light on the evolution of this molecule as a powerful death suppressor (Bellows
et al., 2000). Bcl-2, although anti-apoptotic, on cleavage by caspases is converted
into a potent proapoptotic factor, it was therefore considered important to determine
that this was the same with the viral homologues. All vbcl-2 (EBV, KSHV, HVS and
BHV-4) except MHV-68 bcl-2 were resistant to cleavage by caspases (1, 3 and 8). In
addition the cleaved product of MHV-68 bcl-2 lacked proapoptotic characteristic.
When the C-terminal regions of the different gammaherpesvirus vbcl-2 were
expressed in cells it was found that only KSHV C-terminal region was proapoptotic.
However as the full-length vbcl-2 failed to undergo cleavage by caspases this region
does not appear to be proapoptotic in infected cells (Bellows et al., 2000). This work
showed that although the vbcl-2 shared homology with cellular bcl-2, the
gammaherpesviruses have been successful in retaining only specific properties that
are advantageous for their survival within host cells. EBV BHRF1 (Henderson et al.,
1993), BALF1 (Marshall et al., 1999) and LMP-1 (Rowe et al., 1994) activate
CHAPTER 1 INTRODUCTION 43
cellular bcl-2 expression. This may be a strategy used by the virus to prevent early
apoptotic death of an infected cell.
1.9.3 Modulation of cytokine and chemokine response
In the past decade a large amount of literature has amassed on the proteins encoded
by DNA viruses, especially the herpesvirus and poxvirus groups that can modulate
cytokine and chemokine responses. However, most of our knowledge about their
immuno-modulatory functions comes from structural similarity to known host
proteins or in vitro functional studies. For example, KSHV encode an array of
cytokine and chemokine modulators but their function in vivo is not known as most
of the evidence is from structural homology to cellular proteins and in vitro binding
studies. The in vivo functions of these molecules during host response can only be
determined with the help of animal models.
Almost all the cytokines described previously as important host responses to viruses
such as IFN-a/p, TNF-a, IL-ip and IFN-y can be subverted by different poxvirus
molecules (Kotwal, 2000). Virus encoded proteins secreted outside the host cell are
named "virokines" and a subset of them are called "viroreceptors". Viroreceptors are
homologues of cell surface receptors that can bind to host mediators such as
cytokines and chemokines. Vaccinia viruses secrete two such viroreceptors vTNFr
and vIL-ipr that bind and sequester host TNF-a and IL-1P respectively. These
molecules are seen to restrict host pro-inflammatory responses (Kotwal, 2000).
Among herpesviruses there seem to be more examples of virokines that may subvert
host responses by suppressing the pro-inflammatory cytokine secretion. For example
EBV secreted vIL-10 can negatively regulate IL-12 and thereby affect IFN-y
production. KSHV secretes vIL-6 and HVS a homologue of IL-17 (Spriggs, 1999).
The only soluble cytokine receptor identified in the herpesvirus family to date is
colony-stimulating factor 1 receptor (CSF-1R) encoded by EBV BARE1 (Strockbine
et ai, 1998). Recombinant BARF1 protein inhibits the ability of CSF-1 to induce
proliferation of mouse bone marrow macrophages and secretion of IFN-a by human
monocytes.
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Chemokine mediated cell migration and inflammatory responses have come into
focus and seem to be essential in the movement of cells towards infected regions and
also in movement away from infected sites into lymph nodes carrying important
information for priming the adaptive response to viruses and other pathogens.
Therefore it is not surprising that the viruses have evolved mechanisms to block
these responses. There are different strategies devised by viruses to subvert
chemokine signalling (Price et al., 1999, Tortorella et al., 2000).
One strategy is to code for secretory chemokine binding molecules (vCkBs). These
can bind and sequester chemokines from the vicinity of the infected cell or cells and
thereby prevent chemokine binding to the extracellular matrix and chemotaxis of
effector cells. MHV-68 ORF M3 codes for a novel chemokine binding protein that is
a secreted molecule. In vitro characterisation of the MHV-68 M3 protein has shown
that it is a broad spectrum chemokine binding protein that can bind to a wide range
of chemokines, including CC, CXC, C and CX3C chemokines (Parry et al., 2000,
van Berkel et al., 2000). There were some subsets of these chemokines that M3 did
not bind, for example, some B cell specific CXC chemokines, indicating selective
activity. MHV-68 M3 was found to block calcium signalling induced by RANTES,
MIP-1A and MCP-1 (Parry et al., 2000, van Berkel et al., 2000).
Another strategy viruses use is to code for chemokine binding receptors (vCkBRs)
(Lalani et al., 2000). Cells infected with HCMV express a homologue of CCR5
receptor US28, which can bind to an array of chemokines including RANTES, MCP-
1 and MIP-la/pand prevent their binding to other cells. The binding of these
molecules to US28 leads to their internalisation and degradation (Tortorella et al.,
2000, Fortunato et al., 2000). A number of gammaherpeviruses including KSHV,
HVS and MHV-68 express viral IL-8R. It is a G-coupled receptor (CXCR2) that
binds to IL-8, CXC and CC. The HVS IL-8R is coded by ECRF3 gene and has been
shown to act as a functional receptor that binds to IL-8, GRO/melanoma growth
stimulatory activity (MGSA), and NAP-2 (Nicholas et al., 1992, Ahuja and Murphy,
1993).
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Viruses can also code for chemokine receptor binding proteins (CkRB). KSHV
secretes a variety of chemokine antagonists, vMIP-I and vMIP-II. These antagonists
bind to CCR and CXCR receptors and prevent cellular chemokine binding but also
inhibit signalling down-stream (Klendal et al., 1997, Boshoff et al., 1997, Lalani et
al., 2000).
1.9.4 Modulation of humoral immunity
HSV-1 and HSV-2 encode for proteins that can subvert humoral immunity. The HSV
genes US8 and US7 code for glycoprotein E (gE) and gl proteins can bind to
monomeric as well as aggregates of IgG. They act as Fey receptors (FcyR). The
binding of antibodies through their Fc region to the cell surface of infected cells can
obstruct Fab recognition of antigenic peptides on the same surface. This has been
shown as the reason for the ineffective antibody-dependent cellular cytotoxicity
response in HSV infected cells (Dubin et al., 1991). This could also explain the
reason why so many of the herpesviruses (HCMV, MCMV, VZV) code for FcyR
homologues.
A second target in the host humoral response is the complement cascade. The virus
binding to IgG Fc region prevents the classical complement pathway, in which
complement recognises antibody-coated cells and particles and destroys them.
Viruses also target the alternate pathway by producing proteins that can inactivate
either C3 or the C3 convertase (Lindahl et al., 2000). Gammaherpesviruses such as
HVS, KSHV and MHV-68 code for genes that are homologous to complement
regulatory proteins. The HVS coded HVSCD59 has sequence homology to human
terminal complement regulatory protein CD59 and is expressed mainly during the
lytic cycle of the virus. Cells stably transfected with HVSCD59 are resistant to lysis
by both human and rat serum (Rother et al., 1994).
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1.10 Aim of the Project
The overall aim of the work described in this thesis was to investigate the early
events following MHV-68 infection in vivo in the draining lymph node mainly the
mediastinal lymph node. It was hoped that any information obtained would help
discern:
• The effect of MHV-68 infection on B cells in the mediastinal lymph node during
the very onset of infection.
and
• Cell types other than B cells latently infected in the lymph node and involved in
virus trafficking.
The approaches adopted were:
• To compare events in B cell deficient (pMT) host environment to that in wild
type host.
• To characterise a recombinant MHV-68 virus (LHAgfp) expressing green
fluorescent protein (GFP) and use it as a marker to track infected cells.
• To use the Type I IFN R"~ host that displays amplified disease pathogenesis to
characterise infected cell types.





Unless otherwise stated all chemicals were of analytical grade where available and
supplied by Merck-BDH Chemicals, Poole, Dorset, England, or Sigma-Aldrich
Chemical Co, Poole, Dorset, England.
Life Technologies Ltd supplied plastic ware for tissue culture purposes.
2.1.2 Tissue culture media
Glasgow's modified Eagle's medium (GMEM) (Life Technologies Ltd) and RPMI
1640 (Life Technologies Ltd) were prepared in the department of Veterinary
Pathology, University of Edinburgh.
2.1.3 Virus
Murine gammaherpesvirus-68 (MHV-68) was obtained from Prof. Blaskovic
(Blaskovic et al., 1980) and the clone g2.4 was isolated by Efstathiou et al 1990b.
LHAgfp is a recombinant MHV-68 and was a gift from Dr. D. J. Roy and Dr. J.
Stewart, Department of Veterinary Pathology, University of Edinburgh. It has an
enhanced green fluorescent protein gene (EGFP) under a human cytomegalovirus
(CMV) immediate early promoter (Vector pEGFP-Cl, Clontech Laboratories, USA)
inserted in to the left-hand end of MHV-68. It has a deletion of nucleotides l-3223bp
that comprises five tRNA coding sequences and most of the Ml gene of wild type
MHV-68.
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2.1.4 Mice
Wild type C57BL/6 mice were obtained from B and K Universal Ltd (Hull, UK)
aged 3-4 weeks on arrival. pMT/pMT (Kitamura et al., 1991) on a C57BL/6
background were also obtained from B and K Universal Ltd and bred in-house.
These mice have a targeted lesion in the p-immunoglobulin chain resulting in the
failure to express IgM; consequently, B cells development is arrested at the pre-B-
cell stage. These mice are referred to in this thesis as pMT mice.
IFN-a/p R~" mice (Muller et al., 1994) were obtained from B and K Universal Ltd
and bred in-house.
Wild type 129/Sv/Ev matching the IFN-a/p R_/" background were also obtained from
B and K Universal Ltd and bred in-house. These wild type mice are referred to in this
thesis as WT129.
Male and female mice were infected at 4-7 weeks of age intranasally with 4 x 105
PFU MHV-68 (40pl inoculum) under Halothane anaesthesia.
2.1.5 Cell lines
Baby hamster kidney cell line (BHK-21) (MacPherson and Stoker, 1962) were
maintained in Glasgow's modified Eagle's medium supplemented with 10% tryptose
phosphate broth (TPB) (Life Technologies, Paisley) and 10% new bom calf serum
(NBCS) (Harlan Sera-Lab), L-glutamine (2mM), penicillin (70pg/ml) and
streptomycin (10pg/ml). Cell lines were maintained at 37°C in 5% CO2 incubator.
2.1.6 Biobond Coating
Glass slides (BDH) were washed in 2% Decon detergent followed by distilled water.
Slides were coated with 2% Biobond (British BioCell, International, Cardiff, UK) in
acetone for 4 minutes, rinsed in distilled water and stored for subsequent use.
Table 2.1 Antibodies used in FACS analysis
Primary
Antibodies
Source Dilution Cell Marker Reference
Goat-anti-mouse
IgMp-biotinylated
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1:100 NK cells Salazar-Mather
et al., 1996
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2.2 Methods
2.2.1 Preparation of virus working stock
BHK-21 cells were infected with MHV-68 at a multiplicity of infection (MOI) of
0.001. Suspensions were incubated at 37°C for 1 hour on a shaker. Infected cells
were transferred to T175 tissue culture flasks containing 50ml of complete medium.
5-6 days post-infection the cells were removed along with supernatant using a cell
scraper. The cells were centrifuged at 275g (Beckman TJ-6) for 20 minutes at 4°C.
Cells were resuspended in phosphate buffered saline (PBS) {0.8% sodium chloride,
0.02% potassium chloride, 0.144% disodium hydrogen phosphate (Na2HPC>4) and
0.24% potassium dihydrogen phosphate (KH2PO4) at pH 7.4}. Cells were then
homogenised using a Dounce homogeniser (Wheaton, USA) 20-30 times, over ice
and centrifuged at 750g for 20 minutes at 4°C. Supernatant, which contains the virus,
was removed and kept carefully on ice. The pellet was resuspended in 1ml PBS and
once again homogenised. The homogenate was centrifuged at 750g and the
supernatant was pooled with the previous one, dispensed in 0.2ml volume aliquots
and stored at -70°C.
2.2.2 Cocultivation assay for infective centres in the lymph nodes and spleen
Mice were killed by carbon dioxide (CO2) inhalation. Cervical lymph node (CLN),
mediastinal lymph node (MLN) and spleens were removed into 2ml RPMI 1640
supplemented with 10% foetal calf serum and kept individually on ice. A single cell
suspension was obtained from each of these tissues by dissociation with the help of
scalpel blades. In the case of spleen, erythrocytes (red blood cells) were lysed by
water lysis (1ml sterile dt^O and 9ml PBS). The cells were resuspended in complete
media. The cells were counted after diluting in trypan blue (0.1%) using a
haemocytometer. The cells were cocultivated at different dilution along with lxlO6
BHK-21 cells in RPMI complete medium {RPMI 1640; 10% foetal calf serum; L-
glutamine (2mM); P-mercaptoethanol (0.05mM); penicillin (70pg/ml) and
streptomycin (10pg/ml)} in 60 mm tissue culture dishes at 37°C in 5% CO2 incubator
for 5 days. The monolayers were fixed in 10% formal saline (Surgipath-Europe Ltd)
and stained with 0.1% toluidine blue (w/v in dH20), and the number of infective
CHAPTER 2 MATERIALS AND METHODS 50
centres were counted using a dissection microscope (Wild, Heerbrugg) (method as
described by Sunil-Chandra, 1992a).
2.2.3 Assay for infective virus
Single cell suspensions were obtained from lymph nodes and spleen tissues as
described in the previous method. In the case of lung tissues, they were stored in
vials at -70°C soon after removal from mice. They were thawed and homogenised
individually in 1ml ice cold media using glass homogenisers (Soham Scientific, UK).
Cell homogenates were transferred to cryovials and refrozen at -70°C. The cells were
freeze thawed twice. The cell debris was spun down and the supernatant was
recovered. The supernatant was added at different dilutions to lxlO6 BHK-21 cells in
Glasgow modified Eagle's medium and incubated for an hour at 37°C in a shaker
before plating on to 60mm tissue culture dishes. The cells were then cultured for 4
days at 37°C in 5% CO2. The monolayers were fixed in 10% formal saline and
stained with 0.1% toluidine blue. The plaques on plate were counted using a
dissection microscope.
2.2.4 Biotinylation of antibody
The stock antibody (immunoglobulin from PK136 line) was diluted to lmg/ml in
0.1M bicarbonate buffer (pH8.5). 1ml of the antibody was dialysed against the
bicarbonate buffer at 4°C, overnight. 200pl of biotin (lOmg/ml) in DMSO (dimethyl
sulfoxide) was added to the dialysed antibody in an eppendorf and mixed at 4°C for 5
hours. 500pl of 5% (w/v) sodium azide was added to the antibody solution and this
was dialysed against PBS/0.05% azide, overnight. This was followed by another
dialysis against PBS/20% glycerol overnight.
2.2.5 Flow cytometric analysis of cells (FACS-fluorescent activated cell sorting)
Cell suspensions from tissues were adjusted to 4 x 106 cells per ml in RPMI complete
media and lOOpl (4 x 105 cells) was used for staining with each individual antibody.
The primary antibodies were diluted in FACS buffer (PBS with 1% bovine serum
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albumin and 0.1% sodium azide). The primary antibodies used in FACS are listed in
Table 2.1 under section (2.1). 50pl of diluted antibody was added to the respective
tubes and incubated for 15 minutes at room temperature. The cells were washed
twice using 700pl of FACS buffer. Subsequently the cells were incubated with 50pl
of secondary antibody fluorescent conjugate (PharMingen or Serotec) diluted
appropriately, at room temperature in the dark for 15 minutes. The cells were washed
and fixed in 1% formaldehyde in PBS. The cells were analysed by flow cytometry
(Becton Dickinson 'FACStar' flow cytometer using the Cellquest software).
2.2.6 Imprints
Mice were killed by carbon dioxide inhalation. In the case of the mediastinal lymph
node, the node was removed cut into two halves and the cells were squashed onto a
Biobond coated slide each. The slides were allowed to air dry and then fixed in ice
cold acetone for 2 minutes. In the case of the lung tissue small pieces of the tissue
was cut using scalpel blades. The tissue was then dabbed on to a Biobond coated
slide using forceps. It was then aid dried and fixed.
2.2.7 In vivo depletion of T cells
The CD4+ T cell subset was depleted using the rat monoclonal antibody YTS 191.1
(Cobbold et al., 1984). Mice were injected intravenously in the tail with 0.1ml of
antibody at lOmg/ml stock solution, two days before and two days after MHV-68 or
mock infections. Subsequently, mice were injected with the same dose
intraperitonially 7 days after the original injection. (Method similar to Ehtisham et
al., 1993)
2.2.8 Cytospins
Cells were resuspended at lxl06/ml in PBS and lOOpl was centrifuged on to
Biobond coated slide. The cytospin (Cytospin 2, Shandon) was performed for 5
minutes at 1000 rpm. The cytospins were air-dried, mounted using Citifluor (UKC,
Canterbury, UK) and observed using a fluorescent microscope (Nikon, Diaphot 200).
CHAPTER 2 MATERIALS AND METHODS 52
2.2.9 MHV-68 immunostaining of paraffin-embedded tissues
Paraffin tissue sections cut on to Biobond coated slides had to be dewaxed and
permeablised before the addition of antibodies. Slides were dewaxed by immersion
in xylene for 15 minutes at room temperature. This was followed by a wash in
absolute alcohol for 5 minutes and treatment with 0.3% hydrogen peroxide in
methanol for 30 minutes at room temperature to block the endogenous peroxidase
activity. Tissue sections were then hydrated through a series of alcohol (100%, 95%,
70%, 50% and 30%) for approximately 30 seconds each, washed twice in distilled
water (dH20) for a minute and immersed in 1% Triton X-100 in dH2Ofor 1.5 minutes
followed by two washes (5 minute each) in dH20. Permeablisation of cells was
improved further by carrying out a proteinase-K (10p.g/ml in 20mM Tris and 2mM
calcium chloride at pH7.0) digestion for 20 minutes in a 37°C water-bath. Immersing
slides for 5 minutes in PBS containing glycine (2g/L) and EDTA (ethylene-diamino-
tetra acetic acid) (5mM) inactivated proteinase-K.
Slides were immersed in PBS at all times to prevent drying of tissue sections. Slides
at this stage were ready for antibody staining. The slides were laid out in a moist
chamber and a blocking step using 2% normal goat serum was carried out overnight
to prevent non-specific binding of antibodies. Prior to addition of primary antibody
the blocking serum was decanted. 50pl of rabbit polyclonal MHV-68 antibody
(diluted 1/500 in 2% normal goat serum) was added to each section and placed in the
moist chamber and incubated at room temperature for 2 hours. The slides were
washed three times (5 minutes each) in PBS to remove excess antibody. Goat anti-
rabbit biotinylated IgG (diluted 1/500 in 2% normal goat serum) was added to each
slide and incubated for 2 hours at room temperature. Slides were washed in PBS.
Streptavidin conjugated to horseradish peroxidase (diluted 1/1000 in PBS)
(Boehringer-Mannheim) was added to the sections and incubated for 1 hour at room
temperature. Slides were washed three times in PBS (5 minutes each). 3, 3'-
Diaminobenzidine tablets (Sigma), the substrate for peroxidase (POD), were
dissolved in 5ml dH20 and added to sections. Colour change was monitored closely
and reaction stopped within 5-10 minutes by immersing in PBS.
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Slides were washed in water and lightly counter-stained with Harris's haematoxylin.
The slides were dehydrated by passing through a series of alcohols (30%, 50%, 70%,
90% and 100%) and then dipped in xylene before mounting in Surgipath
'micromount'.
2.2.10 Magnetic activated cell sorting (MACS)
Mediastinal lymph nodes were pooled and dissociated into single cell suspension.
The cells were counted and 5 x 107 cells were resuspended in MACS buffer (PBS
supplemented with 1% bovine serum albumin, 5pM EDTA and 0.1% sodium azide).
To this lOOpl of CDllc (hamster N418) microbeads (Miltenyi Biotec, UK) was
added and incubated for 30 minutes at 10°C. Cells were washed with 20ml of buffer,
centrifuged and resuspended in 500pl buffer.
CD1 lc positive cells were purified by positive selection on RS+ magnetic columns.
During cell staining the columns were placed in the magnetic field of the Vario-
magnetic separator (Miltenyi Biotec) and 500pl of ice-cold buffer passed through to
equilibrate. 500pl of CDllc bound sample was added to the column and negative
cells allowed to flow through. Columns were washed twice with 500pl of ice cold
buffer to remove unbound cells. The column was removed from the separator and
using a syringe 500pl of buffer was back-flushed. The column was replaced in the
magnetic field and buffer allowed to flow through. The column was removed from
the separator, 1ml buffer was added and the positive cells were flushed from the
column using the plunger supplied.
A second RS+ column was placed in the magnetic separator and equilibrated with
buffer. The positive cells from the first column were applied to this column in order
to increase the purity of the CDllc+ cells. The column was washed with buffer.
Then the column was removed from the magnet and positive cells flushed out using a
plunger. The cells were counted and an aliquot taken for FACS analysis. Surface
markers were stained in suspension before centrifugation on to slides in a cytospin.
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2.2.11 Interferon-y CTL assay
In this assay CD8+ T cells are quantitated for their ability to produce interferon-y
(IFN-y) after a short in vitro stimulation (Murali-Krishna et al., 1998). Secretion of
IFN-y is prevented by carrying out the stimulation in the presence of Brefeldin-A
(BFA) a compound that inhibits transport of proteins in to the Golgi from the
Endoplasmic reticulum (ER).
Mediastinal lymph nodes and spleens were removed from MHV-68 infected mice
into RPMI complete medium. Splenocytes were teased out from each spleen
separately while the mediastinal lymph nodes were pooled. Erythrocytes were lysed
by ammonium chloride lysis (2.2.14). Cells were washed, counted and resuspended
at a concentration of 107 cells/ml. The samples were seeded in triplicates. Each of the
wells in 96 well plate (round bottom) was seeded with 1 x 106 cells in 200pl
complete medium containing lOpg/ml BFA (Sigma) and lOU/ml interleukin-2 (Life
Technologies Ltd). The positive control set of wells the cells were stimulated with
50ng/ml PMA (Phorbol myristic acid)(Sigma) and 50ng/ml Ionomycin (Sigma).
MHV-68 specific CD8+ T cells were stimulated using MHC class I specific peptide
epitopes from two early lytic transcripts ORF6 and ORF61. The ORF6 (H-2Db-
restricted) epitope is AGPHNDMEI that is referred to as p56 and the ORF61 (H-2Kb-
restricted) epitope is TSINFVKI that is referred to as p79 (Stevenson et al., 1998).
They were used at a concentration of lpM. Cells were incubated for 5 hours at 37°C
in a 5% CO2 incubator.
Cells were pelleted in the 96 well plate by centrifugation at 275g for 5 minutes at
4°C, washed once with staining wash buffer (SWB: 2% FCS and 0.1% sodium azide
in PBS) containing lOpg/ml BFA. Fc receptors were blocked using anti-CD 16/CD32
(PharMingen, diluted 1/100 in SWB and lOpg/ml BFA) for 10 minutes on ice. Cells
were spun and 50pl of primary antibody (anti-mouse CD8-FITC, Sigma, diluted 1/60
in SWB and lOpg/ml BFA) was added to cells and incubated for 20 minutes on ice.
Cells were washed twice with PBS containing 10pg/ml BFA. The cells were fixed
using lOOpl of PBS containing lOpg/ml BFA with lOOpl of 2% formol saline and
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incubated for 20 minutes at room temperature. Cells at this stage had to be
permeablised in order to facilitate the entry of antibodies that can detect IFN-y
accumulated intracellularly. Permeablisation was carried out by incubation in 0.5%
Saponin (Sigma) in SWB for 10 minutes at RT. The cells were then incubated with
rat anti-mouse IFN-y phycoerythrin conjugate (PharMingen, diluted 1/250 in
permeablisation buffer) or an isotype control (PharMingen, diluted 1/85) for 30
minutes on ice. The cells were washed with PBS to remove unbound antibody and
resuspended in lOOju.1 SWB to be analysed by flow cytometry.
2.2.12 Staining cytospun cells
The cytospun slides were washed in PBS. Slides were treated for 1.5 minutes in 0.1%
(v/v) TritonX-100 then washed 2x5 minutes in dFhO. The cells were blocked with
5% (v/v) normal goat serum (NGS) for half an hour at room temperature. Excess
NGS was removed and primary antibody (polyclonal anti-rabbit MFIV-68) was
added at a dilution of 1:500 in 2% NGS. Slides were incubated for 2 hours at room
temperature then washed 3x5 minutes in PBS. Secondary antibody, goat anti-rabbit
IgG-biotin (1/500 in 2% NGS) was added and slides were incubated for 1 hour.
Slides were washed 3x5 minutes in PBS. Streptavidin-TRITC 1:300 or Streptavidin-
FITC 1:500 was added and incubated for 1 hour. Slides were washed 3x5 minutes in
PBS. The stained cytospins were air dried and mounted using Vecta-shield (Vector
laboratory) and observed using a fluorescent microscope (Nikon, Diaphot 200)
2.2.13 Confocal microscopy
The Confocal microscope used for viewing stained cells was a Leica TCS-NT
(Germany). It is a central facility in the Biomedical Sciences Section, University of
Edinburgh.
2.2.14 Ammonium chloride lysis
Lysis buffer was made up of ammonium chloride (0.16M) and Tris-hydrochloric acid
(0.17M) (pH6.5-7) at a ratio of 9:1 and warmed to 37°C. Cells to be lysed were
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resuspended in 1ml complete media. To this, 3.5ml of the lysis buffer was added, left
to stand for 30 seconds till the solution clarified indicating erythrocyte lysis had
occurred. The cells were spun down and washed twice with complete media.
2.2.15 Electron microscopy
Cells to be analysed for the presence virus particles by transmission electron
microscopy were centrifuged in to a tight pellet and fixed with 3% glutaraldehyde in
0.1M Sodium Cacodylate buffer. Staff at the Electron microscope unit (Royal Dick
School of Veterinary Studies, University of Edinburgh) carried out the subsequent
processing.
2.2.16 Handling of DNA, RNA and molecular biological techniques
Many of these methods used in handling of DNA or RNA were based on methods
given in 'Molecular cloning'-'A laboratory manual' (Sambrook. et ah, 1989)
2.2.17 DNA agarose gel electrophoresis
Electrophoresis of DNA was carried out in 1% (w/v) agarose (Seakem agarose,
Flowgen, UK). Horizontal gels were prepared in TAE buffer (0.04M Tris-acetate and
0.001M EDTA)(Sambrook. et al., 1989) to which was added lpg/ml ethidium
bromide. The gels were electrophoresed at 80mA for 30 minutes to 2 hours in lx
TAE buffer. Samples were diluted in loading buffer (15% {w/v} Ficoll-400 and 0.1%
{w/v} Orange-G dye). DNA size was estimated by comparison with a 1Kb DNA
ladder (Life Technologies Ltd) was used. DNA was viewed over an ultraviolet
transilluminator.
2.2.18 RNA Extraction
Tissue samples were snap frozen in liquid nitrogen as soon as possible after removal
from the animal and kept frozen at -70°C till further use. Tissue samples were
homogenised in 500pl of RNAzol B (Biogenesis, Poole, England). 50pl of
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chloroform was added and samples were mixed well for 15 seconds, then kept on ice
for 5 minutes. The aqueous and phenol phases were separated by centrifugation at
11600g for 15 minutes at 4°C. The aqueous phase was transferred to a fresh tube and
an equal volume of isopropanol added to it. This was kept on ice for an hour and then
centrifuged at 11600g for 15 minutes at 4°C. The pellet was washed once with 70%
(v/v) ethanol and centrifuged at 5800g for 8 minutes at 4°C. The pellet was air dried
for 15 minutes and resuspended in 10pl milliQ-H20 (Millipore).
2.2.19 Preparation of cDNA from total RNA
Prior to reverse transcription (RT) of total RNA, samples were treated with RNAse
free DNAse to ensure removal of any DNA contaminating the total RNA. The
reaction mixture contained 2.5mM di-thiothreitol (DTT), lx reverse transcriptase
buffer and 1U Amp grade DNAse enzyme (Life Technologies Ltd) in a total volume
of 20pl. The reaction was carried out at 37°C for 30 minutes. The enzyme was
inactivated at 80°C for 5 minutes. The above reaction mixture was increased in
volume to 25pl and reverse transcription reaction was set up by adding lOOpM
random primers (Roche); ImM dNTP (Roche); 200U reverse transcriptase
(Superscript II, Life technologies). Reaction was carried out for a 1 hour at 45°C,
then heat inactivated at 95°C for 5 minutes. cDNA (complementary-DNA) was
stored at -20°C.
2.2.20 Polymerase chain reaction (PCR)
A 50pl polymerase chain reaction mixture was prepared with 200nM dNTP, 2mM
MgCl2 and 100 pM forward and reverse primers and 0.5U Taq DNA polymerase
(Life technologies). 50pl of mineral oil was added on top and the tubes were left at
95°C for 5 minutes prior to the PCR cycles. A 35 cycle PCR was carried out:
denaturing 95°C for 45 seconds, annealing 45°C for 1 minutes (or 55°C) extension
72°C for 2 minutes. This was followed by a final cycle at 72°C for 10 minutes. The
primer sequences, the size of the fragment and the annealing temperatures are
tabulated in the Table 2.2.
Table 2.2 PCR Primer sequence
PCR
PRIMERS





P-Actin (F) TGTGATGGTGGGAATGGGTCA 45°C 514 bp
P-Actin (R) TTTGATGTCACGCACGATTTC
ORF50 (F) AAAAGTTCTGCATCCCAGACCC 55°C 293 bp
ORF50 (R) AGGGCTAATGGGTGAAAATGGC
M3 (F) TGGCACTCAAACTTGGTTGTGG 55°C 359 bp
M3 (R) TAACAGGCAGATTGCCATTCCC
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CHAPTER THREE
ROLE OF B CELLS IN THE DRAINING LYMPH NODE
DURING THE EARLY STAGES OF INFECTION
3.1 Introduction
The importance of the draining lymph node associated with the site of primary
infection by viruses has been looked at in great detail over the past decade (Doherty
et al., 1997). It is the site where professional antigen-presenting cells (APC) such as
the dendritic cells, macrophages and B cells migrate following foreign antigenic
exposure. It is at this site that the antigen-presenting cells orchestrate the different
arms of the immune system to control the infection and bring about the clearance and
termination of virus infections. In the case of the Influenza A virus infection of
mouse lungs, the mediastinal lymph node is the main site where the various arms of
the immune system are triggered. The CD8+ T cells primed in the mediastinal lymph
node effect the clearance and control of the virus (Hamilton-Easton and
Eichelberger, 1995, Tripp et al., 1995).
MHV-68 infection of the alveolar epithelial cells in the mouse lungs leads to changes
in the mediastinal lymph node (MLN). Trafficking of virus to the MLN results in the
establishment of latency and lymphadenopathy (Sarawar et al., 1996).
Lymphadenopathy is the result of a single or multiple events such as proliferation of
cells following activation, recruitment of cells and/or retention of cells at the site
(Gresser et al., 1981). The lymph node is constituted of a variety of cell types that
could be affected during the course of the infection depending upon the specific arm
of the immune mechanism that is called into play. It was therefore considered
important to find out whether MHV-68 caused any distinct changes in this
environment during the progression of infection.
In EBV and MHV-68 infections B cells are considered the major subset of cells that
carry latent virus during the initial course of infection. In the case of EBV the issue
of whether B cells directly get infected at the mucosal site or whether there are any
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intermediary cells involved such as epithelial cells or dendritic cells is unsolved
(Anagnostopoulos et al., 1995). In the case of MHV-68 the alveolar epithelial cells
are the primary targets where the virus undergoes a productive infection. Lytic virus
is cleared by day 10 and subsequently latently infected B cells are found in the spleen
(Sunil-Chandra et al., 1992b). The issue of whether virus is transmitted to B cells
directly from infected epithelial cells in the lungs has not been solved even with
MHV-68. There is evidence that B cells are important for establishment of latency in
the spleen as seen from experiments with B cell deficient (pMT) mice (Usherwood et
al., 1996b).
The aim of the work described in this chapter was to analyse the early events of
MHV-68 infection in the mediastinal lymph node including (a) the role of B cells in
the development of early pathogenesis, (b) the involvement of cells other than B cells
in trafficking of virus from the lungs and (c) the role of CD4+ T cells in
lymphadenopathy.
3.2 Mediastinal lymphadenopathy and B cells
3.2.1 Mediastinal lymphadenopathy in the presence and absence of B cells
In order to investigate the importance of B cells in lymphadenopathy the MLN from
mice deficient in B cells (pMT mice, Kitamura et al., 1991) were compared with
wild type C57BL/6 following MHV-68 infection. Uninfected MLN contain between
1-2 million lymphocytes. Therefore, it was necessary to pool lymph nodes from 4-6
mice for each time point under investigation in order to obtain adequate number of
cells for the various assays.
C57BL/6 and pMT mice (4-5 weeks of age) were infected intranasally with 4 x 105
PFU MHV-68. MLN were pooled from 5 mice from each group taken on days 3, 7,
10 post-infection and dissociated to obtain single cells suspensions and counted. The
results are represented in Figure 3.1.
C57-MLN uMT-MLN
Figure 3.1 Lymphadenopathy of the mediastinal lymph node in wild type
C57BL/6 and B cell deficient (pMT) mice C57BL/6 and pMT mice (4-5
weeks of age) were infected intranasally with 4 x 105 PFU MHV-68. MLN cells were
pooled from five mice in each group, counted and used for subsequent analysis as
described in the following sections. The graph shows the average number of cells per
MLN in uninfected MLN ( □) and on 3 (□ ), 7 ( ■) and 10(d) days post-infection.
The fold difference is representative of three independent experiments.
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C57BL/6 mice showed almost a 10-fold increase in cell numbers in the MLN on
days 7 and 10 of MHV-68 infection. The pMT mice failed to show any dramatic
changes in cell numbers as compared to the wild type mice.
The results demonstrate that B cells are involved in the increased cellularity of the
MLN seen during early phases of MHV-68 infection.
3.2.2 Changes in cell populations during the process of lymph node enlargement
In order to investigate further the nature of the cells in the MLN of C57BL/6 mice
we performed FACS analysis on the main cell subsets. MLN cells were stained with
antibodies against surface markers for B cells (anti-mouse-IgMp and anti-mouse-
B220), T cells (anti-mouse-CD4 and anti-mouse-CD8), natural killer cells (anti-
mouse-NKl.l), macrophages (anti-mouse-F4/80) and dendritic cells (anti-mouse-
DEC205). Cells were also stained with antibodies against activation markers for B
and T cell (anti-mouse-CD69) and T cell activation marker (anti-mouse-CD25).
The results are represented in Figures 3.2(a) and 3.2(b). A 4-5-fold increase in the
total number of B cells in the MLN was detected on days 7 and 10 compared to day 3
post-infection. CD4+ and CD8+ T cells did not show similar increases, with CD4+ T
cells showing less than a 2-fold increase. There were increased numbers of natural
killer cells, macrophages and dendritic cells that may also contribute towards the
enlargement of the MLN. However B cell numbers calculated by correlating FACS
percentage to the total number of cells from MLN of C57BL/6 mice were far higher
than any other cell subset in the enlarged MLN on days 7 and 10 post-infection.
It was concluded that B cells are the major contributors to lymphadenopathy seen in
C57BL/6 mice and this is confirmed by the absence of lymph node enlargement in
pMT mice that had no B cells.
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Figure 3.2a Phenotype of cells in the enlarged mediastinal lymph nodes of
C57BL/6 mice C57BL/6 mice were infected intranasally with 4 x 105 PFU
MPFV-68. On days 3( □), 7( ■) and 10 ( □ ), mediastinal lymph nodes (MLN)
were pooled from five mice. The MLNs were dissociated to obtain single cell
suspensions counted and taken for flow cytometric analysis. The cells were stained
with either biotinylated anti-mouse IgMp monoclonal antibody, anti-mouse B220
monoclonal antibody, anti-mouse CD4 (YTS177) monoclonal antibody or anti-
mouse CD8 (YTS105) monoclonal antibody. 10,000 cells were counted in each
analysis. The average number of specific marker-positive cell subsets per MLN is
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Figure 3.2b Phenotype of cells in the enlarged mediastinal lymph nodes of
C57BL/6 mice C57BL/6 mice were infected intranasally with 4 x 1(P PFU
MHV-68. On days 3( □), 7( ■ ) and 10 ( □ ), mediastinal lymph nodes (MLN)
were pooled from five mice. The MLNs were dissociated to obtain single cell
suspensions, counted and taken for flow cytometric analysis. The cells were stained
with either biotinylated anti-mouse NK1.1 monoclonal antibody, anti-mouse F4/80
monoclonal antibody, anti-mouse DEC-205 (NLDC145) monoclonal antibody, anti-
mouse CD25 monoclonal antibody or anti-mouse CD69 monoclonal antibody.
10,000 cells were counted in each analysis. The average number of specific marker-
positive cell subsets per MLN is presented above. The fold difference is
representative of three independent experiments.
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3.2.3 FACS analysis for B cell surface markers
Since B cells were the major subset undergoing proliferation in the MLN of infected
mice the decision was made to look at B cells in more detail using different cell
surface markers and some activation markers that undergo changes during germinal
centre (GC) formation.
The B cell specific surface markers expressed uniformly in most mature B cells are
CD 19, B220 and IgMp. B cells that undergo class switching in GCs lose IgM and
start expressing IgG. They also express MHC class II but the marker is also seen on
macrophages and dendritic cell populations. The activation marker CD69 is
expressed on both activated B and T cells. CD21 and CD23 are expressed on mature
B cells but they are lost as these cells differentiate into antibody producing cells
(Clark and Lane, 1991). CD21 is of interest as EBV infects B cells via CD21
(Nemerow et al., 1987) and leads to subsequent proliferation (Roberts et al., 1996).
CD23 is the low affinity receptor for IgE (Ravetch and Kinet, 1991) and is found on
follicular dendritic cells (FDCs) and monocytes. Both CD21 and CD23 are activated
during EBV infection (Wang et al., 1990) and therefore were of interest in the case
MHV-68 infected B cells.
The MLN were pooled from 5 mice, dissociated into single cells and stained for the
markers discussed above and analysed by flow cytometry. The changes in B cell
surface markers were observed daily over the first seven days of infection and then
on days 10 and 12 in the MLN of C57BL/6 mice. The results are presented in Figure
3.3(a) and 3.3(b).
The Figure 3.3a shows that B cells detected with CD 19, B220 and IgMp had
comparable patterns of staining over the days examined. The total cell number of B
cells as seen from these surface marker showed a 10-15-fold rise on days 5 to 12
compared to number of B cells in uninfected control mice. In the same time course
the CD4+ and CD8+ T cell numbers increased only by 4-5-fold. In the figure 3.3b,
IgMp versus CD69 staining showed that there was minimal B cell activation as
detected by double staining and the increase in CD69 alone could be due to the
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Figure 3.3a Expression of B cell markers in the enlarged lymph nodes of C57BL/6
mice C57BL/6 mice were infected intranasally with 4 x 105 PFU MHV-68. On
days 1-7, 10 and 12, MLN were removed and pooled from five mice. The colour
coding for different days is shown in the panel within the graph. The MLNs were
dissociated to obtain single cell suspensions counted and taken for flow cytometric
analysis. The cells were stained with either anti-mouse CD 19, anti-mouse B220
monoclonal antibody, biotinylated anti-mouse IgMp monoclonal antibody, FITC
conjugated anti-mouse IgG, anti-mouse CD4 (YTS177) monoclonal antibody or anti-
mouse CD8 (YTS105) monoclonal antibody. 10,000 cells were counted in each
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Figure 3.3b Expression of B cell markers in the enlarged lymph nodes of C57BL/6
mice C57BL/6 mice were infected intranasally with 4 x 105 PFU MHV-68. On
days 1-7, 10 and 12, MLN were removed and pooled from five mice. The colour
coding for different days is shown in the panel within the graph. The MLNs were
dissociated to obtain single cell suspensions counted and taken for flow cytometric
analysis. The cells were stained with either biotinylated anti-mouse IgMp
monoclonal antibody, anti-mouse CD21 monoclonal antibody, anti-mouse CD23
monoclonal antibody, FITC conjugated anti-mouse CD69 monoclonal antibody or
FITC conjugated anti-mouse MHC class II monoclonal antibody. The graph also
shows cells double positive for IgMp + CD69, CD21 or CD23. 10,000 cells were
counted in each analysis. The average number of specific marker-positive cell
subsets per MLN is presented.
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expression of this marker on T cells. The IgMp versus CD21 or CD23 levels
increased by days 5 and 6 but had fallen by day 10 post-infection. This might be an
indication of B cells moving in to the germinal centres for clonal selection at this
stage.
The clear rise in B cell numbers detected using an array of surface markers
substantiates the results seen in section 3.2.2. There is a sudden peak of B cells
appearing on day 5, which remain elevated on day 12 post-infection. The cells
double-stained for IgMp/CD21 and IgMp/CD23 increased on days 5 and 6,
indicating that there were many mature B cells being recruited into this region on
these days. The reasons for the massive increase in B cell numbers may be due to
virus coded proteins in the environment leading to B cell accumulation or due to host
cytokine or cellular signalling leading to proliferation.
3.3 CD4+ T cell signalling and B cells in the MLN
3.3.1 Requirement for CD4+ T cell signalling in lymph node enlargement
The increase in the number of B cells in the MLN seen during the initial course of
MHV-68 infection could involve a major role for virus genes in promoting B cell
proliferation and/or a role for CD4+ T cells in driving B cell proliferation.
In this section the role of CD4+ T cells was investigated by depleting these T cells
from mice. The method used is described in section (2.2.7). There were two groups
of mice, one set depleted of CD4+ T cells (Group 2) and another the control group of
mice (Group 1). In order to deplete CD4+ T cells the group 2 mice were injected
intravenously with lmg of YTS191 rat-anti-mouse CD4 antibody in a lOOpl volume.
Two days later both group 1 and group 2 mice were infected intranasally with 4 x 105
PFU MHV-68. On the second day post-infection the group 2 mice were injected
intravenously with lmg of YTS191 antibody. Four mice each were sampled on days
3 and 7. On day 7 the remaining group 2 mice were injected intraperitoneally with
lmg of YTS191 antibody. The MLN from 4 mice were pooled for each group on
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days 3, 7, 10 and 16 post-infection. We confirmed the depletion through FACS
analysis, the results shown in Figure 3.4.
The MLN were pooled, dissociated and total number of cells per MLN was
calculated for the CD4+ T cell depleted group and compared to the control group
over the time course of infection. The results are represented in Figure 3.5.
The CD4+ T cell depleted mice showed an increase in the number of MLN cells over
time particularly on day 10 post-infection there was a 5-fold increase. On the other
hand the infected control group of mice showed a 10-fold increase in the number of
cells on day 10 post-infection. Therefore there was only a 50% reduction in
lymphadenopathy on depleting CD4+ T cells.
The results show that CD4+ T cell signalling is important for the development of
lymphadenopathy to the extent seen in the control group but is not the only reason
the MLN exhibited lymphadenopathy during MHV-68 infection.
3.3.2 B cell numbers in the MLN following CD4+ T cell depletion
In view of the reduction in lymphadenopathy in CD4+ T cell depleted mice the
impact on B cell numbers was investigated. The MLN from 4 mice were pooled from
CD4+ T cell depleted and control mice on days 3, 7, 10 and 16 post-infection. The
MLN were dissociated to obtain single cell suspensions and cells taken for flow
cytometric analysis (FACS). The cells were stained either with anti-mouse CD 19
monoclonal antibody, biotinylated-anti-mouse IgMp monoclonal antibody, FITC-
conjugated anti-mouse IgG monoclonal antibody, FITC-conjugated anti-CD8
monoclonal antibody or FITC-conjugated anti-CD4 monoclonal antibody. The
results are represented in Figure 3.6.
The control group of mice showed a 4-fold increase in the number of B cells on days
7 and 10 compared to day 3 post-infection, similar to what was seen in section 3.2.3.
The CD 19 expressing B cell numbers in the CD4+ T cell depleted group was much
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Figure 3.4 FACS analysis for CD4+ T cells in the MLN The graphs on the left-hand panel
are unstained control cells, right-hand panel are cells stained with anti-mouse CD4+ T cells
from the MLNs of control mice and the middle panel are cells from the MLNs of mice depleted
of CD4+ T cells on days 3, 7, 10 and 16 post-infection. The FACS percentages of CD4+ T cell
are represented above the bars marked M1.
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Figure 3.5 Cellularity of the mediastinal lymph node in C57BL/6 mice depleted of
CD4+ T cells C57BL/6 mice were divided into two groups. Group 1 was the
infected but non-depleted control group and Group 2 was the infected and depleted of
CD4+ T cells. In order to deplete CD4+ T cells the group 2 mice were injected
intravenously with lmg of YTS191 rat-anti-mouse CD4 antibody in a lOOpl volume.
Two days later both Group 1 and Group 2 mice were infected intranasally with 4 x
105 PFU MFIV-68. On the second day post-infection the Group 2 mice were injected
intravenously with lmg of YTS191 antibody. Four mice each were sampled on days 3
and 7. On day 7 the remaining Group 2 mice were injected intraperitoneally with lmg
of antibody. The mediastinal lymph nodes from four mice were pooled for each group
on days 0, 3, 7, 10 and 16 post-infection. The MLNs were dissociated to obtain single
cell suspensions and cell number counted. The graph represents the average cell
numbers per MLN obtained for the control Group 1 (■ ) and the CD4+ T cell depleted
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Figure 3.6 B cell numbers in the mediastinal lymph node of C57BL/6 mice
depleted of CD4+ T cells C57BL/6 mice were divided in to two groups. Group 1
was the infected but non-depleted control group (control) and Group 2 was the
infected and CD4+ T cell depleted group. (The depletion was carried out
successfully as shown in figure 3.4). The mediastinal lymph nodes (MLN) from 4
mice were pooled for each group on days 3( □ ), 7 ( ■ ), 10 ( □ ) and 16(a) post¬
infection. The MLNs were dissociated to obtain single cell suspensions and cells
taken for flow cytometric analysis. The cells were stained with either anti-mouse
CD 19 monoclonal antibody, biotinylated-anti-mouse IgMp monoclonal antibody,
FITC-conjugated anti-mouse IgG monoclonal antibody, FITC-conjugated anti-CD8
monoclonal antibody or FITC-conjugated anti-CD4 monoclonal antibody. The graph
shows the average number of specific marker-positive cell subset per MLN. The fold
difference is representative of three independent experiments.
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lower on day 3 compared to control group, but as the infection progressed a 5-fold
increase was seen on days 10 and 16 post-infection. The IgG surface marker was
used to detect class switching by B cells. The cells were also stained for CD4+ and
CD8+ T cells.
The results in this section show that B cells proliferation is possible in the absence of
CD4+ T cells and could result from the direct proliferation mediated effects of the
virus.
3.3.3 Presence of latently infected cells in the MLN following CD4+ T cell
depletion
Cells carrying latent virus are determined by infective centre assay as described in
the methods section (2.2.2). Productive virus is ascertained using a simple freeze
thawing method described in section (2.2.3) and those values are subtracted from the
number of infective centres to obtain the final value of latently infected cells within
tissues. Usherwood et al (1996a) showed that on depleting CD4+ T cells there was a
comparative reduction in the number of latently infected cells in the spleen of
BALB/c mice. They also observed the absence of splenomegaly on depleting CD4+
T cells.
The following experiments investigated the changes in the number of latently
infected cells in the MLN and spleen on depleting CD4+ T cells in C57BL/6 mice.
The results are presented in Figures 3.7 and 3.8.
The control group of C57BL/6 mice showed a typical increase in the number of
latently infected cells in the MLN on days 10 and 16 post-infection. The CD4+ T cell
depleted mice showed a slight increase in the number of latently infected cells on day
10 post-infection but the overall number of cells was comparatively reduced in the
MLN. In the spleen, too, the number of latently infected cells was reduced in the

















Figure 3.7 Latent virus in the mediastinal lymph node of C57BL/6 mice depleted
of CD4+ T cells C57BL/6 mice were divided into two groups. Group 1 was the
infected but non-depleted control group and Group 2 was the infected and CD4+ T
cell depleted group. In order to deplete CD4+ T cells the group 2 mice were injected
intravenously with lmg of YTS191 rat-anti-mouse CD4 antibody in a lOOpl
volume. Two days later both Group 1 and Group 2 mice were infected intranasally
with 4 x 105 PFU MHV-68. On the second day post-infection the Group 2 mice were
injected intravenously with lmg of YTS191 antibody. Four mice each were sampled
on days 3 and 7. On day 7 the remaining Group 2 mice were injected
intraperitoneally with lmg of antibody. The MLNs from four mice were pooled for
each group on days 3, 7, 10 and 16 post-infection. The MLNs were dissociated to
obtain single cell suspensions and cell numbers counted. The graph represents the
number of infective centres (latent virus) per 107 cells in the MLN of the control
Group 1(b) and the CD4+ T cell depleted Group 2 ( □ ) mice. The fold difference is
representative of three independent experiments.
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Figure 3.8 Latent virus in the spleens of C57BL/6 mice depleted of CD4+ T cells
C57BL/6 mice were divided in to two groups. Group 1 was the infected but
non-depleted control group and Group 2 was the infected and CD4+ T cell depleted
group. In order to deplete CD4+ T cells the group 2 mice were injected intravenously
with lmg of YTS191 rat-anti-mouse CD4 antibody in a lOOpl volume. Two days
later both Group 1 and Group 2 mice were infected intranasally with 4 x 105 PFU
MHV-68. On the second day post-infection the Group 2 mice were injected
intravenously with lmg of YTS191 antibody. Four mice each were sampled on days 3
and 7. On day 7 the remaining Group 2 mice were injected intraperitoneally with lmg
of antibody. The spleens were sampled on days 3, 7, 10 and 16 post-infection. The
spleens were dissociated to obtain single cell suspensions and cell number counted.
The graph represents the number of infective centres (latent virus) per 107 splenocytes
of the control Group 1 ( ■) and the CD4+ T cell depleted Group 2 ( □ ) mice.
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The observations in the MLN show that the establishment of latency very early
during the course of MHV-68 is dependent on the presence of CD4+ T cells just as
was previously observed in the spleen. However, CD4+ T cells may be important
mainly in driving the transient peak of latent infection and not in the long-term
establishment of latency.
3.4 Latently infected cells in the absence of B cells, in the
MLN
3.4.1 Latently infected cells in the MLN of pMT mice
The previous work on the B cell deficient (pMT) mice (Usherwood et al, 1996b)
showed that these mice lacked detectable latently infected cells in the spleens
following MHV-68 infection. This indicated the importance of B cells in establishing
latency in the spleen.
In order to detect whether cells other than B cells were involved in trafficking virus
into the MLN, the pMT mice were compared to the C57BL/6 mice on days 3, 7 and
10 post-infection. The MLN was the main target organ but the cervical lymph node
(CLN) was also examined in order to detect the systemic transfer of virus during
infection. The lymph nodes were pooled and latently infected cells were assayed
using infective centre assay, The results are presented in Figure 3.9.
The pMT mice had a detectable level of latently infected cells in the MLN on days 3
and 7 post-infection similar to the C57BL/6 mice. On day 10 post-infection the
C57BL/6 mice had a large increase in the number of latently infected cells and in
contrast the pMT mice had none. The CLN of pMT mice showed no detectable
levels of latently infected cells on any of the days investigated while the C57BL/6
mice had latently infected cells on days 7 and 10 post-infection.
The results of this experiment demonstrated that the virus could infect cells other
than B cells very early during infection as observed in the pMT mouse MLN.
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3.4.2 Immunostaining for cells expressing virus encoded lytic proteins
Cells with productive virus infection (infective virus) or cells reactivated from
latency express virus encoded proteins that can be detected by immunostaining with
antibodies generated against lytic MHV-68. Immunostaining assay was carried out to
look for lytic virus positive cells in the MLN of pMT mice following MHV-68
infection.
The IFN-a/p R7" mice exhibit higher number of cells infected with virus as
compared to normal wild type mice as deduced from studies on disease pathogenesis
of MHV-68 (Dutia et al., 1999a). Therefore these tissues were used as positive
controls. Lungs and MLN from infected pMT and IFN-a/p R7" mice were fixed in
10% formaldehyde and subsequently paraffin embedded. The paraffin embedded
tissues sections cut on to Biobond coated slides were used for immunostaining as
described in the methods section (2.2.9). The tissue samples were dewaxed and
stained using anti-MHV-68 antibodies.
The immunostained lung and MLN tissues sections of IFN-a/p R7" mice is shown in
Figure 3.10. There were no cells stained with MHV-68 antibodies detectable in the
MLN tissue sections of pMT mice.
3.4.3 Detection of virus particles using electron microscopy
Virus capsids can be detected in cells containing productive virus. Herpesviruses
being large viruses have 120-150nm capsids and can be visualised using a
transmission electron microscope (TEM).
Cells from pMT mice MLN on day 7 post-infection were enriched for surface
marker CD 11c by MACS as described in the methods section (2.2.10) and the
purified cells were fixed for transmission electron microscope (2.2.15). The images
are shown in Figure 3.11.
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Figure 3.10 Lung and MLN tissues from IFN a/ft R-/- mice immunostained for
MHV-68 lytic viral proteins Paraffin embedded tissue sections from IFN-a/p
R"~ mice infected with 4 x 105 PFU MHV-68 on day 7 post-infection were dewaxed
and immunostained for virus coded proteins as described in the methods section
(2.2.9). The tissue sections were incubated with rabbit polyclonal MHV-68 antibody.
The figure represents (A) lung tissue (magnification X200) and (B) MLN
(magnification X200). The positively stained cells are those that are stained dark
brown (indicated by arrows).
Figure 3.11 Transmission Electron Microscopy to detect virus particles in MLN
cells from uMT mice infected with MHV-68 pMT mice were infected with
4 x 105 PFU MHV-68 intranasally. On day 7 post-infection MLNs from 6 mice were
pooled, dissociated into single cells and enriched for the CD1 lc surface marker using
magnetic activated cell sorting (MACS) as described in the methods section (2.2.15).
The enriched cells were subsequently processed for electron microscopic (EM)
analysis. The Figure represents (A) the morphology of the CDllc enriched
population (magnification: X5000), (B) vesicle within the cytoplasm of a cell, arrows
showing virus particle (magnification: X35,000) and (C) the same virus particle
under higher magnification: X60,000.
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The pMT MLN had no cells with capsids that were detectable in the nucleus. There
were a few cells that contained a single capsid in cytoplasmic vesicles. These could
be virus particles that have been engulfed into the cell following virus attachment to
the cell. Therefore, there were no cells detectable in the MLN with replicating virus
as determined by the presence of virus capsids in the nucleus.
3.4.4 Reverse transcription-polymerase chain reaction (RT-PCR) for viral
transcripts on whole tissues
Replicating virus express a large number of genes but during latency most of the
structural gene expression is shutdown and genes involved in maintaining virus
latency are turned on. In the case of MHV-68 clear differences between lytic and
latent genes have not been established. However, an experiment was designed to
look at ORF50 an immediate early transcript and M3 an early/latency associated
transcript in the MLN of pMT mice.
To investigate the gene expression, RT-PCR was carried out on whole lymphoid
tissue. MLN were taken from infected mice on days 3, 5, 7 and 10 post-infection and
snap frozen in liquid nitrogen. RNA was extracted as described in the method section
(2.2.18). 2pg of RNA for each sample was treated with DNAse and an aliquot
removed prior to RT to be used as controls. Complementary-DNA (cDNA) was
made as described in the methods section (2.2.19). The cDNA was used for PCR
amplification of MHV-68 gene transcripts ORF50 and M3 and the cellular P-actin
transcript (control) as described in the methods section (2.2.20). The results are
presented in Figure 3.12. The samples removed prior to RT were used in a PCR with
M3 primers to confirm that the DNAse step was successful.
The RT-PCR results show that both in the MLN of C57BL/6 and the pMT mice
ORF50 and M3 positive transcripts were present on all days investigated.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
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Figure 3.12 RT-PCR for viral transcripts on whole MLNs from uMT and
C57BL/6 mice pMT mice and C57BL/6 mice were infected with 4xl05PFU
MHV-68 intranasally. MLNs from infected mice on days 3, 5, 7 and 10 post¬
infection were snap frozen in liquid nitrogen. cDNA was made from 2pg of RNA
extracted from the individual MLNs as described in the methods sections (2.2.18
and 2.2.19). The cDNA was used for PCR amplification of MHV-68 gene
transcripts as described in the methods section (2.2.20). The figure represents (A)
samples amplified for MHV-68 ORF50, (B) samples amplified for MHV-68 M3 and
(C) samples amplified for cellular p-actin transcript. In the figure the lane number
(1) 1Kb Lambda Marker, (2 and 3) pMT mice MLNs on day 3 post-infection, (4)
C57BL/6 mouse MLN on day 3, (5 and 6) pMT mice MLNs on day 5 post¬
infection, (7 and 8) C57BL/6 mice MLNs on day 5 post-infection, (9 and 10) pMT
mice MLNs on day 7 post-infection, (11 and 12) C57BL/6 mice MLNs on day 7
post-infection, (13 and 14) pMT mice MLNs on day 10 post-infection, (15 and 16)
C57BL/6 mice MLNs on day 10 post-infection and (17) PCR negative control.
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3.5 CD8+ CTL and B cells in the MLN
3.5.1 MHV-68 specific CTL response, in the absence of B cells
The experiments with CD8+ T cell depleted mice (Ehtisham et al., 1993) and with
P2-microglobulin deficient mice (Week et al., 1996) have shown the importance of
CD8+ T cells in MHV-68 infection. The CD8+ T cells play a critical role in the
clearance of lytic MHV-68 from the lungs and also in the prevention of latent virus
reactivation from tissues (Stevenson et al., 1998).
The presence of B cells infected with MHV-68 may play an important role in
enhancing CTL activity in the MLN. In order to determine the importance of B cells
we compared CTL activity in pMT and C57BL/6 mice. The ILN-y CTL assay
described in section (2.2.11) was used to measure the frequency of CTL specific for
the immuno-dominant peptides obtained from ORL6 and ORL61 of MHV-68
(Stevenson et al., 1998). The results are represented in Figure 3.13.
The pMT mice showed CTL activity as early as day 6 in the MLN, although the
numbers fell by days 10 and 17 post-infection. The C57BL/6 mice showed 10-fold
higher virus specific CTLs on days 10 and 17 post-infection compared to pMT mice.
The CTL activity on day 6 post-infection seen in the MLN of pMT mice could be
due to (a) professional APCs presenting antigen from the lung and/or (b) cells in the




































Figure 3.13 MHV-68 specific CTL response in the MLN of pMT and C57BL/6
mice The pMT mice and C57BL/6 mice were infected intranasally with 4 x 105
PFU MHV-68. MLN from 6 mice in each group were pooled and made into single
cell suspensions and 96 well plates were seeded with 1 x 106 cells each. The IFN-y
CTL assay was carried out as described in the method section (2.2.11). Cells were
stimulated using the MHV-68 specific peptides pepl and pep2 coded by the ORF6
and ORF61 respectively. The cells were incubated for 5 hours and double-stained for
CD8+ T cells and for IFN-y in permeablised cells and analysed by flow cytometry.
The graph represents the percentage of CD8+ T cells expressing IFN-y in the MLNs
of pMT mice for pep 1 ( □), pMT mice for pep 2( ■ ), C57BL/6 mice for pep 1( □ )
and C57BL/6 mice for pep 2 ( □ ) on days 3, 6, 10 and 17 post-infection. The error
bars represent the standard error of the mean.
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CHAPTER FOUR
APPLICATION OF A GREEN FLUORESCENT
PROTEIN (GFP) EXPRESSING GAMMAHERPESVIRUS
4.1 Introduction
The experiments described in Chapter 3 (section 3.4) demonstrated the presence of
cells other than B cells infected with MHV-68 in the MLN of pMT mice early in
infection. However, due to the fewer number of positive cells and the sensitivity of
the assays, it was difficult to identify the type of cells that harboured virus.
Therefore, the decision was made to use a recombinant MHV-68 virus expressing
green fluorescent protein (GFP). The recombinant virus, LHAgfp was a gift from Dr.
D. Roy and Dr. J. Stewart (Veterinary Pathology, University of Edinburgh). The
reason that led us to believe that this virus could be a useful tool was that in vitro
cells infected by the virus expressed GFP. If the same occurred in vivo this would be
a marker to help identify cells carrying virus.
In the case of human gammaherpesvirus infections such as EBV and KSHV the
primary cell targets infected by the virus have remained controversial. In individuals
infected with KSHV, different cell types have been shown to carry latent virus but
the primary site of infection and cell type infected is not clearly understood. In EBV
infection, B cells have been shown to be the major reservoirs of virus during latency
but whether they are the first cells to be infected is under debate (Faulkner et al.,
2000). MHV-68 infection of mice is an amenable model and is an ideal system to
study the cell types infected at the very early stage of infection and their role in
trafficking virus to other tissues. Intranasal infection of mice has shown that
epithelial cells and monocytes are infected in the lungs (Sunil-Chandra et al., 1992a).
It has also been shown that B cells are capable of transferring virus to the spleen. In
experiments where MHV-68 infected pMT mice were injected with B cells from
uninfected mice, the virus was subsequently detected in the spleen (Stewart et al.,
1998). The experiment showed that B cells could become infected directly from the
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lungs, but the question as to whether during normal infection all the B cells were
infected from the lungs or whether there were other cells acting as reservoirs in the
MLN has not been addressed.
Dendritic cells are professional antigen-presenting cells (APC) and their role in
immune surveillance is indisputable with their ability to capture and transfer antigens
from foreign organisms to sites of immune activity. Lungs being an important tissue
that remains in continuous contact with the environment, dendritic cells play a very
critical role at this site. The immature dendritic cells present in the lungs on antigenic
exposure start maturing and move into draining lymph nodes where they act as
effective antigen-presenting cells. In recent years there has been evidence that a
number of viruses infect dendritic cells and use them for their own advantage to
traffic to tissues within the host and to manipulate immune activation. Studies with
HIV indicated that dendritic cells from the mucosal sites could acquire the virus and
migrate to the draining lymph node where the virus could subsequently infect CD4+
T cells (Knight and Patterson, 1997). This is a compelling mechanism that might also
be exploited by other viruses. This chapter examines this mechanism with respect to
MHV-68.
LHAgfp has a GFP gene under the human cytomegalovirus (HCMV) immediate-
early promoter inserted into the left-hand terminal end of the virus. This insertion has
led to the deletion of five tRNA sequences and the Ml gene from the MHV-68
genome. Wild type MHV-68 has eight tRNA sequences that are expressed in infected
cells both during lytic and latent phases of the virus infection but their function is
unknown (Bowden et al., 1997). The published work on the Ml gene indicates that
the Ml gene deletion mutant has an increased ability to reactivate from latency
(Clambey et al., 2000). Therefore, this recombinant virus could behave differently
from the wild type MHV-68. In order to determine any changes in pathogenesis or
establishment of latency, studies on pathogenesis were carried out with LHAgfp in
comparison with wild type MHV-68 and the results are presented in the following
section.
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4.2 Characterisation of LHAgfp
4.2.1 Infective virus in the lungs of C57BL/6 mice infected with LHAgfp as
compared to wild type MHV-68
The experiments described in this section were aimed to investigate the in vivo
growth characteristics of the recombinant LHAgfp virus as compared to the wild type
MHV-68. The virus titres in the lungs and number of latently infected cells in the
mediastinal lymph node and spleen were examined.
Intranasal administration of virus leads to the infection of alveolar epithelial cells. At
this stage the virus undergoes lytic replication. C57BL/6 mice were infected with 4 x
105 PFU of either LHAgfp or MHV-68. C57BL/6 mice were used because the studies
with LHAgfp as a marker virus were to be carried out in the pMT mice of the same
background. The lungs were removed, homogenised and the amount of replicating
virus determined using the infective virus assay as described in the methods section
(2.2.3). The results are represented in Figure 4.1.
The wild type virus (MHV-68) showed typical growth patterns in the lungs in
agreement with previous studies (Usherwood et al., 1996b), where the virus titres
peaked around day 8 and were absent by day 10 post-infection. In the case of the
recombinant virus (LHAgfp) the titres peaked around day 4 and the levels fell by day
8 post-infection. However, there was no statistically significant (Student t-Test
analysis) difference between the two groups.
4.2.2 Latently infected cells in the mediastinal lymph node
The results in Chapter 3 demonstrate the importance of the MLN during the
progression of MHV-68 infection. The results showed that even as the lytic phase
progresses in the lungs, MHV-68 latent in certain types of cells is transferred to other
sites such as the MLN and eventually the spleen. It was therefore essential to
determine the presence of latently infected cells in the MLN that may be present in































Figure 4.1 Infective virus in the lungs of C57BL/6 mice infected with either
LHAgfp or MHV-68 C57BL/6 mice were divided in to two groups. Group 1(D)
mice were infected intranasally with 4 x 105 PFU MHV-68. Group 2(A) mice were
infected intranasally with 4 x HP PFU LHAgfp. Lungs from four mice in each group
was removed on days 2, 4, 6, 8 and 10 post-infection and frozen at -70°C.
Subsequently, the lungs were homogenised and assayed for infective virus particles.
The graph represents the number of infective virus as plaque forming units (PFU) per
set of lungs, in logarithmic scale on the y-axis and days post-infection on the x-axis.
The coloured number adjacent to the points on the graph show the number of
overlapped points for the respective group. The graph is representative of two
independent experiments.
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extremely debilitated the host immune response would clear the virus from the lungs
and there would be no systemic transfer of virus. The MLN would be the ideal site to
look for any such changes during the early stages of infection.
MLN were removed at times post-infection, starting at day 6 and up to day 31. The
MLN were pooled from four C57BL/6 mice for each virus, homogenised and the
number of latently infected cells determined using the infective centre assay as
described in the method section (2.2.2). The results are represented in Figure 4.2.
Latently infected cells were observed in the case of both LHAgfp and wild type
MHV-68. The wild type MHV-68 showed a distinct peak of latently infected cells on
days 10 and 15 post-infection, but this peak failed to appear in the case of the
recombinant LHAgfp.
The results demonstrate that the recombinant virus is able to spread systemically and
the infection progression is similar to the wild type virus as it appears in the MLN
and it is also able to establish latency.
4.2.3 Extent of Iymphadenopathy
Lymph node enlargement was a noticeable change during MHV-68 infection
(Sarawar et al., 1996). Therefore it was considered important to determine the total
number of lymphocytes accumulating in the MLN during LHAgfp infection. The
results are represented in Figure 4.3.
It was observed that the extent of lymphadenopathy in the MLN of mice infected
with LHAgfp closely resembled the wild type MHV-68 infected mice. The reduced
number of latently infected cells in the MLN of mice infected with LHAgfp (as
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Figure 4.2 Latent virus in the mediastinal lymph node of C57BL/6 mice
infected with either LHAgfp or MHV-68 C57BL/6 mice were divided in to
two groups. Group l(m ) mice were infected intranasally with 4x10^ PFU MHV-68.
Group 2(D) mice were infected intranasally with 4 x 105 PFU LHAgfp. MLNs
were pooled from four mice in each group on days 6, 10, 15, 18, 27 and 31 post¬
infection. The MLNs were dissociated to obtain single cell suspensions and plated
with BHK cells to assay for infective centres as described in methods section (2.2.2).
The graph represents the latent virus per 107 MLN cells on the y-axis against days
post-infection on the x-axis. The graph is representative of two independent
experiments.
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Figure 4.3 Lymphadenopathy of the mediastinal lymph node of C57BL/6 mice
infected with either LHAgfp or MHV-68 C57BL/6 mice were divided in to
two groups. Group l(d ) mice were infected intranasally with 4xl05 PFU MHV-68.
Group 2(D) mice were infected intranasally with 4 x 105 PFU LHAgfp. MLNs were
pooled from four mice in each group on days 6, 10, 15, 18, 27 and 31 post-infection.
The MLNs were dissociated to obtain single cell suspensions and counted. The graph
represents the average number of MLN cells (x 106) on the y-axis against days post¬
infection on the x-axis. The graph is representative of two independent experiments.
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4.2.4 Latently infected cells in the spleen
The experiment was aimed at measuring the levels of latently infected cells in the
spleens of mice infected with either LHAgfp or wild type MHV-68. The spleens from
infected mice were removed at different day points of infection and the number of
latently infected cells measured using infective centre assay as described in the
methods section (2.2.2). The results are represented in Figure 4.4.
Latently infected cells were detected as early as day 7 post-infection and there were
similar numbers of latently infected cells in the case of both LHAgfp and wild type
MHV-68 on day 10 post-infection. However, on day 15 the peak levels of latently
infected cells in wild type MHV-68 were not seen with LHAgfp, by day 28 and 31
both viruses showed the same levels of latency.
These results demonstrate a significant difference on day 15 post-infection in the
spleens of wild type MHV-68 and LHAgfp infected mice (p = 0.0001, analysed using
Student's t-Test). However, LHAgfp was capable of establishing an overall latency
pattern similar to wild type MHV-68. Therefore, LHAgfp could be used as a marker
virus to seek answers to questions regarding virus trafficking and the cell types
involved.
4.3 LHAgfp as a tool to study the trafficking of virus in vivo
4.3.1 GFP positive cells in the lungs and mediastinal lymph node imprints
The results from MHV-68 infected pMT mice (presented in section 3.4)
demonstrated that cells other than B cells could be detected with latent virus during
the early stages of infection.
To investigate whether LHAgfp behaved similarly to wild type MHV-68 in the
MLN of pMT mice, pMT mice were infected intranasally with 4 x 105 PFU LHAgfp.
The lungs and the MLN were removed and tissue imprints were made as described in
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Figure 4.4 Latent virus in the spleens of C57BL/6 mice infected with either
LHAgfp or MHV-68 C57BL/6 mice were divided in to two groups. Group 1(D)
mice were infected intranasally with 4 x 105 PFU MHV-68. Group 2(A) mice were
infected intranasally with 4 x 105 PFU LHAgfp. Spleens were removed from four
mice in each group on days 6, 10, 15, 18, 27 and 31 post-infection. The spleens were
sheared to obtain single cell suspensions and plated with BHK cells to assay for
infectious centres as described in methods section (2.2.2). The graph represents the
latent virus per 107 splenocytes in logarithmic scale on the y-axis against days post¬
infection on the x-axis. The graph is representative of two independent experiments.
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to look for GFP expressing cells at various days of infection. The fluorescence
micrographs obtained on day 5 post-infection in the lung and MLN imprints of pMT
mice are represented in Figure 4.5.
Cells expressing GFP were identified in lung tissue and, at lower levels in the MLN
on day 5 post-infection. Therefore, using LHAgfp it was possible to detect the rare
cells infected by the virus. This was the first demonstration that this recombinant
virus could express GFP "in vivo", aiding in tracking infected cells.
4.3.2 CDllc expressing cells enriched from pMT mice MLN
There is evidence that gammaherpesviruses are capable of infecting monocytes.
During KSHV infection there are instances where monocytes isolated from patients
suffering from Kaposi's sarcoma lesions have been found to be infected with the
virus (Blasig et al., 1997). In the case of MHV-68 there is evidence from
immunostained lung tissues that large monocytic cells were infected with MHV-68
(Sunil-Chandra et al., 1992a). There is also evidence that macrophages in the
peritoneal fluid become latently infected following MHV-68 infection (Week et al.,
1999b).
The CD1 lc surface marker is present on most subtypes of dendritic cells although it
is also seen in small amounts on macrophages and B cells; it is the best broad-
spectrum marker for murine dendritic cells (Steinman, 1991). The decision was made
to examine the dendritic cell population that drains into the MLN from the lungs as a
candidate cell type that might be susceptible to infection very early during MHV-68
infection.
Magnetic beads coated with hamster anti-mouse CD 11 c (N418) antibodies were
purchased from Miltenyi Biotech. The assay was carried out as described in the
methods section (2.2.10). pMT mice were infected with 4 x 105 PFU LHAgfp. MLN
from 7 mice were pooled to obtain single cell suspensions. The cells were incubated
with CDllc coated magnetic beads, washed and then passed through the MACS
Figure 4.5 GFP positive cells in the lungs and mediastinal lymph node imprints
of |aMT mouse infected with LHAgfp pMT mice were infected intranasally
with 4 x 105 PFU LHAgfp. On day 5 post-infection the lungs and MLN were
sampled from mice and dabbed on to Biobond coated slides as described in the
methods section (2.2.6). The slides were fixed with ice cold acetone, air dried and
viewed under a fluorescence microscope. The panel marked (A) in the figure
represents lung imprints, panel (B) represents imprints of cells from the MLN,
showing GFP expressing cells (magnification: X320).
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columns. The cells recovered from the columns were subjected to FACS analyses, to
ascertain that the enriched cells were large morphologically and expressed CD1 lc on
staining with anti-hamster IgG conjugated to PE. The cells were also analysed for
intracellular GFP expression. The results are represented in the Figure 4.6.
The FACS analysed dot plot in Figure 4.6 (3.a) shows the scatter data of cells that
were positively enriched for CD1 lc+ cells, which were slightly larger cells compared
to the total cell population {Figure 4.6 (l.a)} or the unbound cells (flow through)
{Figure 4.6 (2.a)}. The FACS staining in Figure 4.6 (3.b) shows the FACS staining
for CDllc+ cells on the y-axis, where 55% of the cells expressed this marker. The
FACS staining on the x-axis shows the cells expressing GFP. Of the 55% CDllc
positive cells around 3% of the cells were also positive for GFP
The results obtained from the FACS analyses demonstrated that there were cells
positive for CD 11 c that were also expressing GFP and they can be obtained from the
MLN of pMT mice infected with LHAgfp on day 5 post-infection.
4.3.3 CDllc enriched cells expressing GFP stained with F4/80
The FACS analysis of the MACS enriched cells showed that 55% were CDllc
expressing cells and the rest were CD1 lc- cells. Therefore it was deemed necessary
to stain these cells with other surface markers to ascertain that there were no other
cell types expressing GFP in the pMT mouse MLN. The published data (Week et al.,
1999b) on F4/80 positive macrophages carrying latent virus in the peritoneal exudate
cells (PECs) of normal mice prompted the use of this surface marker.
The cells were selected by MACS for CDllc and the enriched population was
resuspended in a small amount of FACS buffer and stained with monoclonal
antibody against F4/80, as described in the methods section (2.2.5). Subsequently the
cells were cytospun on to Biobond coated slides and viewed using a Leitz Confocal
microscope. The results are presented in Figure 4.7.
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Figure 4.6 FACS analysis dot plots representing scatter data and staining of
CD1 lc cells, obtained from MACS enrichment of pMT mouse MLN pMT mice
were infected intranasally with 4 x 105 PFU LHAgfp. On day 5 post-infection the
MLN were pooled from seven mice and dissociated to obtain single cell suspensions.
The cells were counted, resuspended in MACS buffer and incubated with hamster
anti-mouse CD1 lc antibody (clone N418) coated magnetic beads (Miltenyi Biotech)
as described in the method section (2.2.10). A small aliquot of cells was removed for
FACS analysis of the total cell population. The rest of the cells were passed through
the MACs columns. The unbound cells (flow through) were also collected for
analysis. The bound cells were removed from the column and passed through a
second column to decrease the amount of contaminating cell population. All the
aliquots of cells were stained with anti-hamster IgG conjugated to PE. In the figure
panels l.a, 2.a and 3.a represent the forward scatter (x-axis) and side scatter (y-axis)
of the total cells prior to passing through the column, the unbound cells and the
MACS enriched cells respectively. The panels l.b, 2.b and 3.b represents the staining
profile with anti-hamster IgG-PE (y-axis) and the intracellular GFP expression (x-
axis) of the total cells prior to passing through the column, the unbound cells and the
MACS enriched cells respectively.
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Figure 4.7 GFP expressing cells stained with F4/80 antibody
Figure 4.7 GFP expressing cells stained with F4/80 antibody pMT mice were
infected intranasally with 4 x 105 PFU LHAgfp. On day 5 infection mediastinal
lymph nodes (MLN) from seven mice were pooled and dissociated to obtain single
cell suspensions. The cells were firstly MACS enriched for CD lie as discussed in
the section 4.3.2. The enriched cells were resuspended and stained with anti-mouse
F4/80 monoclonal antibody followed by anti-rat IgG conjugated to TRITC. The cells
were cytospun on to Biobond coated slides and viewed under a confocal microscope.
The figure represents confocal images of these cells (magnification: X600). In the
figure the panels la, lb and lc are images from the same field; la, shows
intracellular GFP (green) expression; lb, shows TRITC staining (red) of cells
expressing F4/80; lc, shows the overlap of la and lb where a cell expressing GFP is
also positive for F4/80 staining. The panels 2a, 2b and 2c is another field. It is
ordered similar to panels la to lc.
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The fluorescence images for cellular expression of GFP confirm that the cells
examined contained diffused GFP within cells and not GFP in vacuoles from
engulfed virus infected cells. The results show GFP expressing cells stained with
F4/80 surface marker. This could mean that macrophages expressing F4/80 too were
cells that carried latent virus during the early course of infection and can be found
localised in the MLN.
4.3.4 The advantages of using the IFN-a/p R7" mouse system which displays an
exaggerated MHV-68 disease pathogenesis
The work with the pMT mouse system provided very important evidence as to the
cell types that may be involved in trafficking virus into the MLN at very early stages
of infection. However, the work with this system was restricted because of the small
number of cells infected. In order to amplify the number of cells infected at early
times in the MLN an alternative mouse model was investigated-the IFN-a/p R7"
mouse system. This system was of interest, as it would not only make it possible to
increase the number of infected cells but also indicate what happens in the absence of
interferon signalling in the MLN of MHV-68 infected mice.
Previous work (Dutia et al., 1999a) on IFN-a/p R7" mice infected with MHV-68
shows that this system is extremely susceptible to the virus and it exhibits
disseminated infection in which more than 80% of mice succumb to the disease even
with the normal dose of 4 x 105 PFU MHV-68. The data also showed that there is a
100-fold increase in the number of latently infected cells in the spleens as compared
to the wild type counterpart, WT129 mice. The number of latently infected cells in
the spleens is controlled over time in the spleen. These results demonstrate the
importance of IFN-a/p in clearance of lytic lung infection and in keeping the number
of latently infected cells under check during early MHV-68 infection.
To investigate the level of infection in CDllc+ cells obtained from IFN-a/p R7"
mice at early times post-infection IFN-a/p R7" mice were infected intranasally with 4
x 105 PFU LHAgfp and MLN were pooled from 6 mice on day 5 infection and
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dissociated into single cell suspensions. The cells were incubated with CDllc
magnetic beads and MACS separation carried out. They were analysed using FACS,
as shown in Figure 4.8. The Figure 4.9 represents cells enriched for CDllc+ from
MLN on day 4 post-infection showing intracellular GFP expression.
The results demonstrated that the MACS method enriched CD1 lc cells by 50% from
MLN of IFN a/p R_/" mice. Of those cells, 10% also expressed GFP. This result
confirms that, even in the presence of B cells, CDllc+ cells can be infected during
the early stages of infection in the MLN. In the IFN-a/p R ~ mice there were three
times more CDllc+ cells expressing GFP as compared to the pMT mice. The
fluorescence micrographs of the cells show a uniform expression of GFP in the
cytoplasm, confirming that the GFP is from within these cells and not from vacuoles
carrying engulfed cells.
4.3.5 CDllc enriched cells expressing GFP confirmed with surface staining
The MACS enriched CD1 lc cells were stained and analysed under high power using
a Leitz Confocal microscope. The enriched cells were analysed for FACS using anti-
hamster IgG conjugated to PE that bound primary CDllc antibody (clone N418).
Although the wavelength of PE staining was not ideal for the fluorescence
microscope the results for GFP expressing cells and images are presented in Figure
4.10 (La and Lb).
The enriched cells were also stained with another anti-CD 1 lc (clone HL-3) antibody
conjugated to biotin (PharMingen). The cells were washed and subsequently stained
with streptavidin conjugated to TRITC. The confocal micrograph images are
represented in Figure 4.10 (2.a and 2.b). The Figure 4.10 (3.a and 3.b) shows the
enriched cells that were stained with anti-mouse DEC-205 (NLDC145) followed by
anti-rat IgG conjugated to TRITC.
The staining of GFP positive cells with anti-CD lie by two methods confirmed that
virus was infecting the CDllc+ population. Some of the GFP expressing cells were
1. a. l.b.










10° 10' 102 103 10"
2. a. 2. b.














10° io' io2 io3 104
3. a. 3. b.
Figure 4.8 FACS analysis dot plots representing scatter data and staining
obtained from MACS enrichment of IFN-a/B R-/- mouse MLN
Figure 4.8 FACS analysis dot plots representing scatter data and staining of
CD1 lc cells, obtained from MACS enrichment of IFN-a/p R-/- mouse MLN IFN-
a/p R_/" mice mice were infected intranasally with 4 x 105 PFU LHAgfp. On day 5
post-infection the MLN were pooled from seven mice and dissociated to obtain
single cell suspensions. The cells were counted, resuspended in MACS buffer and
incubated with hamster anti-mouse CD lie antibody (clone N418) coated magnetic
beads (Miltenyi Biotech) as described in the method section (2.2.10). A small aliquot
of cells was removed for FACS analysis of the total cell population. The rest of the
cells were passed through the MACs columns. The unbound cells (flow through)
were collected for analysis too. The bound cells were removed from the column and
passed through a second column to decrease the amount of contaminating cell
population. All the aliquots of cells were stained with anti-hamster IgG conjugated
to PE. In the figure panels l.a, 2.a and 3.a represent the forward scatter (x-axis) and
side scatter (y-axis) of the total cells prior to passing through the column, the
unbound cells and the MACS enriched cells respectively. The panels Lb, 2.b and 3.b
represents the staining profile with anti-hamster IgG-PE (y-axis) and the intracellular
GFP expression (x-axis) of the total cells prior to passing through the column, the
unbound cells and the MACS enriched cells respectively.
Figure 4.9 Fluorescence images of cells enriched for CD1 lc using MACS
IFN-a/p R_/" mice were infected intranasally with 4 x 105 PFU LHAgfp.
Mediastinal lymph nodes from seven mice were pooled on day 4 post-infection.
The cells were enriched for CDllc cells using MACS as discussed in the
methods section (2.2.10). The enriched cells were cytospun on to Biobond coated
slides and viewed under a fluorescence microscope. The figure represents the
intracellular expression of green fluorescent protein (GFP) in a few of the cells.
The panel on the right-hand side is a higher magnification (X320) of cells seen
on the left-hand side panel (X200).
Figure 4.10 CD1 lc enriched cells from IFN-q/B R-/- mice MLN, expressing
GFP and stained for surface markers
Figure 4.10 CD1 lc enriched cells from IFN-q/p R-/- mice MLN, expressing
GFP and stained for surface markers IFN-a/p R"/_ mice were infected
intranasally with 4 x 105 PFU LHAgfp. The mediastinal lymph nodes were pooled
from 7 mice, dissociated to obtain single cell suspensions and cells were used for
MACS enrichment as described in the methods section (2.2.10). The cells were
enriched using magnetic beads (Miltenyi Biotech) coated with hamster anti-mouse
CD 11c monoclonal antibody (clone N418). All the panels in the figure represent
cells that were obtained after CD 11c enrichment and viewed under a Confocal
microscope. The panels l.a and l.b in the figure represent cells that were stained
with anti-hamster IgG conjugated to PE. These cells were used for FACS analysis
and the data is represented in figure 4.8. The panel l.a shows the intracellular GFP
expression in a cell and panel l.b shows the same cell stained with anti-hamster PE
antibody. The panels 2.a and 2.b represent cells that were stained with CD1 lc-biotin
(clone HL-3) and streptavidin-TRITC. The panel 2.a shows GFP expression in a cell
and panel 2.b shows the same cell stained with CD 1 lc-biotin plus streptavidin-
TRITC. The panels 3.a and 3.b represent cells that were stained with anti-mouse
DEC-205 (NLDC145). 3.a shows GFP expression in a cell and 3.b shows the same
cell stained with anti-mouse DEC-205 followed by anti-rat IgG conjugated to
TRITC. Magnification: X600.
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also stained with DEC-205 a dendritic cell specific surface marker. This data gave
further confirmation of the presence of CDllc+ cells infected with LHAgfp in the
MLN during the early stages of infection.
4.4 Pathogenesis of LHAgfp in IFN-a/p R"/_ mice versus WT129
mice
4.4.1 Infective virus in the lungs
Pathogenesis of LHAgfp was examined in IFN-a/p R"" and WT129 mice over a time
course of infection to verify that the recombinant virus exhibited amplified disease
pathogenesis similar to wild type MHV-68. The experiment would also provide us
with answers as to whether the CD1 lc+ cells infected by the virus persisted over the
full duration of infection.
IFN-a/p R~" and WT129 mice were infected with 4 x 105 PFU LHAgfp. The lung
tissue was removed from three mice in each group on days 3, 5, 7 and 10 post¬
infection and frozen at -70°C. Subsequently the lungs were homogenised and assayed
for infective virus as described in the methods section (2.2.3). The results are
represented in Figure 4.11.
The results demonstrated that as early as day 3 post-infection the IFN-a/p R mice
had 20-30 times more infective virus in the lung tissue compared to the WT129 mice.
By day 10 post-infection the virus levels were declining in the WT129 mice lungs
while the lung tissues in the IFN-a/p R"~ system showed more than a 100 fold higher
infective virus levels. IFN-a/p and IFN-a/p receptor induced signalling are clearly
important in controlling the virus load in the lungs. This data is similar to the
previously published data with wild type MHV-68 (Dutia et al., 1999). Therefore the
recombinant LHAgfp virus has similar characteristics to the wild type virus in the
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Figure 4.11 Infective virus in the lungs of IFN-q/13 R-/- and WT129 mice infected
with LHAgfp IFN-a/p R-/- and WT129 mice were infected intranasally with 4 x
105 PFU LFIAgfp. Lungs from three mice in each group were removed on days 3, 5,
7 and 10 and frozen at -70°C. Subsequently, the lungs were homogenised and
assayed for infective virus particles as described in the methods section (2.2.3). The
graph represents the number of infective virus as plaque forming units (PFU) per set
of lungs, in the IFN-a/p R_/ (A ) and in WT129 mice (□ ), in logarithmic scale on the
y-axis and days post-infection on the x-axis.
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4.4.2 Lymphadenopathy
The MLN of C57BL/6 mice infected with LHAgfp showed lymphadenopathy similar
to that observed with the wild type MHV-68 infected mice (section 4.2.3). In order to
look for similar changes the total number of cells in the MLN of IFN-a/p R"" mice
and WT129 mice infected with LHAgfp were analysed. The results are represented in
Figure 4.12.
WT129 mice exhibited enlargement of the MLN similar to C57BL/6 mice, but the
IFN-a/p R~/_ mice showed a different pattern. There was a fall in the number of
lymphocytes on day 7 post-infection and a subsequent increase but not to the levels
observed with wild type mice.
The results show that different events take place in the MLN of IFN-a/p R~"
environment compared to the wild type mice infected with LHAgfp. However the
effect on the MLN of IFN-a/p Rv" mice infected with wild type MHV-68 virus has
not been examined so far and it would be interesting to see whether similar
differences can be detected. These events in the MLN may not be solely virus-driven
as the IFN-a/p secretion has been linked to lymphadenopathy (Gresser et al., 1981).
Therefore IFN-a/p receptor-dependent signalling may be a key inducer of
lymphadenopathy in MHV-68 infection.
4.4.3 Latently infected cells in the mediastinal lymph node and spleen
The latently infected cells in the MLN and spleens of the infected animals were
analysed using the infective centre assay as described in the methods section (2.2.2).
The results are represented in Figure 4.13 and 4.14.
The latently infected cells in the MLN of IFN-a/p R"A mice on day 3 post-infection
were 10-fold higher than the levels in WT129 mice. By day 7 post-infection that had
increased dramatically to 50-fold. However by days 10 and 14 post-infection the
levels of latently infected cells in the MLN of IFN-a/p R_/" mice had fallen to the
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Figure 4.12 Lymphadenopathy of the mediastinal lymph node of IFN-a/B R-/-
and WT129 mice infected with LHAgfp IFN-a/p R~/_ and WT129 mice were
infected intranasally with 4 x 1 (P PFU LHAgfp. MLNs were pooled from six mice in
each group on days 3, 5, 7, 10 and 14 post-infection. The MLNs were dissociated to
obtain single cell suspensions and total cell numbers per MLN was counted. The
graph shows the number of MLN cells in the IFN-a/p R_/" mice ( ■ ) and WT129













Day 3 Day 7 Day 10 Day 14
Figure 4.13 Latent virus in the mediastinal lymph node of IFN-q/B R-/- and
WT129 mice infected with LHAgfp IFN-a/p R_/ and WT129 mice were
infected intranasally with 4 x 1 (P PFU LHAgfp. MLNs were pooled from six mice in
each group on days 3, 7, 10 and 14 post-infection. The MLNs were dissociated to
obtain single cell suspensions and plated with BHK cells to assay for latently
infected cells using infective centre assay as described in methods section (2.2.2).
The graph represents the latent virus per 107 MLN cells in IFN- a/p R"/_ ( ■ ) and





























Figure 4.14 Latent virus in the spleens of IFN-q/b R-/- and WT129 mice infected
with LHAgfp IFN-a/p R_/" and WT129 mice were infected intranasally with 4
x 1(P PFU LHAgfp. Spleens were removed from three mice in each group on days 3,
7, 10 and 14 post-infection. The spleens were dissociated to obtain single cell
suspensions and plated with BHK cells to assay for latently infected cells using
infective centre assay as described in methods section (2.2.2). The graph represents
the latent virus per 107 splenocytes in spleens of the IFN-a/p R_/" ( A ) and WT129
mice ( □) on the y-axis against days post-infection on the x-axis.
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The spleens of IFN-a/(3 R_/" mice infected with LHAgfp directly reflect the events in
the MLN. By day 7 post-infection there was a 100-fold increase in the number of
latently infected cells as compared to the WT129 mice. These numbers were reduced
by day 10 and 14 post-infection.
4.4.4 Cryosections of the MLN and spleens of IFN-a/p R" " mice to identify cells
expressing GFP
The advantage of using LHAgfp is emphasised mainly by the ability to express GFP
in infected cells in vivo as shown previously. It could help trace the localisation of
infected cells within tissues and even help understand trafficking of virus. Figure
4.15 (A and B) shows a tissue sections from the MLN of IFN-a/p R~" mice taken on
day 5 post-infection. Cells expressing GFP were seen mainly located near the margin
of the lymph node rather than the central regions. Single cells expressing GFP could
also be detected from the tissue section in Figure 4.15 (C). However, in the tissues
from WT129 mice the frequency of cells expressing GFP was low and hence it was
difficult to find GFP positive tissue sections.
The infective centre patterns in the spleen of the IFN-a/(3 R" mice infected with
LHAgfp on day 7 post-infection showed a very striking difference to the rest of the
days of infection and also to that of the wild type mice. Therefore, it was considered
important to check whether this was also reflected by the intracellular expression of
GFP in these tissues.
On day 8 post-infection spleen tissue was removed from IFN-a/p R~~ and frozen for
cryo-sectioning using isopentane/dry ice. Subsequently sections of the frozen tissue
were viewed under a fluorescence microscope. The images are presented in Figure
4.15 (D).
The images show that on day 8 post-infection the tissues had large patches of GFP
expressing cells in these tissues. This may correlate with the large amount of latently
Figure 4.15 Cryosections of tissues from IFN-a/B R-/- mice to identify cells
expressing GFP IFN-a/p R'A mice were infected intranasally with 4 x 105 PFU
LHAgfp. On day 5 post-infection the MLN from these mice were removed and
frozen for cryo-sectioning. The figures shows (A) the images from a fluorescence
microscope of the MLN (magnification: X320), (B) the same field as (A) under
normal light showing the margin of the MLN and triangles indicate the localisation
of GFP positive cells, (C) a morphologically large single cell (magnification: X800)
from the MLN on day 5 post-infection. Figure (D) is a tissue section from the spleen
of IFN-a/p R_/" mice on day 8 post-infection (magnification: X200).
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infected cells detected on day 7 post-infection in these tissues as seen with infective
centre assays examined in the previous section (4.4.3).
4.5 FACS analysis for various cell populations and the
pattern of GFP expression in the MLN of IFN-a/p R_/" and
WT129 mice
Sections 4.3.2 and 4.3.4 demonstrated that by FACS analysis it is possible to detect
CDllc+/GFP expressing cells that may be infected with the LHAgfp virus. In order
to determine the in vivo infection kinetics of different cell subsets over the first two
weeks of infection, lymphocytes from the MLN of IFN-a/p R"~ and WT129 mice
were analysed in a similar fashion at different time intervals.
IFN-a/p R~~ and WT129 mice were infected intranasally with 4 x 105 PFU of
LHAgfp. MLN were pooled from 6 mice in each group on days 5, 7, 10 and 14 post¬
infection. The MLN were dissociated to obtain single cell suspensions, counted and
used for FACS analysis. The cells were stained with antibodies against specific
surface markers to identify the cell subset. Positive cells were stained with PE
conjugated antibodies and analysed by FACS. The intracellular GFP expression was
analysed on the FL-1 axis. The results are presented in Figure 4.16. The graphs show
the FACS percentage of specific cell subsets found in the MLN over the course of
infection and also the FACS percentage of the respective cell type that was
expressing GFP.
4.5.1 CDllc staining for dendritic cells
The graph 4.16 (La and Lb) shows the FACS percentages of MLN cells stained with
hamster-anti-mouse CD1 lc (clone HL-3) biotin conjugate, followed by streptavidin-
PE. The CDllc surface staining was used as a marker to identify dendritic cell
population. The graph 4.16 (La) shows the percentage of CD1 lc+ cells in the MLN
of IFN-a/[3 R~~ mice. On days 5 and 7 post-infection 3-5% of MLN cells were
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Figure 4.16 The FACS percentages of different cell types and the percentage
expressing GFP, in the mediastinal lymph node of IFN-a/ft R-/- and WT129 mice
infected with LHAgfp IFN-a/(3 R_/" and WT129 mice were infected intranasally
with 4 x 105 PFU LHAgfp. MLNs were pooled from six mice in each group on days
5, 7, 10 and 14 post-infection. The MLNs were dissociated to obtain single cell
suspensions counted and taken for flow cytometric analysis (FACS). The cells were
stained with either hamster anti-mouse CDllc biotin conjugated monoclonal
antibody, rat anti-mouse F4/80 monoclonal antibody, rat anti-mouse CD 19
monoclonal antibody, rat anti-mouse CD4 monoclonal antibody (YTS 191) or rat
anti-mouse CD8 monoclonal antibody (YTS 169). Antibody positive cells were
detected by staining with PE-conjugates. The FACS analysis was performed to
determine the cells expressing these markers on FL-2 axis and the cells expressing
intracellular GFP on FL-1 axis. 50,000 cells were acquired from each sample for
analysis. The Figures l.a, 2.a, 3.a, 4.a and 5.a show analyses of cells obtained from
the MLN of IFN-a/p R_/" mice. The figures l.b, 2.b, 3.b, 4.b and 5.b represent
analyses of cells obtained from the MLN of WT129 mice. In the figures the red bars
( □ ) show percentage of cells obtained through the staining patterns with the surface
antibodies and the green bars ( □ ) show the percentage of the respective cell type
also expressing intracellular GFP. The figures l.a and l.b show the FACS
percentages of cells stained with anti-CDllc antibody; 2.a and 2.b are for cell
stained with anti-F4/80 antibody ; 3.a and 3.b are for cells stained with anti-CD 19
antibody; 4.a and 4.b are for cells stained with anti-CD4 antibody; and 5.a and 5.b
are for cells stained with anti-CD8 antibody.
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cells, 20% were also found to be expressing GFP on days 5 and 7 post-infection but
the percentages decreased to 3-5% on subsequent days analysed.
The graph 4.16 (l.b) represents the analysis of MLN cells from the WT129 mice. In
these mice, there were 2-3% CDllc+ cells on days 5 and 7, and around 1-2% on
days 10 and 14 post-infection. Among these CD1 lc+ cells, 9% were also expressing
GFP on days 5 and 7 post-infection. The GFP expressing cells were fewer on day 10
but increased to 3% on day 14 post-infection.
The results demonstrate that many more CD1 lc+ cells express GFP in the first week
of infection than in the second week of infection both in the immuno-deficient and
the wild type environments.
4.5.2 F4/80 staining for macrophages
The graphs 4.16 (2.a and 2.b) show FACS percentages of cells that were stained with
rat-anti-mouse F4/80 antibody followed by anti-rat IgG conjugated to PE. The graph
4.16 (2.a) shows the number of F4/80 stained macrophages in the MLN of IFN-a/(3
Rv" mice. On days 5 and 7 post-infection there were 4-5% macrophages in this
environment. Of these cells 12-14% were detected with intracellular GFP expression.
By days 10 and 14 post infection the percentages of macrophages decreased to less
than 1% but there were still 3% to 7% of the cells expressing GFP, respectively.
The graph 4.16 (2.b) shows the number of macrophages in the WT129 mice MLN.
On days 5 and 7 post-infection there were 2-4% F4/80+ cells but that fell to less than
1% by days 10 and 14 post-infection. Nevertheless, on days 5, 7 and 14 there were
over 3% of these cells that were also expressing GFP.
The results demonstrate that both in the IFN a/(3-Rv" and the WT129 mice F4/80+
cells expressing GFP can be found, showing that these cells are susceptible to
LHAgfp infection. However in the absence of interferon receptor-mediated signalling
there was a 3-fold greater number of F4/80+ cells expressing GFP.
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4.5.3 CD19 staining for B cells
B cell populations were detected using rat-anti-mouse CD 19 antibody staining,
followed by anti-rat IgG conjugated to PE. The results are presented in Figure 4.16
(3.a and 3.b). The graph 4.16 (3.a) shows the percentage of B cells in the MLN of
IFN-a/p R~~ mice. On days 5 and 7 post-infection around 30% B cells are seen in
this tissue but by days 10 and 14 post-infection the percentages decreased to around
15%. Among these cells on day 7, 2.5% cells also expressed GFP, the levels were
lower on all other days of infection recorded with percentage of GFP expressing cells
between 0.1-0.3%.
The Figure 4.16 (3.b) shows the percentage of CD 19+ cells in the MLN of WT129
mice. The percentage of CD 19+ cells on days 5 and 7 post-infection was 45-50%.
However, on days 10 and 14 post-infection in this environment, unlike in the
immuno-deficient system, the CD 19+ cell population remained over 35% of total
MLN cells. The GFP expressing CD 19+ cell percentages were as low as 0.05% on
day 10 and only as high as 0.22% on day 7 post-infection.
The results demonstrate that in the IFN-a/p Rmice the percentages of B cells
decreased in the first 2 weeks post-infection as compared to the B cell percentages in
the MLN of WT129 mice. This difference may be one of the reasons for the
reduction in lymphadenopathy observed in the IFN-a/p R~~ mice (see section 4.4.2).
In both the host systems the percentage of GFP expressing CD 19+ B cells was much
lower than that observed with CD1 lc+ and F4/80+ cells.
4.5.4 Staining for CD4+ T cells
CD4+ T cells were identified using rat-anti-mouse CD4 antibody (YTS191) followed
by anti-rat IgG conjugated to PE. The results are presented in the Figure 4.16 (4.a
and 4.b). The Figure 4.16 (4.a) shows the percentages of CD4+ cells in the MLN of
IFN-a/p R"~ mice. On days 5, 7, 10 and 14 post-infection the levels of CD4+ cell
were between 25-35%. The GFP expressing cells were 1.3% and 2.5% on days 5 and
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7, respectively. However, these percentages fell to 0.04% and 0.08% by days 10 and
14 post-infection.
The Figure 4.16 (4.b) shows the percentages of CD4+ cells in the MLN of WT129
mice. The percentages on days 5, 7, 10 and 14 post-infection were between 25-35%.
The GFP expressing cells among them were either absent or below levels of
detection on day 10 and around 0.04% and 0.09% on the subsequent days.
The results demonstrate that the percentages of CD4+ T cell in both the host systems
were similar, although the percentages of GFP expressing cells in the IFN-a/p R""
were higher on days 5 and 7 post-infection than in WT129 mice. This difference in
the percentages of GFP expressing cells was similar to that observed with the other
cell types examined previously.
4.5.5 Staining for CD8+ T cells
CD8+ T cells were detected using rat-anti-mouse CD8 antibody (YTS169) followed
by anti-rat IgG conjugated to PE. The results are presented in Figure 4.16 (5.a and
5.b). The Figure 4.16 (5.a) shows the percentage of CD8+ cells in the MLN of IFN-
a/p R_/" mice. On days 5 and 7 post-infection there were 15% CD8+ T cells and
among these 1.7% and 3.7% of cells also expressed GFP, respectively. The
percentage of CD8+ T cells on days 10 and day 14 post-infection rose to around 25%
but the percentages of GFP expressing cells fell to 0.04% and 0.2%, respectively.
The Figure 4.16 (5.b) shows the CD8+ T cell percentages in the MLN of WT129
mice. The percentages of CD8+ cells on days 5, 7, 10 and 14 post-infection
fluctuated between 10-20%. On day 5, 1.33% of the total percentage of 17% of
CD8+ cells were detected with GFP expression. The levels fell to 0.96% on day 7
and 0.19% on day 14 post-infection.
The results demonstrate that there were 25% CD8+ T cells on days 10 and 14
compared to 15% on days 5 and 7 post-infection in the MLN of IFN-a/p R'1' mice. In
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WT129 mice the CD8+ T cells were around 15% throughout the course of infection.
This might indicate the recruitment of more CD8+ T cells to control MHV-68
infection in the MLN in the absence of an effective anti-viral IFN-a/p response.
The Figure 4.17 is another representation of the data from the above experiment in
which the total cell numbers expressing GFP from each cell type was calculated by
multiplying FACS percentages by the total number of cells in each lymph node. The
data is plotted for each cell type on the days post-infection that were investigated.
The graphs compare the approximate number of cells from each cell type expressing
GFP on different days post-infection. It also compares LHAgfp infection in IFN-
a/p R~" and WT129 mice.
The cell types compared are those that express the surface markers CD lie, F4/80,
CD 19, CD4 or CD8. The FACS percentages of cells expressing GFP in the MLN of
IFN-a/p R"~ and WT129 mice on days 5 and 7 post-infection showed that the wild
type mice had fewer GFP expressing cells compared to the immuno-deficient system.
By day 10 and day 14 post-infection the levels of GFP expressing cells had
decreased in both mouse strains.
4.6 The FACS percentages of cells expressing GFP in the
spleens of IFN-a/p R"/_ mice and WT129 mice
The Figure 4.18 shows the FACS percentages of different subsets of cells expressing
different markers (CD1 lc, F4/80, CD 19, CD4 and CD8) and the percentage of those
expressing GFP in the spleens. The FACS percentages for three spleens were
analysed in the IFN-a/p R/_ and the WT129 mice. The data is presented with error
bars representing the standard error of the mean.
The graph 4.18 (l.a) shows the FACS percentages of CDllc+ cells, which were 4-
5% of the total cell population in the spleens of IFN-a/p R_/" mice, and these
percentages remained elevated on days 5, 7, 10 and 14 post-infection. The GFP
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Figure 4.17 The numbers of cells expressing GFP in the mediastinal lymph
node of IFN-q/(3 R-/- and WT129 mice infected with LFIAgfp
Figure 4.17 The total numbers of cells expressing GFP in the mediastinal lymph
node of IFN-a/[3 R-/- and WT129 mice infected with LHAgfp IFN-a/p R_/"
and WT129 mice were infected intranasally with 4 x 105 PFU LHAgfp. MLNs were
removed from six mice in each group on days 5, 7, 10 and 14 post-infection. The
MLNs were dissociated to obtain single cell suspensions, counted and taken for flow
cytometric analysis (FACS). The cells were stained with either hamster anti-mouse
CDllc biotin conjugated monoclonal antibody, rat anti-mouse F4/80 monoclonal
antibody, rat anti-mouse CD 19 monoclonal antibody, rat anti-mouse CD4 (YTS191)
monoclonal antibody or rat anti-mouse CD8(YTS169) monoclonal antibody.The
figure represents the total number of cells in each cell type calculated by multiplying
the FACS percentages to the number of cells in the MLN of IFN-a/p R"A( □) and
WT129 mice ( □).
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Figure 4.18 The FACS percentages of different cell types and the percentage
expressing GFP in the spleens of IFN-a/p R-/- and WT129 mice infected with
LHAgfp
Figure 4.18 The FACS percentages of different cell types and the percentage
expressing GFP in the spleen of IFN-a/B R-/- and WT129 mice infected with
LHAgfp IFN-a/p R"A and WT129 mice were infected intranasally with 4 x 105
PFU LFlAgfp. Spleens were removed from three mice in each group on days 5, 7, 10
and 14 post-infection. The spleens were dissociated to obtain single cell suspensions
counted and taken for flow cytometric analysis (FACS). The cells were stained with
either hamster anti-mouse CDllc biotin conjugated monoclonal antibody, rat anti-
mouse F4/80 monoclonal antibody, rat anti-mouse CD 19 monoclonal antibody, rat
anti-mouse CD4 monoclonal antibody (YTS 191) or rat anti-mouse CD8 monoclonal
antibody (YTS 169). Antibody positive cells were detected by staining with PE-
conjugates. The FACS analysis was performed to determine the cells expressing
these markers on FL-2 axis the cells expressing intracellular GFP on FL-1 axis.
50,000 cells were acquired from each sample for analysis. The Figures l.a, 2.a, 3.a,
4.a and 5.a show analyses of splenocytes obtained from the spleens of IFN-a/p R_/"
mice. The figures 1 .b, 2.b, 3.b, 4.b and 5.b represent analyses of splenocytes obtained
from the spleens of WT129 mice. In the figures the purple bars ( □ ) show percentage
of cells obtained through the staining patterns with the surface antibodies and the red
bars (□ ) show the percentage of the respective cell type also expressing intracellular
GFP. The figures l.a and l.b show the FACS percentages of cells stained with anti-
CDllc antibody; 2.a and 2.b are for cell stained with anti-F4/80 antibody ; 3.a and
3.b are for cells stained with anti-CD 19 antibody; 4.a and 4.b are for cells stained
with anti-CD4 antibody; and 5.a and 5.b are for cells stained with anti-CD8 antibody.
The error bars represent standard errors of the mean of three spleens in each case.
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on day 7, while they were around 10-13% on days 5 and 14 with the lowest level of
2% seen on day 10 post-infection. The graph 4.18 (l.b) shows the percentages in the
spleens of WT129 mice in which the CD1 lc+ cells ranged between 3-5% on the days
examined. The spleens of WT129 mice had 7-10% GFP expressing CD1 lc+ cells on
days 5 and 7, and approximately 2% on day 14 post-infection.
The graph 4.18 (l.a) shows that 6-7% F4/80+ cells were infected in the spleens of
IFN-a/p Rmice on all four days post-infection. The GFP expressing cells among
these cells ranged from 6%> on day 5 to 14% on day 7. This declined to 1% on day 10
but rose to 8% on day 14 post-infection. The graph 4.18 (Lb) shows F4/80+ cells in
the spleens of WT129 mice, which fell from 10% on day 5 to 4% on day 14 post¬
infection. The expression of GFP expressing cells was 8-10% on days 5 and 7, and
3% and 5% on days 10 and 14 post-infection, respectively.
The frequency of GFP expression in CD1 lc+ and F4/80+ cells was higher than the
other populations such as CD 19+, CD4+ or CD8+ cells. The patterns of GFP
expression in the spleen resemble those seen in the MLN. The disadvantage is that
the GFP expression does not indicate whether these cells were undergoing lytic or
latent infection.
An interesting observation in the spleens was that the percentages of B cells (CD 19+
staining) in the WT129 mice stays constant while in the IFN-a/(3 R~~ mice only 20%
of total cells on day 14 were B cells compared to 50% on day 5 post-infection. On
the other hand in the IFN-a/p R A system the CD8+ cells (mainly T cells) rose from
10% on day 5 to 30-40% on day 14 post-infection while in the WT129 mice the
levels remained almost constant. The percentages of different cell types have not
been examined in the IFN-a/p R~" system infected with wild type MHV-68 and it
would be interesting to see whether similar changes take place during infection.
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CHAPTER FIVE
DISCUSSION
MHV-68 disease pathogenesis has so far focused on the lungs as the primary site
following intranasal infection with the virus undergoing lytic replication in alveolar
epithelial cells. This is followed by latent infection of B cells that are found localised
mainly in the spleen. Subsequent studies have also shown the presence of latent virus
in alveolar epithelial cells (Stewart et al., 1998), F4/80+ macrophages in the
peritoneum (Week et al., 1999b), CDllb+ macrophages and CDllc+ dendritic cells
in the spleen (Flano et al., 2000). However, the presence of B cells in the host
environment was shown to be essential for the maintenance of latency in the spleen
(Usherwood et al., 1996b) as well as in the transfer of virus from the lungs to the
spleen (Stewart et al., 1998). The work described in this thesis focuses on the
intermediary site of infection, the mediastinal lymph node (MLN) and has
investigated the importance of B cells and other cells in trafficking virus as well as in
the maintenance of latency at this site.
These results describe the role of B cells during MHV-68 disease pathogenesis in the
MLN by comparing normal mice to B cell deficient (pMT) mice. The
lymphadenopathy in C57BL/6 mice was attributed mainly to the accumulation of B
cells at this site and this observation was substantiated by the absence of
lymphadenopathy in pMT mice. The expansion of B cells in the MLN of C57BL/6
mice was partly dependent on CD4+ T cell signalling. The MLN of pMT mice also
provided an opportunity to investigate whether cells other than B cells were latently
infected with MHV-68. The use of a green fluorescent protein (GFP) expressing
recombinant virus, LHAgfp, as a tool for studying tropism helped isolate and
characterise cell types susceptible to virus infection in the MLN. Cells from the
MLN of pMT mice infected with LHAgfp were enriched for the CD lie marker,
specific for dendritic cells, and found to express GFP. LHAgfp infection of IFN-a/p
R"" mice demonstrated that even in the presence of B cells, dendritic cells expressing
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CDllc and macrophages expressing F4/80 surface markers were infected in the
MLN.
5.1 MLN is a critical site in MHV-68 pathogenesis where the B
cells play an important role
5.1.1 Requirement for B cells in lymphadenopathy
In C57BL/6 mice infected with 4 x 105 PFU MHV-68 intranasally, the MLN had
enlarged by 10-fold during the first ten days post-infection. This observation is
similar to the results published by Sarawar et al (1996) where a 5-10 fold increase in
cellularity was detected in the MLN of C57BL/6J mice infected with 4 x 103 PFU
MHV-68. Analysis of the cell subsets in the enlarged lymph nodes of C57BL/6 mice
revealed a 10-15 fold increase in B cell numbers and a 4-5 fold increase in the CD4+
and CD8+ T cell numbers. The importance of B cells in establishing
lymphadenopathy is highlighted in B cell deficient (pMT) mice. The pMT mice
showed a lack of lymphadenopathy with a reduction of all subsets of cells compared
to C57BL/6 mice. The increase in cellularity in the MLN has also been observed in
the case of other respiratory viruses such as Influenza A virus (Allan et al, 1990).
However, this dramatic accumulation of B cells in the MLN early in MHV-68
infection is probably an important strategy used by this virus to disseminate within
the host. Cells stained for activation markers like CD69 and CD25 showed that there
was an increase in CD69 a marker found on B and T cells but there was also an
increase in CD25 a marker found on T cells on days 7 and 10 post-infection.
However, double staining for IgMp + CD69 showed minimal level of staining
indicating that the increase in CD69 marker was mainly due to T cells expression
rather than from activated/proliferation B cells.
EBV is known to infect B cells directly at the mucosal surface. Virus-encoded
transcripts such as viral IL-10 can induce proliferation of B cells. Studies on B cells
obtained from EBV infected patients have shown that the virus alone can provide
these cells with transformation and proliferation signals (Rowe et al., 1991, Kempkes
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et al., 1995). In the case of patients suffering from acute EBV infection (infectious
mononucleosis), a rapid polyclonal expansion of the B cell pool is seen prior to the
development of an effective cellular response (Rickinson and Keiff, 1996). There is
evidence in vitro that MHV-68 can cause proliferation, albeit not on the scale of
EBV (Dutia et al., 1999b, Stevenson and Doherty, 1999). Viral proteins similar to
LMP-1 that provide direct B cell proliferation signals have not been found in MHV-
68 infection to date. Consequently, the increase in the number of B cells over the first
10 days of infection could be in part attributed to a virus driven polyclonal expansion
or a CD4+ T cell-dependent expansion.
5.1.2 B cell expansion is only partly dependent on CD4+ T cell signalling
To investigate whether one of the factors in the expansion of B cells is due to CD4+
T cell signalling, these cells were depleted in vivo prior to infection with MHV-68.
Following depletion of CD4+ T cells, lymphadenopathy developed at a slower rate
and the magnitude of the response was greatly reduced compared to that seen in
normal mice, with only a 5-fold increase in B cell numbers. CD8+ T cell numbers in
the MLN of depleted mice increased, but this could be a mechanism to compensate
for the absence of CD4+ T cells in this tissue following their depletion. A similar
observation was made in the MLN of CD4+ T cell depleted mice infected with
Influenza A virus where an increase in CD8+ T cell numbers were detected during
the course of infection (Allan et al., 1990). The manifestation of lymphadenopathy in
the CD4+ T cell depleted mice and the increase in B cell numbers observed on day
10 coincide and it can be said that even in the absence of CD4+ T cells, B cells
remain the major subset responsible for the enlarged lymph node. The reasons for
this could be due to (i) virus-induced B cell proliferation, (ii) CD4+ T cell
independent proliferation or (iii) recruitment of B cells signalled by secreted host
proteins.
There is evidence that in vitro B cells infected with MHV-68 can proliferate in the
absence of CD4+ T cells as seen by the expression of the CD69 activation marker
and the secretion of IgM antibodies. Although in vivo similar changes were not
observed, it was demonstrated that CD4+ T cell signalling was required for class
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switching and clonal selection of IgG secreting B cells in the long run (Stevenson
and Doherty, 1999). The experiments described in this thesis have shown that in vivo
there might be a small window where B cells are capable of accumulating in the
MLN in the absence of direct CD4+ T cell stimulus.
The CD4+ T cell depletion experiments with BALB/c mice showed an absence of
splenomegaly and a reduction in the levels of latently infected cells (Usherwood et
al., 1996a). The experiments described here show a similar reduction in the number
of latently infected cells in C57BL/6 mice depleted of CD4+ T cells on day 16 post¬
infection in the spleen. In addition, it was shown that the number of latently infected
cells was greatly reduced in the MLN of CD4+ T cell depleted mice compared to
control mice. Therefore, it can be said that the CD4+ T cells play an important role in
the effective establishment of latency in the MLN similar to that seen in the spleen.
5.1.3 B cells are required for long-term latency and viral dissemination from the
MLN
It was previously shown that pMT mice infected with MHV-68 failed to develop
splenomegaly and a latent infection in the spleen (Usherwood, et al., 1996b).
Experiments in chapter 3 demonstrated that on days 5 and 7 post-infection latently
infected cells were present in the MLN of pMT mice. These infected cells became
undetectable by day 10 post-infection as determined by the infective centre assay. In
contrast, in the MLN of C57BL/6 mice the levels of latently infected cells were 6-
fold higher on day 10 compared to day 7 post-infection. Attempts to identify cells
carrying productive virus in the MLN of pMT mice through immunostaining and
transmission electron microscopy proved to be unsuccessful. However when RT-
PCR that affords greater sensitivity was used viral gene transcripts for ORF50 the
immediate early gene was detected on all days investigated including day 10 post¬
infection in the MLNs of pMT mice. The detection of viral gene expression for M3
both an early and latency associated gene transcript indicated that the virus could be
present in a latent state with some cells having a basal level of productive infection.
It may be concluded that B cells are essential for the presence of detectable levels of
latency in the MLN.
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The role of B cells in the transfer of virus to other tissues was highlighted in the work
of Stewart et al (1998). They showed that the transfer of uninfected B cells to pMT
mice (which have virus persisting in lung, but no evidence of latent infection in the
spleen) resulted in virus DNA being detected in the spleen. The experiments
described in the previous chapters substantiate some of these observations through
experiments where latently infected cells although detectable in the MLN of pMT
mice in the first week post-infection, could not be detected in the cervical lymph
node (CLN). While in the C57BL/6 mice latently infected cells were detected in the
CLN during the progression of infection, proving that in the absence of B cells the
systemic transfer of virus is limited.
The MLN is a critical tissue in MHV-68 infection and may be compared with tonsils
used in the study of EBV infection. The human tonsils from EBV infected
asymptomatic patients and IM patients have provided very useful insight in to the in
vivo infection of B cells and different latency stages adopted by the virus. A recent
study by Thorley-Lawson's group describes different gene expression patterns that
are dependent on the differentiation stage of the infected B cells (Babcock et al.,
2000b). A different study on the tonsillar tissue from IM patients, using PCR on
single cells isolated by laser microdissection showed that EBV infected B cells
arising from a single clone can exhibit different morphology as well as different EBV
gene expression patterns (Kurth et al., 2000). It is speculated that these are some of
the ways by which the virus evades immune surveillance. These techniques could be
used in future work to unravel B cell latency patterns during MHV-68 infection, at a
single cell level in the MLN.
5.1.4 Latently infected B cells are required for the presence of an active MHV-
68 specific CTL response in the MLN
There were clear differences between the CTL response to MHV-68 infection in
C57BL/6 and pMT mice. CTLs were directed against peptides p56 and p79, which
have been shown to be highly immunodominant epitopes obtained from lytic
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transcripts ORF6 and ORF61 respectively (Stevenson et al., 1998). Using the IFN-y
CTL assay as a means of quantitating the percentage of peptide specific CD8+ T
cells, a 1% response on day 10 and a 0.2-0.5% response on day 15 post-infection was
observed for p56 and p79 in the MLN of C57BL/6J mice (Stevenson et al., 1999a).
A similar response was observed in the MLNs of C57BL/6 mice as shown in Figure
3.13, however in the MLNs of pMT mice the response was only around 0.2%
peptide specific T cells on days 10 and 17 post-infection.
Both in C57BL/6 as well as in pMT mice a slightly higher response was seen on day
6 post-infection, which could be interpreted to be due to the ongoing lytic infection
in the lung. The reduction in CTL response in pMT mice compared to C57BL/6 mice
seems to indicate that in the absence of infected B cells at this site the response fades
away at a faster rate. In other words infected B cells might be required for the
maintenance of CTL response in the MLN.
5.2 Cells other than B cells are infected in the MLN
5.2.1 Dendritic cells and macrophages, target cells for MHV-68 infection in the
MLN
The mouse MLN is an extremely small tissue with less than 2 million cells and in the
work described in chapters 3 and 4, MLN from 4 to 6 mice were pooled together in
order to carry out different assays. Latently infected cells were detected in the MLN
of pMT mice infected with MHV-68 on days 5 and 7 post-infection. However,
relatively small numbers were detected which made phenotyping these cells a
difficult exercise. To overcome this a GFP 'marked' virus-LHAgfp was used. This
greatly improved detection of infected cells and GFP expressing CDllc+ dendritic
cells were detected in the MLN. This observation suggested that the latently infected
cells in the MLN of pMT mice infected with MHV-68 could have a CDllc
phenotype. The results with IFN-a/p R"~ and WT129 mice confirmed that CDllc+
dendritic cells and F4/80+ macrophages are infected during the very onset of
infection in the MLN.
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It is possible that some of the GFP expressing cells had phagocytosed GFP
expressing infected cells or apoptosing cells in the lymph node. However, in this case
the GFP is likely to have a punctate appearance in the cell, indicating localisation
within vacuoles. Comparisons can be made with a recombinant Venezuelan equine
encephalitis (VEE) virus expressing GFP and the characterisation of infected cells in
a mouse model in vivo (MacDonald and Johnston, 2000). They identified that cells
with a diffuse GFP expression were the virus-infected cells, which were later
identified as dendritic cells and cells with punctate GFP staining pattern which were
considered to be the result of phagocytosis. Based on this evidence it is likely that
cells with the diffuse GFP expression are infected with LHAgfp.
Dendritic cells were enriched from the MLN of pMT mice using hamster anti-mouse
CDllc antibodies (clone N418) bound to magnetic beads. The FACS analysis of
isolated cells showed 55% of these cells to be definitely positive for CDllc and of
those 3% were also found to be expressing intracellular GFP. Surface staining for
macrophage specific F4/80 marker indicated that some of the GFP expressing cells
were macrophages. It is possible that F4/80+ macrophages are infected in the lymph
node or become infected in the lungs and move into the lymph node at the on-set of
MHV-68 infection. However, there is evidence that freshly isolated dendritic cells
from the spleen expressing CDllc marker can express low levels of macrophage
markers such as F4/80 and Mac-1 (Leenen et al., 1998). It is known that the
expression of macrophage markers at low levels in these dendritic cells is only an
indication of these cells differentiating from immature cells to mature dendritic cells.
These cells, when isolated and cultured in vitro, lost the macrophage markers and
expressed mature dendritic cell markers (Leenen et al., 1998). Therefore, from the
results presented here regarding the presence of F4/80+ cells expressing GFP among
the cells enriched for CD1 lc, it is difficult to say whether they were macrophages or
immature dendritic cells.
The MLN of IFN-a/p R~~ mice enriched for CDllc+ cells also showed 50% purity
and of those around 10% expressed intracellular GFP. There was a three-fold
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increase in the number of CDllc+ cells expressing GFP in IFN-a/p R_/" mice
compared to pMT mice. This increased number of cells in IFN-a/p R~~ mice made it
possible to set up analysis using flow cytometry for determining the cell subsets
expressing GFP. A high frequency of GFP positive cells were observed among the
F4/80 and CD1 lc populations from MLN and spleen of IFN-a/p R~~ mice on days 5
and 7 post-infection. In contrast, relatively few B cells were GFP positive despite the
absence of an anti-viral IFN-a/p response. The WT129 mice had fewer GFP positive
cells, but F4/80+ and CDllc+ fraction contained the majority of GFP expressing
cells in the first week post-infection.
At the time these experiments were being carried out a paper published by Flano et al
(2000) showed that dendritic cells and macrophages in the spleen were carriers of
latent MHV-68. They were able to FACsort for CD1 lc+ dendritic cells and CD1 lb+
macrophages from the spleens of MHV-68 infected C57BL/6 mice. When they
compared the number of dendritic cells, macrophages and B cells, they found
dendritic cells to have the highest number of latently infected cells. Seven-fold more
dendritic cells were latently infected compared to B cells on day 14 post-infection.
Although this data looked only at one time point post-infection in the spleen, it does
substantiate some of the observations made in chapter 4 regarding the susceptibility
of dendritic cells to MHV-68 and the increased frequency of GFP expressing
CD1 lc+ cells in the MLN and spleen of IFN-a/p R7" and WT129 mice.
5.2.2 Dendritic cells in trafficking virus
Studies on rat lung tissues have shown the presence of an extensive network of
dendritic cells in the airways and interstitium of the lung. Following infection with
Sendai virus, dendritic cell numbers increase in the lung (McWilliam et al., 1997). A
recent study in vivo by intratracheal instillation of fluorescein isothiocyanate (FITC)-
conjugated macromolecules in mice has shown migration of dendritic cells from the
airway mucosa to the thoracic lymph node (TLNs). They show that specific subsets
of CDllc+ and MHC class 11+ dendritic cells called airway-derived lymph node
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dendritic cells (AW-LNDCs) upon antigen exposure migrate from the lungs to the T
cell rich regions in the TLNs (Vermaelen et al., 2001).
Based on the evidence above it is hypothesised that the CDllc+ and F4/80+ cells
expressing GFP seen in the MLN as early as day 5 are cells that were trafficked from
the lungs into the lymph node following MHV-68 infection. In future work it will be
interesting to determine whether these subsets of cells were positive for virus in the
lung.
5.2.3 Dendritic cells and macrophages as reservoirs of virus
Studies have shown Langerhans cells in the vaginal mucosa to be infected with SIV
in monkeys and also with HIV in mouse models (Miller and Hu, 1999, Masurier et
al., 1998). Immature dendritic cells have also been shown to harbour replicating M-
tropic HIV and these cells were able to transmit virus to T cells. Recently a dendritic
cell specific C-type lectin, DC-SIGN was identified with specific affinity for HIV
gpl20. HIV virions can bind to this molecule on the surface of dendritic cells and
subsequently infect cells that express CD4 and chemokine receptors (Geijtenbeek et
al., 2000).
In the case of MHV-68 infection the CDllc+ and F4/80+ cells could carry latent
virus or they may be undergoing transient replication. It is possible that during
MHV-68 infection the CD1 lc+ and F4/80+ cells could also act as reservoirs of virus
from which B cells in the MLN could become infected. However in the absence of B
cells these cells may not be able to maintain long-term latency.
5.3 Pathogenesis and use of recombinant LHAgfp
5.3.1 Effects on disease pathogenesis of LHAgfp as a result of the deleted genes
During the construction of this virus the insertion of the GFP gene had led to the
deletion of five tRNAs and the Ml gene coding regions from the wild type MHV-68
genome (Roy, Stewart and Dutia personal communication). Published data on a
recombinant MHV-68 virus with deletion of the first four tRNAs and the Ml gene
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(Simas et al., 1998) showed that the absence of these genes did not alter the growth
patterns in vitro nor alter the growth properties and disease pathogenesis in vivo. This
was confirmed using MHV-68 Ml knockout virus (Clambey et al., 2000). The
absence of the Ml gene did not show any significant difference in disease
pathogenesis or in the establishment of latency. However this group did observe that
the Ml knockout virus had a higher rate of reactivation compared to wild type virus.
LHAgfp and wild type MHV-68 showed a similar tissue distribution and the LHAgfp
virus was successful in establishing latency in infected animals. The main difference
was that the peak levels of latently infected cells in the MLN and spleen using wild
type MHV-68 seen during the first two weeks post-infection were not observed in
LHAgfp infected tissues. This means that the five tRNAs and Ml genes could be
important in amplifying the numbers of latently infected cells within these tissues.
An alternative explanation comes from the work of Clambey et al (2000) on the role
of the LacZ expression in an Ml knockout virus. They observed decreased levels of
latently infected cells in the spleen on day 9 infection of mice infected
intraperitoneally, indicating that this region of the genome could have an unknown
regulatory function. However it must be considered from these results that the peak
levels of latently infected cells is not essential for the establishment of long-term
latency in these tissues, indicating that the virus may have alternate pathways not
evident from the disease kinetics in successfully establishing latency in the host.
5.3.2 LHAgfp, a useful marker virus
As described in section (5.2), the relatively fewer numbers of latently infected cells
in the MLN of MHV-68 infected pMT mice made phenotyping difficult using
immunostaining assays or RNA in-situ hybridisation techniques. The in vivo
expression of GFP in virus infected LHAgfp became a useful tool and helped identify
virus infected cells by their GFP expression. There is no evidence from the results of
in vivo characterisation studies described in the preceding chapters or from
previously published data to believe that LHAgfp would behave any different from
the wild type virus in the ability to infect susceptible cell types in vivo.
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Enriched CDllc cells when viewed under the fluorescence microscope were
identified as infected from the diffused pattern of GFP expression. It was also
possible to stain the cells with surface antibodies to confirm the cell type. Similarly,
stained cells were also used in flow cytometry to determine the percentages of
CDllc cells in the MLN of pMT and IFN-a/p R"A mice that were also expressing
GFP. This method was used to determine the percentages of different cell subsets
expressing GFP over the time course of infection. Tissue cryosections from the MLN
and spleen of LHAgfp infected mice helped determine the regions where GFP
expressing cells localised. However, advanced microdissection techniques may have
to be used in future to isolate cells from different regions and determine the specific
cell type and differentiation states.
The slight drawback with this marker virus is that the state of infection of these cells
cannot be determined from the GFP expression either to be lytic or latent infection.
This could be overcome with the generation of antibodies specific to MHV-68 latent
proteins e.g. M2, which can be used in conjunction with the above mentioned
techniques to differentiate the GFP expression within lytic and latently infected cells.
5.4 Pathogenesis of LHAgfp in IFN-a/p R'and WT129 mice
5.4.1 Disease pathogenesis in the lung, MLN and spleen
Type 1 interferon has been shown to play a very important regulatory role during
virus infections by controlling replication of virus within infected cells and also by
inhibiting virus infection in neighbouring cells (Biron, 1998). IFN-a/p R_/" infected
with LHAgfp exhibited a 100 fold higher level of infective virus in the lungs
compared to WT129 mice on day 10 post-infection. The higher level of infective
virus seen with LHAgfp is similar to the published data on lung infection in IFN-a/p
R~~ mice infected with wild type MHV-68 (Dutia et al., 1999a). The data on MHV-
68 infection of IFN-a/p R~" mice and the IRF mice deficient of IFN-a/p
downstream signalling emphasise the importance of this signalling pathway in
regulating MHV-68 infection (Dutia et al., 1999a).
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The MLN and spleen tissues from LHAgfp infected IFN-a/p R~~ mice showed a
sudden peak of latently infected cells on day 7 post-infection compared to WT129
mice. The cryosections obtained on day 8 from the spleen show patches of GFP
expressing cells were distributed throughout this tissue. The numbers of latently
infected cells fall to normal by days 10 and 14 post-infection. This might indicate
that at this point other arms of the immune system have taken over the control and
elimination of virus from these tissues.
The characterisation studies with LHAgfp in C57BL/6 mice showed that the virus
fails to present peak levels of latent virus two weeks post-infection as observed
during wild type MHV-68 infection. However LHAgfp infection of IFN a/p R~" mice
exhibited disease pathogenesis in the MLN and spleen similar to wild type MHV-68
infection where an increased number of latent virus was seen around day 7 post¬
infection. This variation in disease kinetics of LHAgfp infected IFN a/p R/_ mice
could be due to an immunomodulatory role played by either the missing vtRNAs or
the GFP gene under the CMV promoter. These observations could only be confirmed
using targeted rescuant viruses.
The FACS percentages of CD8+ T cells represented in figures 4.16 and 4.18 in the
MLN and spleen respectively, might be showing the involvement of these cells in the
control of virus. The data clearly shows that on days 10 and 14 compared to days 5
and 7 post-infection; both in the MLN and spleen of IFN-a/p R_/" mice there were
increased percentages of CD8+ T cells. This was not the case with WT129 mice,
where the CD8+ T cell percentages did not change drastically over the course of
infection. However, further experiments are needed to find out whether the increased
percentage of CD8+ T cells corresponds to increased levels of MHV-68 specific
CTL activity.
5.4.2 Reduced lymphadenopathy in IFN-a/p R";" mice
The IFN-a/p R"~ mice infected with LHAgfp showed a reduction in
lymphadenopathy. When the cell subsets were analysed, a dramatic reduction in the
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number of B cells was observed. This effect could not have been due to the deleted
genes in LHAgfp as the WT129 mice showed accumulation of B cells and
lymphadenopathy similar to C57BL/6 mice infected with wild type MHV-68 virus.
Therefore, the reduction in lymphadenopathy in IFN-a/p R"/_ mice could be
attributed directly to the absence of IFN-a/p as it has been demonstrated to be a
potent cytokine that induces proliferation, recruitment or retention of cells that in
turn can lead to lymphadenopathy (Gresser et al., 1981). It is however fascinating
that in the MLN of IFN-a/p R"~ mice B cells, in particular, fail to accumulate
following LHAgfp infection. All the factors controlling lymphadenopathy during
MHV-68 infection are not fully understood and clearly there are large numbers of
contributing factors that need further investigation.
5.5 Future work
In both the MLN and spleen of LHAgfp infected IFN-a/p R_/" and WT129 mice
CD4+ and CD8+ cells were found to also express GFP. There has not been any
published data on T cells being infected, although there could be low levels of
infectivity. A possible explanation for the observation could be that CD4 expression
was from myeloid dendritic cells and macrophages while the CD8 expression is by
the lymphoid subset of dendritic cells (Pulendran et al, 2001, Jenkins et al., 2001).
The work on different subtypes of dendritic cells, their lineage and localisation in
different compartments of the lymph node are under current research focus in other
laboratories. It would be interesting to find out whether some subtypes of dendritic
cells are more susceptible to MHV-68 infection which might in turn help discern
whether they closely interact with B cells/T cells and transfer virus amongst each
other.
In vitro work with virus infected dendritic cells has demonstrated that this can lead to
either an efficient antigen-presentation and/or immunosuppression due to impairment
or depletion of dendritic cells. For example, in vitro HSV infected mature dendritic
cells were found to have drastically reduced capacity to stimulate T cells (Kruse et
al., 2000). They also showed degradation of a maturation marker CD86, although
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this study did not address the consequence. In the case of LCMV a mutant clone of
the Armstrong strain was found specifically to infect dendritic cells instead of
macrophages. It has been shown to bring about immunosuppression in mice infected
with this virus by causing degradation of infected dendritic cells (Borrow et al.,
1995). The infection of professional antigen-presenting cells such as CDllc+
dendritic cells and F4/80+ macrophages early in the course of MHV-68 infection
could mean a careful regulation of cellular events and/or regulation of immune
response.
5.6 Summary
To summarise, the work described in this thesis has helped identify cellular events
that take place in the MLN following MHV-68 infection. It has shown that cell types
such as CDllc+ and F4/80+ cells are infected by MHV-68 at this site very early
during infection. The work described the in vivo characterisation of the GFP
expressing recombinant virus, LHAgfp and has addressed some of the applications of
this virus in detecting infected cells. It has also investigated the pathogenesis and
cellular tropism of LHAgfp in IFN-a/p R"~ and WT129 mice.
Cellular events are a key to our understanding of virus infections and their regulation
by the host immune response. In the case of MHV-68, work at the single cell level is
required to answer some of the cellular events more precisely. It is hoped that the
work described in this thesis has shed some light to our current understanding of in
vivo virus/host interactions during MHV-68 infection.
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